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Abstract 
 
Whole genome amplification amplifies the entire genome in a few hours from samples of 
minimal  DNA  quantities,  even  from  single  cells.  This  may  have  many  applications, 
especially in prenatal diagnosis, PGD and PGS. 
 
The hypothesis for chapter 3 was:  Can multiple displacement amplification (MDA) be 
used as a universal step prior to molecular analysis for PGD? WGA using MDA (Qiagen) 
was used on single cells in order to overcome the problem of limited DNA in PGD. MDA 
allows the diagnosis through haplotyping or a combination of direct and indirect mutation 
analysis.  Different  cell  types,  including  buccal  cells,  lymphocytes,  fibroblasts  and 
blastomeres were examined. A modification on the cell lysis buffer was also tested in 
order to achieve more accurate results. PGD seems to benefit from MDA when multiple 
tests are performed for direct and indirect analysis. The modified lysis buffer (exclusion 
of  DTT)  produced  better  results  than  the  other  lysis  buffers  and  buccal  cells  do  not 
produce as accurate results as other cell types. The hypothesis was met as the amount of 
DNA produced by MDA can be used for direct and indirect testing and haplotyping.  
 
The hypothesis for chapter 4 was: Is it possible to accurately assess the chromosomes of a 
single cell by a CGH?  WGA was achieved by MDA and GenomePlex (Sigma) on single 
lymphocytes, fibroblasts and blastomeres prior to a CGH analysis. The difficulty of this 
technique  was  the  high  background  noise  that  was  produced  by  WGA  that  makes 
interpretation difficult. Different lysis buffers, modifications of the WGA reaction and 
analysis  software  were  examined  for  better  results.  A CGH  slides  from  different 
companies and institutions were used. The results showed that GenomePlex produced 
less  background  noise  compared  to  MDA  but  the  amplification  efficiency  of  the 
technique was less reliable. The BlueGnome Cytochip arrays produced the best compared 
to arrays from any other companies or institutions. More experiments would be necessary 
to  determine  if  the  hypothesis  was  met  as  a  number  of  chromosomal  abnormalities 
detected were not always confirmed by other experiments. 
   6 
The hypothesis for chapter 5 was: Can aneuploidy be detected in coelomic fluid using a 
CGH?  The possibility of using WGA and a CGH on coelomic fluid was tested as this 
could  be  used  as  an  early  form  of  prenatal  diagnosis.  Coelomic  fluid  was  collected 
between  the  5
th  and  11
th  week  of  pregnancy  from  women  undergoing  termination  of 
pregnancy.    MDA  and  GenomePlex  were  used  to  amplify  the  DNA  prior  to  a CGH 
analysis. Both genomic (high resolution) and constitutional (low resolution) arrays were 
tested.  The  results  showed  that  aneuploidy  can  be  detected  by  a CGH.  BlueGnome 
Cytochip slides produced the best results. A triploid sample was detected as normal. The 
hypothesis  was  met  and  even  higher  resolution  could  be  achieved  with  the  use  of 
GenomePlex and BlueGnome Cytochip arrays. 
 
WGA may be very important for downstream genetic tests when the DNA is from very 
low quality and quantity.  Further optimisation of the technique is needed in order to 
achieve similar results to those of good quality genomic DNA. Arrays from different 
companies or institutions may produce very different results. In conclusion, the results 
showed that WGA can benefit PGD and PND, and a CGH gives great potential to PGS 
and coelomic fluid diagnosis. 
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Chapter 1 
 
 Introduction 
 
1.1 Genetic testing 
 
DNA  is  the  fundamental  substance  for  every  living  organism  which  is  passed  from 
generation to generation. Abnormal DNA is responsible for certain diseases and defects 
which are known as genetic disorders. The evolution in the field of genetics has allowed 
the identification of genetic abnormalities even before the symptoms appear. Specific 
genetic  tests  can  be  performed  focusing  at  the  molecular  or  chromosomal  level  after 
obtaining  DNA  from  the  individual.  In  many  cases  of  genetic  diseases  there  is  no 
treatment. In such cases the avoidance of transmitting this harmful genetic disease to the 
next generations is essential. The earliest stage that a genetic test can be performed is at 
the 8 cell stage in which the test can predict if the developing organism will develop a 
specific disorder. 
 
1.1.1 Meiosis 
 
A genetic abnormality can be transmitted from one generation to the other as an inherited 
mutation, can be a novel mutation in a somatic cell (like cancer) or can arise during the 
very complex mechanism of meiosis of the gametes or in the first cell divisions (post  
zygotic errors). In animals meiosis involves a process in which specific cells follow two 
consecutive cell divisions in order to produce haploid cells, the gametes (Strachan and 
Read, 1999). The gametes in humans are the spermatozoa that are produced in the male 
reproductive system (testis) and the oocytes that are produced in the female reproductive 
system  (ovary).  The  production  of  spermatozoa  (spermatogenesis)  and  oocytes 
(oogenesis)  is  a  very  complex  mechanism.  Spermatogenesis  takes  place  in  the  testis 
where spermatogonia cells (priomordial germ cells that have entered the testis) proliferate 
by  mitotic  division  until  they  differentiate  to  primary  spermatocytes  (diploid  cell) 
(Gilbert, 2001). Primary spermatocytes enter meiosis which will produce four mature 
spermatozoa.  In  meiosis  I,  the  DNA  is  compacted  to  46  chromosomes  (23  pairs  of   16 
homologous chromosomes) that are aligned in pairs in the centre of the cell. Crossing 
over takes place and the first meiotic division is completed with the production of two 
cells  (secondary  spermatocytes)  where  each  contains  one  set  of  homologous 
chromosomes with the two sister chromatids connected at the centromere. In meiosis II, 
the centromeres divide and the sister chromatids are separated apart resulting in four cells 
(spermatids)  from  the  two  secondary  spermatocytes.  The  spermatids  will  mature  and 
differentiate into spermatozoa (Figure 1). Spermatogenesis is a process that happens from 
puberty throughout the adult life of male organisms (Mueller and Young, 2001). 
 
In contrast to spermatogenesis, oogenesis does not happen from puberty throughout the 
adult life of the females. Oogenesis starts from the first months of the embryonic life 
where  oogonia  (priomordial  germ  cells  that  have  entered  the  ovaries)  proliferate  and 
develop to primary oocytes which will start the meiosis. At birth, the primary oocytes 
have  entered  a  phase  of  maturation  arrest  (dictyotene  stage)  in  which  they  remain 
suspended until puberty (Strachan and Read, 1999). Meiosis I is completed in the follicle 
before ovulation, where a single secondary oocyte and a polar body is formed. Unlike 
spermatogenesis, the secondary oocyte receives the majority of the cytoplasm compared 
to  the  polar  body.  The  secondary  oocyte  enters  meiosis  II  stage  but  arrests  at  the 
metaphase  II stage. Meiosis II  will only be completed if fertilisation occurs after the 
oocyte is being released by the follicle in the oviduct (figure 1). In case of fertilisation a 
second polar body will be formed. As meiosis in females can take up to 50 years to be 
completed,  there  is  an  increased  risk  of  chromosomal  abnormalities  connected  with 
maternal age related to meiosis errors (Mueller and Young, 2001). 
 
1.1.2 Fertilisation and preimplantation development 
 
Fertilisation occurs when the male and female gametes fuse and produce a new organism. 
Fertilisation takes place in the ampulla of the oviduct, a region close to the ovary. In 
humans,  millions  of  spermatozoa  will  surround  the  female  gamete  but  only  one  will 
manage to drill the zona pellucida and release the sperm DNA inside the oocyte. After 
fertilisation, the first mitotic division of the new organism (cleavage) begins in the next   17 
24 hours while the new organism moves towards the uterus. After the first cleavage, 
DNA  transcription  also  begins  and  maternal  mRNA  degrades.  The  two  cells  divide 
asynchronously until they reach eight cells in the following two days. Until that stage the 
cells have a loose  arrangement with space between them (cleavage stage). After that 
stage, the cells form tight junctions with each other and maximizing their contact and 
become  a  compact  ball  of  cells  (phenomenon  of  compaction).Asynchronous  mitotic 
division continues and in the following days the embryo moves from the morula stage to 
the blastocyst stage, where differentiation of the cells occurs. The cells located in the 
inner core form the inner cell mass (ICM) are the ones that will give rise to all tissues of 
the  embryo  body  and  some  extraembryonic  tissues  (amnion,  yolk  sack  and  allantois) 
whereas the cells in the outer core form the trophectoderm which is responsible for the 
production of the placenta (Gilbert, 2001).. As the blastocyst is growing and dividing, it 
reaches the uterus on day 6 7, removes the zona pellucida (hatching) and it is finally 
implanted at the uterus between days 8 and 9 (figure 2). 
 
1.1.3 Assisted reproduction technology 
 
Assisted reproduction technology (ART) refers to methods used in order to achieve a 
pregnancy that are usually used in couples with fertility problems. Fertility problems can 
be present in males and females. Common infertility problems of males is azoospermia 
(complete absence of sperm in the semen) and oligospermia (<20 million sperms/ ml per 
ejaculation produced) which can be due to hormonal problems, environmental factors, 
infenctions or chromosomal abnormalities. In females infertility problems can be related 
with  the  oocyte  (chromosomal  abnormalities,  advanced  maternal  age)  or  with  the 
ovulation (mainly hormonal problems) or with the anatomy of the female genital tract 
(like endometriosis). The most common ART is in vitro fertilisation (IVF) in which the 
oocyte is fertilised in vitro by spermatozoa outside the womb (Mueller and Young, 2001). 
Different techniques have been developed for  IVF, including intra cytoplasmic sperm 
injection (ICSI) where a single sperm is injected in the oocyte via a microneedle (figure 
1.3) and assisted zona hatching (AZH) where a small opening of the zona pellucida is 
made prior to embryo transfer that helps the embryo in the implantation process in the   18 
uterus. IVF embryos can also be biopsied and chromosomal and molecular diagnosis can 
be performed in order to avoid genetic abnormalities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.1:  Spermatogenesis  and  oogenesis.  This  figure  gives  a  schematic 
representation  of  how  female  and  male  primordial  germ  cells  develop  and  divide  to 
produce  oocytes  and  spermatozoa  respectively  (figure  adapted  from  Memorial 
University, Canada, http://www.mun.ca/biology).   19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Fertilisation and preimplantation development. This diagram shows all the 
stages from ovulation of the oocyte, to fertilisation, preimplantation development and 
final implantation at the uterus after eight to nine days (figure adopted from the National 
Institutes of health resource for stem cell research, http://stemcells.nih.gov). 
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Figure  1.3:  ICSI.  This  diagram  shows  how  ICSI  is  performed.  A  microneedle  that 
contains a single sperm is injecting the oocyte and releases the sperm in order to assist 
fertilisation.  (Figure  adopted  from  Colorado  Reproductive  endocrinology  website, 
www.coloradofertility.com) 
 
1.2 Preimplantation Genetic Diagnosis 
 
Preimplantation genetic diagnosis (PGD) involves the genetic analysis of cells from an 
oocyte  or  embryo  for  a  specific  molecular  mutation  or  chromosomal  abnormality 
(Fragouli, 2007). The purpose of PGD is to determine which embryos that are generated 
by IVF are normal for the specific genes and chromosomes for which they are assessed 
so that these can be selected for implantation (Wells, 2004). The PGD tests that are being 
performed due to single gene diseases use the polymerase chain reaction (PCR) technique 
whereas PGD tests for chromosomal abnormalities use fluorescent in situ hybridisation 
(FISH) analysis of single blastomeres (Harper et al., 2008a).  
 
Regarding single gene diseases, more than two hundred have been tested in clinical PGD 
(Fragouli et al., 2007). In theory, every known single gene mutation could be diagnosed 
at a single cell (Spits et al., 2009). However, in practice, PGD PCR protocols can be very 
difficult to be optimised, due to the limited amount of DNA present for diagnosis.  The 
most  common  PGD  tests  for  single  gene  defects  used  are  cystic  fibrosis,  beta 
thalassaemia, myotonic dystrophy, Huntington’s disease and fragile X syndrome (Spits et   21 
al., 2009; Fragouli et al., 2007). The same monogenic disorders are the most commonly 
tested  in  prenatal  diagnosis.  In  PGD  however,  there  is  also  an  increasing  number  of 
diseases that are not offered in prenatal diagnosis; these are late onset diseases (such as 
cancer), human leukocyte antigen (HLA) testing and predisposition syndromes (Goosens 
et al., 2008). 
 
Fluorescent PCR (F PCR) is most commonly used in PGD PCR protocols as it is over a 
thousand times more sensitive than the PCR analysis on ethidium bromide stained gels. 
According to the PGD protocol, other post PCR methods can be used, including the use 
of restriction endonucleases leading to restriction fragment length polymorphism (RFLP), 
minisequencing, quantitive real time PCR and amplification refractory mutation system 
(ARMS) (Spits et al., 2009; Fiorentino et al., 2003; Pierce et al., 2003). 
 
Initial  experiments  for  PGD  were  performed  in  mice  (Monk  et  al.,  1987).  The  first 
clinical PGD cycles were reported in 1990 in which PCR amplified a repeat sequence on 
the long arm of chromosome Y that was used to distinguish male from female embryos in 
families that were carriers of an  X linked  recessive disease (Handyside et  al., 1990). 
Since then, many single gene disorders have been diagnosed with the use of PCR in PGD 
(Harper et al., 2006). Interphase FISH substituted PCR for X linked recessive diseases in 
1993, as it was considered to be a more robust and efficient method (Delhanty et al., 
1993). The technique evolved very rapidly in the PGD field and now is used to for a 
variety  of  chromosomal  aberrations  with  the  majority  being  reciprocal  translocations 
(Harper et al., 2008b). 
 
Couples that may undertake PGD are those that are at risk of transmitting a recessive, 
dominant  or  X linked  single  gene  disorder  that  is  lethal,  seriously  debilitating,  life 
threatening later in life or carriers of structural chromosomal abnormalities. Such couples 
may be against terminating an affected pregnancy because of ethical or religious reasons. 
PGD can also be carried out for predisposition syndromes and HLA antigen matching 
(Wells, 2004).  
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1.3 Preimplantation genetic screening 
 
Preimplantation genetic screening (PGS) is a genetic test that uses PGD technology, but 
with a different purpose (Twisk et al., 2006). PGS is used to screen for chromosomal 
aneuploidies in IVF embryos. In theory, aneuploidy screening of the blastomeres or polar 
bodies would help to implant only the chromosomally normal embryos and this would 
lead to improved pregnancy rates after IVF and decreased miscarriage. 
 
PGS has been applied widely by many clinics to IVF patients but controversial data have 
been published regarding if IVF benefits from PGS and in which IVF groups should be 
applied  (Donoso  et  al.,  2007).  Some  groups  have  concluded  that  PGS  should  not  be 
applied to any IVF patient (Mastenbroek et al., 2007) whereas others recommended that 
PGS should be part to every IVF cycle (Kuliev et al., 2003). Universal application of 
PGS in IVF patients should be mathematically flawed due to false negative diagnostic 
rates (1.2 4.7% as suggested from Munne et al., 2005) and due to existence of mosaicism 
and self  correction of preimplantation stage embryos. On the other hand, excluding PGS 
for all IVF patient groups should not be concluded due to the different techniques (use of 
one or two blastomeres or polar body), laboratory performance and varying degrees of 
embryo manipulation used in different clinics. Most of the studies however conclude that 
IVF benefits from PGS when applied in certain groups of IVF patients (Staessen et al., 
2008). The indications for PGS includes advance maternal age (Staessen et al., 2008), 
repeated  implantation  failure,  repeated  early  miscarriage  and  severe  male  infertility 
(Harper et al., 2009; Twisk et al., 2006).  
 
The vast majority of PGS tests involve FISH for five to 15 chromosomes whereas in rare 
cases metaphase comparative genomic hybridisation (m CGH) has been applied in polar 
bodies and single blastomeres in which all chromosomes are screened (Baart et al., 2007; 
Wilton et al., 2003; Wells et al., 2002). Although m CGH has technical limitations due to 
the extensive time needed for diagnosis, very recently microarray CGH (a CGH) has 
started gaining ground in PGS analysis and the first clinical case of PGS with the use of 
a CGH was reported (Hellani et al., 2008). Following that a number of pre clinical PGS   23 
studies with the use of a CGH have been published providing very promising results for 
future use of the technique. 
 
1.4 Biopsy methods 
 
Polar body, cleavage stage or blastocyst biopsy has to be performed prior to PGD or 
PGS. Each of the biopsy methods has advantages and limitations (Sermon et al., 2004). In 
polar body (PB) biopsy, polar bodies are aspired after a small cut is made in the zona 
pellucida by sharp needles or laser (Sermon et al., 2004). This technique is useful only for 
the genotype analysis of the oocyte and not the embryo. 
 
In  cleavage stage  biopsy,  the  embryos  are  grown  in  vitro  after  fertilisation  in  an 
appropriate environment until they reach the 6  to 8 cell stage which occurs on the third 
day after insemination. In order to remove one or two cells from the embryo the zona 
pellucida is breached, using an acid solution or laser and a biopsy pipette is introduced 
through  the  hole  into  the  embryo  from  where  the  cells  are  aspirated  (De  Vos  and 
Streirteghem, 2001). This biopsy technique is used most often compared to others and 
allows detection of the maternal, paternal and postzygotic errors. It was earlier evaluated 
on mouse embryos by various groups before it was applied in human embryos (Nijs et al., 
1988; Krzyminska et al., 1990; Kola and Wilton, 1991). 
 
In blastocyst biopsy, the embryos are left to grow until the blastocyst stage which gives 
the advantage that more cells can be obtained for analysis. The cells that are biopsied are 
the trophectoderm cells and not the inner cell mass. Mosaicism of the trophoectoderm 
cells may increase the chances of misdiagnosis as later in pregnancy confined placental 
mosaicism (CPM) is observed (Kalousek and Dill, 1983).  The main disadvantage of this 
biopsy method is that fewer embryos reach this stage in culture and the time left for 
diagnosis is limited. In a study performed by McArthur et al. (2005) 21% of the cases had 
no embryos suitable for biopsy. 
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1.5 Diagnosis techniques 
 
PCR and FISH are the techniques that are routinely used for clinical PGD and PGS cases. 
The method used depends on the disease. PCR is used when the couple is at risk of 
transmitting a single gene disease. In most cases the specific mutation has to be known 
(Piyamongkol  et  al.,  2003).  FISH  is  used  to  examine  chromosomes  in  the  case  of 
Roberstonian or reciprocal translocations and for PGS. 
 
1.5.1 Polymerase Chain Reaction 
 
PCR is one of the most powerful and useful tools of genetics. It was introduced 20 years 
ago by Kary Mullis who was awarded the Nobel Prize for Chemistry in 1993 (Mullis et 
al., 1990). PCR was the first method of analysis used in PGD and is still used for the 
identification of single gene diseases. Nowadays, more than 200 single gene diseases can 
be diagnosed in PGD with PCR and the number will increase as a result of increase in 
patient demands (Harper et al., 2008a). PCR for PGD requires more thermo cycles to be 
performed than normal PCR because of the limited amount of DNA that is present (6 
12pg). The limited amount of DNA is also responsible for certain problems, such as 
contamination,  allele  drop  out  (ADO)  and  failure  of  amplification,  that  make  the 
diagnosis more complicated. 
 
1.5.1.1 Contamination 
 
Contamination  is  a  risk  of  the  PCR  technique  as  DNA  can  become  air borne  in  the 
laboratory  from  cells  or  from  previous  PCR  products  and  influence  the  result  of  the 
diagnosis especially in PGD, because there is minimal DNA available for diagnosis and 
stringent  experimental  conditions  have  to  be  taken  to  avoid  contamination.  The 
experimental  conditions  include  performing  the  pre PCR  reaction  in  DNA  free 
environments,  separated  from  the  post PCR  reaction,  with  separate  laboratory  coats, 
gloves, tubes, tips, pipettes, reagents and generally all the equipment that is used (Findlay   25 
et al., 2001). In addition to the contamination that can occur from the laboratory, in PGD 
contamination  can  also  occur  from  extraneous  sperm  that  is  embedded  in  the  zona 
pellucida (paternal contamination) or  cumulus cells that surround the embryo (maternal 
contamination)  (Wilton  et  al.,  2009).    Paternal  and  maternal  contamination  can  be 
avoided when specialized techniques are used such as intracytoplasmic sperm injection 
(ICSI) and removal of the cumulus cells (Marijo, 2000; Liebaers et al., 1998; Findlay et 
al., 2001). Further insurance that the cells examined are not contaminated from any other 
source is achieved by multiplex PCR which uses a set of highly polymorphic markers. 
These markers, usually short tandem repeats (STRs), are called “contamination markers” 
and have to be heterozygous and informative in the maternal and paternal DNA so that 
the embryonic cells should have one copy from each parent (Harper and Wells, 1999). 
The contamination markers used are usually closely located to the site of the mutation so 
that  they  can  be  linked.  In  case  the  phase  of  the  mutation  and  the  allele  of  the 
contaminated marker are known it would give even more reliable results. If more than 
two alleles of the contamination markers are present in the PCR product this would reveal 
that the samples were contaminated. 
 
1.5.1.2 Allele drop out 
 
Allele drop out (ADO) is the event where there is failure of the amplification of one of 
the two alleles in a cell heterozygous for this region. This produces an inaccurate result 
where the DNA can be considered as homozygous for that locus although it is not.  ADO 
is unique to PCR where DNA is from one to five cells and it can affect either allele. 
There is no clear explanation of what causes ADO but assumptions suggest that it is a 
result of DNA degradation which leads to PCR refractory breaks in both DNA strands 
(Piyamongkol et al., 2003).  Furthermore, not optimised PCR conditions and incomplete 
cell lysis could lead to ADO because the DNA is not easily accessible (Thornhill et al., 
2005).  ADO  only  becomes  a  problem  in  PGD  for  dominant  diseases  and  compound 
heterozygotes. In recessive mutations both alleles are the same and only one allele is 
expected but in dominant disorders there can be amplification of only the normal allele   26 
which would lead to misdiagnosis (Wilton et al., 2009). ADO in optimised protocols for 
single cells can be as high as 20% (Piyamongkol et al., 2003).  
 Three different methods have been used in order to overcome ADO. The most important 
method is the use of highly sensitive fluorescent PCR (F PCR) which is one thousand 
times more sensitive for the detection of PCR products than normal PCR. As F PCR is 
more sensitive, ADO could be minimised in products that there is strong amplification 
bias  in  one  of  the  alleles.  In  addition,  linked  markers,  the  same  ones  used  for 
contamination, can be used in multiplex PCR together with the mutation primers in order 
to decrease the misdiagnosis which could appear because of ADO (Wells, 2004). This 
technique relies on the fact that ADO can be present irrespectively from the location of 
the primers even if the multiplex primers are very close. Again, it would be important to 
know the haplotype of the disease mutation and the linked marker. Even if one of the 
primers fails to show a result a conclusion can be drawn about the presence or not of the 
disease (Piyamongkol et al., 2003). For example, if ADO is 20% for the disease primers 
and the same for linked markers, and the phase is known, in multiplex PCR the overall 
ADO would be 0.2x0.2= 0.04 or 4%. PCR on DNA from two cells has shown to decrease 
the misdiagnosis resulting from ADO (Ao et al., 1998). In the case of three cells ADO is 
almost  eliminated.  This  implies  that  ADO  is  a  problem  arising  only  in  single  cell 
diagnosis (Ao et al., 1998). However, when examining embryonic cells at cleavage stages 
a maximum of two cells can be obtained for diagnosis. Moreover, some embryos on day 
3 are not able to lose two cells and only one cell is biopsied (Wells and Delhanty, 2001). 
Other techniques that would decrease ADO have been reported but so far there is still no 
reliable  data  of  significant  improvement.  These  techniques  include  increasing  of 
denaturation temperature in the first ten cycles (Ray and Handyside, 1996), increasing the 
melting temperature and denaturation time (El  Hasmemite and Delhanty, 1997) and use 
of appropriate lysis buffers and polymerases (Thornhill et al., 2001).  
 
ADO is still one of the greatest problems in PGD as all the methods mentioned above do 
not consistently eliminate it but only reduce it. ADO has been shown to have different 
rates in different types of cells. This is a fact that has to be taken in consideration because   27 
in PGD research and work up of PGD protocols different types of cells are analysed apart 
from blastomeres, such as buccal cells and lymphocytes (Piyamongkol et al., 2003).   
 
1.5.1.3 Total amplification failure 
 
Another problem that exists in single cell PCR is total amplification failure (TAF) which 
is the non amplification of any of the alleles. Amplification failure may occur for the 
same reasons as ADO but it is also detected in homozygote alleles. TAF could also exist 
due to technical problems, like poorly optimised PCR protocols, incomplete cell lysis, 
anucleate cells or even human error where the cells are not transferred in the tube during 
the cell transfer (Wilton et al., 2009). In clinical PGD cases an embryo is excluded from 
transfer  if  the  PCR  of  the  blastomere  shows  TAF.  However,  this  again  results  in  a 
decreased rate of embryos that are available for transfer (Piyamongkol et al., 2003). 
 
The problems that arise with PCR appear mainly due to the limiting amount of DNA 
present in a single cell that would not happen if the starting DNA was more. In order to 
overcome the problem of limited amount of DNA the entire genome of the cells can be 
amplified by whole genome amplification prior to molecular analysis.  
 
1.5.2  Whole genome amplification 
 
Whole genome amplification (WGA) is a relatively new tool in molecular biology that 
uniformly amplifies the entire genome with minimal bias and would have a substantial 
impact on the capability to perform comprehensive molecular and cytogenetic analysis 
using small patient specimens, even single cells (Luthra and Medeiros, 2004). WGA has 
been  found  to  be  very  useful  in  different  fields  including  cancer,  forensic,  paleo 
archaeological studies, PGD and most types of genetic tests where the DNA is limited 
(Luthra and Medeiros, 2004; Dean et al., 2002). 
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1.5.2.1 PCR based WGA techniques 
 
Alu PCR was the first reported WGA method (Nelson et al., 1989). The primers anneal 
to repetitive sequences such as Alu repeats which are distributed along the genome, and 
this leads to amplification of the entire genome and not just a small region (Nelson et al., 
1989).  This  approach  proved  unsatisfactory  as  Alu  repeats  tend  to  be  clustered  in 
heterochromatic regions and the result was a bias amplification of these regions rather 
than  the  whole  genome  (Hughes  et  al.,  2005).  Nevertheless,  this  has  led  to  the 
development  of  other  PCR based  techniques  with  a  similar  philosophy,  namely 
degenerate oligonucleotide primed PCR (DOP PCR), primer extension preamplification 
(PEP), linker adaptor (LA) PCR, and GenomePlex. 
 
The  first  reliable  WGA  techniques  were  DOP PCR  and  PEP.  DOP PCR  was  first 
introduced by Telenius et al. (1992) and it has been used widely as an easy and reliable 
technique  for  whole  genome  amplification.  The  technique  relies  on  standard  PCR  to 
amplify a specific region of the genome but with some modifications that allow the whole 
genome to be equally amplified. The differences are in the primers. In DOP PCR only 
one  set  of  primers  is  used  that  is  partially  degenerate  (5’ 
CCGACTCGAGNNNNNNATGTGG 3’). This partial degeneration allows the primers to 
bind  unspecifically  to  the  DNA  template  at  low  stringency  conditions.  The  second 
difference  includes  the  thermal  cycling  condition,  where  in  DOP PCR  there  are  two 
different stages. In the first five to eight cycles, there are low stringency conditions which 
allow the 3’end of the primer to bind unspecifically at sites of the genome and only 
according to the complementarity to the 6bp precise sequence of the 5’end. After these 
cycles, the conditions become more stringent by increasing the annealing temperature and 
with the facilitation of the random hexamer sequence (NNNNNN) it enables efficient 
primer annealing and amplification of only the initial fragments that are tagged with the 
specific  part  of  the  primer.  This  second  round  typically  lasts  for  about  25 30  cycles 
(Telenius et al., 1992; Hughes et al., 2005). Several  groups have tried to modify the 
technique  by  lowering  the  required  amount  of  starting  template,  improving  genome   29 
coverage and increasing the DNA yield, fidelity and fragment length (Kittler et al., 2002; 
Hirose et al., 2001; Larsen et al., 2001). 
 
PEP was also developed in 1992 (Zang et al., 1992). The main difference with DOP PCR 
is  that  PEP  utilises  complete  degenerate  primers  of  15bp.  In  theory,  the  primer  mix 
consists  of  10
9  sequences  (4
15).    PEP  includes  50  PCR  cycles  in  which  the  DNA  is 
denatured at 92
oC. The primers anneal in the beginning at 37
oC for 2 minutes and then 
the annealing temperature increases by 0.1
oC/second up to 55
oC (Zhang et al., 1992). A 
more recent modification of this technique, which uses a polymerase with proofreading 
activity, further improves the technique (i PEP) (Sun et al., 2005; Dietmaier et al., 1999). 
 
The amount of DNA obtained after WGA with i PEP is 0.2 0.8 g and 4 6 g afer DOP 
PCR. The product length ranges from 100 1000 bp for both techniques (Arneson et al., 
2008; Bannai and Tokunaga, 2005; Sun et al., 2005). These techniques have been applied 
successfully in many applications including microsatellite analysis (Zheng et al., 2001), 
loss  of  heterozygosity  (LOH)  for  cancer  studies  (Simpson  et  al.,  2003),  sequencing 
(Dietmaier  et  al.,  1999),  m CGH  (Harada  et  al.,  2002),  a CGH  (Peng  et  al.,  2003), 
mutation  detection  by  single  strand  conformation  polymorphism  (SSCP)  and 
heteroduplex analysis (Bardaux et al., 2001). Successful amplification from degraded and 
damaged DNA has also been applied successfully (Heinmoller et al., 2002). PEP and 
DOP PCR have been applied in clinical PGD and prenatal diagnosis (PND) (Peng et al., 
2007). 
 
GenomePlex is a relative new WGA technique based on PCR which seems to be more 
promising compared to the other PCR based WGA techniques (Little et al., 2005). Unlike 
DOP PCR and PEP which use degenerate primers, this method is based on reformatting 
gDNA  into  “inherently amplifiable  DNA  molecules  of  controllable  size”,  named 
plexisomes.  In  the  GenomePlex  reaction,  the  DNA  is  first  randomly  chemically 
fragmented to smaller pieces of average 500bp. Plexisomes are produced by attaching 
universal adapters to both ends of each fragmented DNA piece. The plexisomes, which 
form the OmniPlex library, are then amplified with the help of a single primer that binds   30 
to  the  universal  adapters  and  high fidelity  DNA  polymerase  via  traditional  PCR  for 
limited cycles (Langmore, 2002; figure 1.1). 
 
 
Figure  1.1:  Diagram  of  GenomePlex  WGA  method:  This  figure  illustrates  the 
GenomePlex method for WGA. The genomic DNA is first fragmented into small pieces, 
converted to PCR amplifiable units (OmniPlex library) and then amplified with the use of 
universal primers that bind to the universal adapters. This figure was adapted from The 
Sigma-Aldrich official website (www.sigmaaldrich.com). 
 
GenomePlex produces 500 1000 fold amplification of DNA with an average of 600bp 
product length (Arneson et al., 2008). The superiority of GenomePlex compared to other 
PCR based techniques relies on the fact that there is no non specific DNA formation and 
it can successfully amplify samples from degraded DNA (Little et al., 2006).Experiments 
have also shown that GenomePlex does not produce amplification bias (Barker et al., 
2004). Although it has recently been developed, it has already been applied in different 
genetic tests, including high resolution analysis with a CGH in samples from formalin   31 
fixed paraffin embedded (FFPE) archival specimens (Little et al., 2006) and single cells 
(Fiegler et al., 2006). A clinical PGD application with GenomePlex was also reported 
recently (Chen et al., 2008). 
 
1.5.2.2 The Phi29 Polymerase 
 
Phi29  polymerase  is  the  viral  protein  2  found  in  bacteriophage  Phi29  from  Bacillus 
subtilis  (Hermoso  et  al.,  1985;  Blanco  et  al.,  1989).  It  is  a  protein primed  DNA 
dependant  replicase  and  belongs  to  the  eukaryotic type  family  of  DNA  polymerases 
(family  B)  (Blanco  and  Salas,  1996).  This  bacteriophage  contains  a  linear,  double 
stranded DNA of 19,285 bp together with a terminal protein, p3, which is covalently 
connected to both 5’ ends of the DNA by a phosphodiester bond between the OH group 
of serine residue 232 and 5’  dAMP (Blanco et al., 1989).  In vivo and in vitro studies 
have shown that Phi29 polymerase is the only enzyme that is required for the synthesis of 
the entire genome. The only other protein that is required for the synthesis of DNA is 
protein p3 which is used as the initiation primer. Moreover, genetic and biochemical 
analysis of the Phi29 polymerase have pointed out the necessity of this enzyme in DNA 
synthesis in vivo and in vitro (Inciatre et al., 1980; Shih et al., 1982).  
 
Phi29 polymerase consists of a single polypeptide of 66 kD (272 amino acids). Despite 
the small size for an enzyme it has multiple enzymatic activities in the single polypeptide 
chain which make it distinguishable from most other DNA polymerases (Rodriguez et al., 
2005;  Blanco  and  Salas,  1996).  Its  DNA  polymerization  activity  includes  high 
processivity and strand displacement during the polymerization process, which induces 
its catalytic properties. Phi29 polymerase has recently been found to owe these properties 
to a specific subdomain named terminal protein region 2 (TPR 2) and for this reason it 
has the highest processivity described for a DNA polymerase (>70 kb) (Rodriguez et al., 
2005).   In contrast to replication systems  found in other organisms, such as E. Coli, 
where the presence of accessory proteins are crucial to confer processivity to the DNA 
polymerase by clamping the polymerase to the primer template, Phi29 polymerase does 
not need these proteins and is able to catalyze the reaction alone with high processivity.   32 
This probably arises from the unusually strong binding of the enzyme to single stranded 
DNA (Blanco et al., 1989). The initial clamping is associated with the terminal protein p3 
through deoxynucleotidylation and requires the presence of divalent metal ions (figure 
1.2). Thus, the intrinsic insertion discrimination values range from 10
4 to 10
6 and with the 
help of 3’ 5’ exonuclease activity, this range is further improved 100  fold (Garmendia et 
al,. 1992; Esteban et al., 1993).  
 
Another  interesting  feature  of  Phi29  polymerase  is  that  it  has  unwinding  properties. 
Unwinding  of  the  parental  DNA  helix  is  an  important  requirement  for  efficient 
replication  of  duplex  DNA.  In  most  DNA  replication  systems  this  is  achieved  by 
monomeric or multimeric enzymes which are called helicases and their role is to melt the 
dsDNA in an ATP dependent fashion. In contrast to these systems, Phi29 polymerase is 
able to use double helical DNA templates without the help of any unwinding proteins. 
This again has been found to relative to the TPR 2 subdomain (Rodriguez et al., 2005). 
 
Moreover, Phi29 polymerase initiates DNA replication at the origins which are located at 
both ends of the linear genome. This is done by catalyzing the addition of the initial 
dAMP onto the OH group of Ser 232 of the protein p3 which acts as a primer (Salas, 
1991).  Then,  a  transition  stage  occurs  in  which  protein  p3  priming  changes  to  DNA 
priming. Finally, Phi29 polymerase replicates the entire genome progressively without 
dissociating from the DNA (Blanco et al., 1989; Rodriguez et al., 2005). The existence of 
two replication origins placed at both ends of the duplex DNA chromosome allows both 
strands to be replicated continuously (symmetric replication) in contrast to the classical 
discontinuous model which necessitates the synthesis of RNA primed Okazaki fragments 
and additional accessory proteins (asymmetric replication). In this sense, the catalytic 
properties of the Phi29  polymerase, high processivity and strand displacement ability 
seem to be well designed to support this symmetric mode of replication (Maki et al., 
1988; Blanco et al., 1989).   
 
The  unusual  properties  of  the  Phi29  polymerase,  which  have  been  studied  for  many 
years, have made it a revolutionary element for a completely different approach of WGA.   33 
Specifically, the high processivity and the intrinsic strand displacement capacity of this 
polymerase  have  allowed  the  development  of  multiple  displacement  amplification 
(MDA) (Dean et al., 2002; Rodriguez et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Structure of Phi29 polymerase with terminal protein. This figure shows the 
different parts of the Phi29 polymerase, including the TPR2 and the exonuclease activity 
region and the connection with the terminal protein p3. The figure was adapted from 
Kamtekar et al., 2006). 
 
1.5.2.3 Multiple displacement amplification 
 
MDA depends on previous findings of isothermal rolling  circle amplification (RCA). 
RCA is a technique that uses Phi29 polymerase together with random hexamer primers to 
amplify large circular DNA templates such as plasmids and bacteriophage DNA (Dean et 
al., 2001; Dean et al., 2002). Interestingly, using the same reagents, linear genomic DNA 
could  also  be  amplified.  Initially  a  major  problem  with  MDA  reactions  was  the 
degradation  of  ssDNA  due  to  the  3’  to  5’  exonuclease  activity  of  the  enzyme.  This 
activity,  in  addition  to  the  proof reading  capability,  avidly  degrades  single stranded 
oligonucleotides such as the random hexamer primers. In order to solve this problem, 
random  hexamer  primers  that  are  protected  from  degradation  were  designed  (exo 
resistant)  primers.  These  primers  contain  two  phosphorothioate  linkages  at  the   34 
3’terminus. Thus, the primers are protected from degradation allowing amplification of 
genomic DNA (Dean et al., 2002). 
 
For  the  reaction  to  take  place,  the  genomic  DNA  has  initially  to  be  denatured.  The 
denaturation is usually achieved by treatment with KOH. Then, the exo resistant primers 
bind to the ssDNA. After that, Phi29 polymerase starts the extension of the primers. The 
exponential amplification is due to the ability of the enzyme to create a new replication 
fork whenever it meets dsDNA. Furthermore, Phi29 polymerase has the ability to invade 
the duplex 5’ end of the downstream primer and create a new replication fork. More 
random primers bind to the displaced strand and the polymerase rapidly synthesizes more 
dsDNA. The overall result is thought to be a ‘hyper branched’ structure which amplifies 
the entire genome in an exponential fashion (Lasken, 2005).   
 
 
Figure 1.6: Diagram of MDA. MDA amplifies the DNA in an exponential fashion. First 
the hexamer primers bind to single stranded DNA (A), and then the polymerase starts to 
amplify towards the 5’ end of DNA (B). Due to the helical activities, the downstream 
strand will unfold and a new single strand will appear (B). New primers will bind on the 
new single strand (C) and this will continue and amplify the DNA in an exponential 
fashion (D) (adapted from GE HealthCare Official Website, www.gehealthcare.com).   35 
 
As  well  as  Phi29  polymerase,  MDA  can  also  be  accomplished  with  the  use  of  Bst 
polymerase and T4 gene 32 protein in conjunction with modified random primers instead 
of  Phi29  polymerase.  The  difference  between  these  two  enzymes  is  that  Phi29 
polymerase has  a  greater strand displacement activity (SDA) than Bst  polymerase/T4 
gene 32 protein cocktail. However, Phi29 polymerase results in greater under and over 
representation of sequences when compared to the Bst enzyme (Lage et al., 2003). 
  
WGA by MDA results in 80 g of DNA which ranges from 2kb up to 100kb product 
length with an average of 12kb. The amplification bias range between loci is less than 6 
fold and the polymerase error rate is less than 10
 6. MDA products from starting template 
as little as 0.03ng of gDNA could produce a number of robust molecular analysis tests 
(Dean et al., 2003) whereas Paez et al., (2004) estimated a 99.82% genome coverage of 
MDA  products  when  the  starting  DNA  material  was  10ng.  Although  it  is  a  recent 
development, MDA has already been applied to a CGH (Lage et al., 2003), SNP analysis 
(Tranah et al., 2003), quantitative PCR (Dean et al., 2002) and microsatellite analysis 
(Hosono et al., 2003). 
 
Very recently a new isothermal amplification technique was developed named primase 
based WGA. This technique utilises the in vivo synthesis of primers rather than addition 
of synthetic primers by T7 gp4 primase and T7 polymerase for DNA replication at 37
oC 
(Li et al., 2008). Nevertheless, this technique has not been validated yet. 
 
1.5.3 WGA limitations 
 
Each WGA technique has advantages  and disadvantages. The  abilities of each WGA 
technique relies on the capacity of complete unbiased genome coverage, maximum fold 
amplification and yield, amplification product length, fidelity of the DNA polymerase 
and  ability  of  amplification  from  small  amounts  of  starting  DNA  template  including 
single cells (Lasken and Egholm, 2003). 
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When the starting DNA template is more than 10ng and the DNA comes from fresh 
tissue, MDA seems to have much greater abilities compared to PCR based techniques. 
The large amount of DNA produced with high average length is in contrast with DOP 
PCR, PEP and GenomePlex. Moreover, the amplification bias range between loci is 10
3 
10
6 fold in PEP and DOP PCR compared to the 6  fold of MDA.  Finally, the  DNA 
polymerase error rate is less than 10
 6 whereas in PEP it is 3 x 10
 4 to 1 x 10
 5, in DOP 
PCR it is 3 x 10
 4 and in i PEP it is 10
 5 (Larsken and Egholm, 2003; Hughes et al., 
2005). MDA can only give reliable results when the DNA comes from fresh tissue. PCR 
based methods and especially GenomePlex have shown reliable results from poor quality 
DNA (Little et al., 2006; Hughes et al., 2005). 
 
One of the biggest challenges of WGA is to achieve robust amplification from less than 
10ng of DNA as a starting template, including single cells where the DNA is only 6pg. 
All these techniques often produce a severe decrease of the fidelity of the experiment and 
increase of the ADO rate when the starting DNA template is less than 1ng (Kittler et al., 
2002). Nevertheless, there are some groups that have managed successful results with 
less starting material (Huang et al., 2000). In 2005 the first clinical application of MDA 
for PGD was reported (Hellani, 2005). 
 
WGA could be considered the key to overcome a major difficulty of PGD, which is the 
limited amount of DNA available for the diagnosis. So far, different WGA methods have 
been  used  in  PGD  for  clinical  purposes  or  for  research  in  single  cells,  including 
blastomeres. MDA is the latest method of WGA but it is being used more often in PGD. 
MDA has been applied in clinical PGD in a number of cases including Marfan Syndrome 
(Lledo et at., 2006), β thalassaemia and cystic fibrosis (Hellani et al., 2005), fragile X 
syndrome (Burlet et al., 2006) and for preimplantation genetic haplotyping (PGH) for 
Myotonic dystrophy and cystic fibrosis (Renwick et al., 2006). MDA was recently used 
for PGS using microarrays (Hellani et al., 2008). In research MDA has been successfully 
applied both for molecular analysis (Spits et al., 2006) but also for the use of a CGH 
(Caignec et al., 2006) and m CGH (Ng et al., 2005). DOP PCR has limited use in clinical   37 
PGD (Wells et al., 2002; Wilton et al., 2005) and research on single cells (Fragouli et al., 
2006, Wells et al., 1998). 
 
1.5.4 Preimplantation genetic haplotyping  
 
Preimplantation genetic haplotyping (PGH) takes advantage of the amplification of the 
entire genome with WGA prior to molecular analysis. WGA of the DNA from a single 
blastomere is carried out prior to multiplex or singleplex PCR of many short tandem 
repeat (STR) markers for haplotyping. In order to reveal the haplotype of the embryo, the 
DNA from two affected relatives has to be obtained. As many tests have to be performed 
and only a single cell is used for the diagnosis, amplification of the entire genome with 
the use of whole genome amplification is necessary. The advantages of this technique is 
that it overcomes the difficulty of optimising the PGD case separately for each patient as 
it is a universal technique that can be applied in most patients and that the application of 
multiplex  PCR  is  on  large  amounts  of  DNA  rather  than  DNA  from  a  single  cell. 
Misdiagnosis could occur due to recombination events during meiosis (Renwick et al., 
2007; Renwick et al., 2006). 
 
1.5.5 Fluorescent in situ hybridisation  
 
Fluorescent  in  situ  hybridisation  (FISH)  is  a  method  in  which  already  produced 
fluorescently tagged DNA probes bind to specific complementary regions of the sample 
nucleus  and  form  a  stable  DNA  hybrid  complex.  In  PGD  the  nuclei  derive  from 
blastomeres that are lysed onto a slide using lysis buffer and then are fixed.  FISH probes 
are derived from cloned DNA fragments that have been inserted and amplified in vectors 
such as bacterial artificial chromosomes (BACs), yeast artificial chromosomes (YACs), 
plasmids and cosmids which are then fluorescently labelled (Knight and Flint, 2000). 
These probes can bind to repeat sequences (repeat sequence probes), to the telomeres of 
the short or long arms of the chromosomes (subtelomeric probes) or they can be locus 
specific and bind to specific regions of a chromosome corresponding to specific genes 
and their surrounding sequences (locus specific probes). FISH is known to detect many   38 
chromosomal abnormalities, it is very accurate and it is rapid as it can be applied directly 
to interphase nuclei (Haaf and Ward, 1994). As in PCR, it was first applied for sexing the 
embryos in order to overcome the problem of X linked diseases but nowadays it is used 
for most chromosomal abnormalities. One disadvantage of interphase FISH is that the 
technique’s efficiency decreases as the number of probes increases (Harper and Wells, 
1999).  Other  problems  that  can  lead  to  misdiagnosis  are  mosaicism  and  signal 
overlapping (Wells and Harper, 1999). A crucial point of FISH is the fixation of the 
embryonic nucleus on the slide which has to ensure no loss of genetic material and the 
best nuclear morphology. Apart from PGD, FISH is used in the vast majority of the PGS 
cases which involves the analysis of five to 15 chromosomes (Baart et al., 2007). 
 
1.5.6 Metaphase comparative genomic hybridisation 
 
M CGH is a technique that allows the detection of chromosomal gains and losses of the 
entire  genome  of  the  cells  that  are  being  assessed  (Weiss  et  al.,  1999).  It  was  first 
described by Kalliomeni et al (1992) and by Manoir et al. (1993) in order to identify 
chromosome abnormalities in tumours. In this technique the test DNA is labelled with 
green  fluorescence  and  mixed  with  the  same  amount  of  a  reference  DNA,  which  is 
chromosomally normal, and is labelled with a red fluorescence. The mix is hybridised 
onto normal 46, XY metaphase spreads on a microscope slide. The test and reference 
DNA compete in order to bind to the complementary sites of the spread chromosomes. In 
case there is a chromosomal gain or loss in the test DNA, the proportion of green/red 
fluorescently labelled DNA at this specific site will not be equal to one and it would 
result in more green or red in this region. Computer software is used for analysis of each 
chromosome. In sites where the test and reference DNA are equal the result would be a 
yellow or orange colour. According to m CGH experiments the crucial detection size is 
estimated to be about 10 20Mb but the resolution can be much higher according to the 
percentage of loss or gain of the chromosomes. For example, in case of no copies present 
at a region (100% deletion) the resolution can be up to 1 2MB (Lapierre and Tachdjian, 
2005). 
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For research purposes single blastomere m CGH was first applied 1999 (Wells et al., 
1999; Voullaire et al., 1999). The first clinical PGS cases using m CGH were reported in 
in 2001 with single blastomeres and 2002 with polar bodies (Wilton et al., 2001; Wells et 
al., 2002). However, a crucial problem with m CGH is that it requires five days for the 
experimental procedure and analysis and the embryos have to be cryopreserved which 
decreases  implantation  rates  (Wilton,  2004).  Polar  body  diagnosis  does  not  require 
cryopreservation (Obradors et al., 2008).  In addition, the amount of DNA available from 
a single cell is 6 12pg whereas a normal m CGH experiment would require microgram 
quantities of DNA. This problem was solved with the use of WGA techniques. 
 
1.5.7 Array comparative genomic hybridisation 
 
Microarrays are the most powerful tool in genetics as it allows the analysis of thousands 
of results simultaneously in a fast, reliable and sensitive way (Glentis et al., 2006a). The 
development  started  in  the  mid  1980s  from  two  other  techniques;  enzyme linked 
immunosorbent assay (ELISA) which was used for specific protein detection and dot 
blotting which was used for specific nucleic acid detection. The progress of microarrays 
has  been  very  rapid,  especially  with  the  use  of  chemiluminescent  and  fluorescent 
substances instead of immunoassays, which are much more sensitive, and the use of  an 
inert solid support, which is much more amenable to miniaturisation and fluorescence 
based detection, so that the reaction could be restricted in microspots allocated in the 
solid  support  (Ekins  and  Chu,  1999).  Microarrays  were  first  developed  for  gene 
expression  analysis  but  they  were  soon  used  for  cytogenetic  analysis.  This  type  of 
microarray was named a CGH and was first reported in 1997 (Solinas Toldo et al., 1997). 
Since the human genome project has been completed the main interest in genetics is to 
understand  how  changes  at  the  molecular  and  chromosomal  level  can  lead  to  the 
complexity of the eukaryotic cellular network and how some changes may lead to genetic 
diseases and syndromes (Sevenet and Cussenot, 2003). 
 
A CGH is very similar and has the same principle as m CGH. The basic difference is that 
the  target  DNA  for  hybridisation  is  not  metaphase  chromosomes  but  cloned  DNA   40 
segments, like BACs, PCR generated sequences, cDNA clones or oligonucleotides. The 
use of cloned DNA segments allows automated and faster analysis of the results, higher 
resolution  according  to  the  number  of  target  DNA  spotted  on  the  array  and  greater 
sensitivity due to the fluorescent dyes used (Shaffer and Bejjani, 2004). A CGH has been 
very useful in various fields and especially in areas where undiagnosed and unknown 
cytogenetic  malformations  may  occur,  such  as  cancer  studies,  cases  of  unexplained 
mental retardation and spontaneous abortions (Schaeffer et al., 2004). The high resolution 
and the automation of the technique provide a clear advantage over karyotyping, FISH 
and m CGH. 
 
 Apart  from  research  purposes,  a CGH  could  be  very  helpful  for  clinical  cytogenetic 
diagnosis and especially for prenatal diagnosis and PGS. However, the diagnosis could be 
difficult and tricky due to the huge amount of information provided by an array. As many 
regions  of  the  genome  include  unknown  polymorphisms  and  copy  number  variants 
(variant regions of at least 1,000bp in length) with unknown clinical outcome, a high 
resolution analysis of prenatal samples or single blastomeres make the interpretation of 
such experiments even more difficult (Shaffer and Bejjani, 2004). 
 
As it is a very complex process, there is much time and effort required in order to design 
a microarray experiment so that it is biologically and statistically robust. Many different 
technologies and strategies for DNA microarrays have been developed for DNA probes, 
labelling,  platforms,  fabrication  types,  scanning,  and  data  analysis  and  interpretation, 
each with advantages and disadvantages (Glentis et al., 2006a). In order to use the most 
appropriate  microarray  for  the  experiment,  all  the  different  technologies  must  be 
considered (Cheung et al., 1999). 
 
1.5.7.1 Probes 
 
The first step of a microarray experiment is to select the probes that will be immobilised 
to the platform. There are two basic types of probes for producing DNA microarrays; pre 
synthesised  DNA or in  situ synthesised oligonucleotides (Cheung et al., 1999).  Pre   41 
synthesised  DNA  probes  can  be  PCR  fragments  or  genomic  fragments  derived  from 
library clones, such as BAC vectors and bacteriophage P1 vectors. The length of DNA 
clones varies from 200 bp up to several kilo bases. Oligonucleotide probes are usually 
20 80 mer long and are synthesised either on the microarray platform or by conventional 
synthesis before immobilisation to the platform (Choudhuri, 2004). 
 
1.5.7.2 Microarray Platforms 
 
One of the features of microarrays is the use of solid platforms on which probes are 
immobilised.  Solid  platforms  can  be  made  from  silicon based  materials  or  synthetic 
polymers, such as nylon, nitrocellulose and glass (Cai et al., 2002). Research on different 
types  of  surfaces  to  which  DNA  can  bind  has  lead  to  the  conclusion  that  solid, 
impermeable surfaces have a variety of advantages over porous membranes and gel pads 
(McGall, 1997). The solid membranes are non porous and the liquid cannot penetrate the 
surface,  which  gives  direct  access  to  the  targets  to  hybridise  to  the  probes  without 
diffusing  in  the  pores.  Good  mixing  is  required  to  enhance  the  rate  of  hybridisation 
(Duggan  et  al.,  1999).  The  washing  step  is  much  easier,  faster  and  improves 
reproducibility because there is no diffusion in surfaces made from rigid substrates. In 
addition,  characteristics  like  flatness,  rigidity  and  transparency  are  advantageous  for 
image acquisition and processing.  Finally, solid platforms benefit the incorporation into 
flow  cells  for  the  automated  process  which  is  essential  for  high  throughput  analysis 
(Duggan et al., 1999). 
 
Glass surfaces also have unique advantages over nylon and other solid surfaces used to 
make microarrays. DNA can attach both covalently and non covalently on glass surfaces 
according to how they have been treated (Baum et al., 2003). Glass surfaces are more 
tolerant  to  high  temperature  and  washes  with  high  ionic  strength  compared  to  other 
surfaces. Glass helps minimize the background noise to signal ratio because it has low 
fluorescence.  Two  different  targets  can  be  labelled  with  different  fluorochromes  and 
simultaneously incubated to the microarray in a single reaction, something that it is not 
possible with nylon surfaces (Baum et al., 2003).   42 
 
1.5.7.3 Fabrication 
 
There are two main methods for immobilising the probes on the microarray platforms; 
the in situ synthesis and the deposition by spotting. The photolithographic technique or 
chemical synthesis is used for in situ synthesis of the oligonucleotides (Choudhuri, 2004). 
The  photolithographic  method  uses  synthetic  linkers  that  are  modified  with 
photochemically removable protecting groups and photolithographic masks to direct the 
light in the desired areas (Lipshutz et al., 1999). New photolithographic methods have 
been developed that use a digital micromirror device (DMD) and digital light processor 
(DLP) with the advantage being that high density arrays can be produced in a cheaper 
way (Hardiman, 2004). 
 
In spotting arrays, the probes are usually chosen from databases (GenBank, dbEST and 
UniGene) (Bowtell, 1999). The DNA has to be purified so that there is no contamination 
to the microarray platform. In PCR the DNA is usually purified by precipitation and gel 
filtration  in  order  to  remove  salts,  detergents,  PCR  primers,  proteins  and  cellular 
components that are usually found in the PCR mixture (Duggan et al., 1999). Robotic 
technology is then used in order to collect and deposit the purified DNA. The DNA 
transfer uses pins or needles (Choudhuri, 2004). The printing is achieved by contact of 
the pin with the surface that delivers the solution. The pins are moved to the next spot and 
the cycle is repeated. A few thousand to 30,000 probes can be printed on the microarray 
surface.  The  performance  of  the  high speed  robotics  mainly  relies  on  the  shape, 
reproducibility  and  durability  of  the  pins  (Bowtell,  1999).  Uneven  pins  may  deliver 
unequal DNA solution and influence the analysis of the experiment. Ink jetting is a more 
advanced technique that has been developed which sprays the DNA on the surface. The 
advantage is there is no contact between the pin and the solid surface and so ink jetting 
ensures that the spots have a more uniform size (Choudhuri, 2004). 
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1.5.7.4 DNA sample labelling 
 
The next step of a microarray experiment is to label the sample DNA that will hybridise 
with the probes. One crucial factor is the purification of the targets prior to labelling 
because  cellular  components,  such  as  proteins,  lipids  and  carbohydrates  can  mediate 
significant non specific binding of the labelled targets to the solid surface (Duggan et al., 
1999). Two colour experiments are conducted for a CGH where two different labelled 
samples  (target  and  control)  are  co hybridised  in  a  competitive  way  and  results  are 
defined in ratiometric terms (Hardiman, 2004). Radioactive elements, such as 
35P dCTP, 
are  not  ideal  for  microarray  experiments  because  of  the  microarrays  physiology. 
Microarray elements are physically close to each other and strong hybridisation with a 
radioactive target may cause problems as it can easily interfere with detection of weak 
hybridisation in surrounding targets. Fluorescent labels (cyanine Cy3 and Cy5 and Alexa 
fluor 555 and 647 dyes) have many advantages. They have good photostability and yield 
and they are widely separated in their excitation and emission spectra allowing highly 
discriminating optical filtration (Duggan et al., 1999). 
 
Labelling can be achieved with direct or indirect incorporation of the fluorochromes in 
the DNA samples. In direct incorporation, fluorochromes incorporate to the DNA sample 
directly with the use of Klenow fragment enzyme whereas in indirect incorporation there 
is  a  two  step  reaction.  First  amino allyl  deoxyridine  trisphosphate  (AA dUTP)  is 
incorporated in the nucleic acid and then the fluorochromes bind to the nucleic acid by 
chemical coupling with AA dUTP. 
 
1.6 Prenatal diagnosis and screening 
 
Prenatal  testing  can  be  separated  in  screening  and  diagnosis.  Screening  tests  involve 
ultrasonography for the visualisation and examination of the fetus by appraising different 
measurements,  such  as  nuchal  translucency,  and  maternal  serum  screening  which 
measures the levels of specific proteints, such as pregnancy associated plasma protein A 
(PAPP A), α feto protein, inhibin A, β human chorionic gonadotrophin (hCG), hyper   44 
glycosated  hCG  and  oestiol  in  the  maternal  blood.  Screening  is  not  100%  accurate. 
Invasive diagnosis methods are performed in pregnant women who have a history of 
previous miscarriages, have a genetic condition in the family, or when ultrasound and 
maternal  serum  screening  have  shown  indications  for  congenital  malformation  of  the 
fetus. The diagnostic tests include amniocentesis and chorionic villus sampling (CVS) in 
which fetal DNA is obtained for genetic diagnosis from which an accurate result can be 
obtained. Amniotic fluid is collected by amniocentesis between the 14
th and the 20
th week 
of gestation whereas chorionic villi are collected by CVS from 9.5 until 12.5 weeks. Fetal 
DNA  is  extracted  for  molecular  or  molecular  cytogenetic  analysis  or  fetal  cells  are 
cultured  and  prepared  for  cytogenetic  analysis  of  chromosomal  abnormalities  by 
karyotyping. 
 
Another alternative invasive technique for prenatal diagnosis is coelocentesis in which 
coelomic fluid is aspired in order to obtain fetal cells (Jurkovic et al., 1993). Coelomic 
fluid is present inside the exo coelomic cavity which is developed in pregnancies in the 
4
th week (Boyd and Hamilton, 1967). The exo coelomic cavity is formed by a membrane 
that separates it from the amniotic cavity and is clearly identified with the use of high 
resolution trans vaginal ultrasound (Jauniaux et al., 2003). Coelomic fluid can be aspired 
from the 5
th until the 12
th week of gestation with the use of a needle that is trans vaginal 
inserted into the exo coelomic cavity under ultrasound guidance. The great advantage of 
this technique is that prenatal diagnosis can be done much earlier compared to the other 
techniques.  However,  the  limited  amount  of  DNA  is  a  major  drawback  for  clinical 
application and it is currently not performed for prenatal diagnosis.  
 
1.7 Aims 
 
Whole genome amplification can be considered a powerful tool in molecular biology, 
especially  in  the  fields  where  DNA  is  limited  and  precious.  Very  good  results  are 
achieved  when  the  starting  DNA  template  is  more  than  1ng  and  is  good  quality. 
However,  in  many  genetic  fields  good  quality  DNA  and  such  quantities  cannot  be 
obtained. In PGD, where the DNA derives from a single cell only, WGA could be the key 
for  overcoming  the  majority  of  the  problems  that  are  encountered  in  single  cell   45 
diagnostics. The main aim of this project was to produce WGA products from single cells 
or small numbers of cells in order to achieve robust and reliable molecular and molecular 
cytogenetic analysis. This project concentrated on the advantages and disadvantages of 
different techniques to determine when and how WGA could be useful when there are 
small quantities of DNA. Although the main focus was on PGD, single cell analysis 
could  be  very  useful  in  different  areas,  including  blastomere  research  on  aneuploid 
mechanisms, prenatal diagnosis, cancer research and forensic sciences. 
 
The project was separated in to three chapters. In the first chapter, single cell WGA was 
evaluated for molecular analysis with the use of PCR. PCR is one of the fundamental 
tools of molecular biology and it is widely used in clinical PGD for monogenic diseases. 
However, at the single cell level, optimisation of a PCR protocol is difficult and time 
consuming,  whereas  more  DNA  would  be  beneficial  for  performing  multiple 
experiments, haplotyping and repeating an experiment that has failed. Hypothesis: Can 
MDA be used as a universal step prior to molecular analysis for PGD? 
 
The aim of the molecular project was to assess the efficiency and the accuracy of MDA 
on  single  cells  using  well  established  PCR  protocols  that  have  been  optimised  and 
applied  in  clinical  PGD.  The  reason  for  choosing  optimised  PCR  protocols  was  to 
eliminate  the  chances  that  experiments  would  not  work  due  to  PCR  insufficiency. 
Different  cell  types  (lymphocytes,  fibroblasts,  buccal  cells  and  blastomeres)  were 
considered and compared. Each cell type may respond differently due to different DNA 
quality  and  compaction.  Although  blastomeres  are  the  key  cell  types  for  PGD, 
lymphocytes  and  buccal  cells  are  widely  used  for  optimisation  protocols  prior  to  a 
clinical case. Cell types that respond in a similar way to blastomeres should be used for 
optimisation of clinical PGD cases. Three different lysis methods were compared for the 
lysis of the cells prior to WGA as lysis plays a crucial role in the way the DNA becomes 
accessible  to  the  WGA  enzymes.  These  were  an  enzymatic  lysis  (proteinase  K),  an 
osmotic lysis (alkaline lysis buffer, ALB) and a modification of the ALB lysis where 
DTT  was  excluded  from  the  lysis  buffer.  DTT  was  excluded  in  the  ALB  modified 
method because it has been may damage the DNA (Spits et al., 2006). For the molecular   46 
project  the  only  WGA  method  used  was  MDA  because  it  is  the  only  method  that 
produces long DNA strands which are necessary for molecular analysis when the DNA 
comes from a single cell. 
 
In the second chapter two different WGA techniques were used to amplify DNA from 
single cells and then the products were analysed by a CGH. Hypothesis: Is it possible to 
accurately assess the chromosomes of a single cell by a CGH?  
 
The WGA techniques used were MDA and GenomePlex, which give the best genomic 
representation  and  the  minimum  amplification  bias.  Lymphocytes,  fibroblasts  and 
blastomeres  were  used  as  sources  of  single  cells  to  obtain  DNA.  Buccal  cells  were 
excluded from this project due to their poor quality of DNA. Proteinase K and ALB 
without DTT were used for single cell lysis. BAC a CGH slides of different resolutions 
(10MB 100KB) were used. The aims of this project were to test if WGA products from 
single cells can be applied in a CGH and if a high resolution could be achieved in order 
to  detect  small  chromosome  abnormalities.  The  motivation  for  this  project  was  that 
microarrays are considered to be a very powerful tool in molecular biology and they were 
tested to determine if they would work at the single cell level. The benefits of optimising 
single cell a CGH would not only be reflective in clinical PGD and PGS but it could also 
invade research areas related to single cells, including tumour cells, where chromosomal 
analysis  of  the  entire  genome  of  specific  cells  would  be  achieved.  Although  WGA 
products from single cells have been successfully applied in m CGH, the use of a CGH 
could increase the resolution analysis, minimise the time for diagnosis and will automate 
the technique. 
 
In the final chapter, DNA extracted from coelomic fluid was amplified by MDA and 
GenomePlex  and  analysed  by  a CGH.  Hypothesis:  Can  aneuploidy  be  detected  in 
coelomic fluid using a CGH? 
 
The aim of this project was to assess if DNA extracted from coelomic fluid could be 
successfully analysed by a CGH. The challenge of this project was that the poor quality   47 
and very small amount of DNA present in coelomic fluid may hamper the analysis by a 
CGH. Because minimum collection of coelomic fluid has been suggested to limit fetal 
loss by coelocentesis, the maximum volume of coelomic fluid used for WGA was 1ml 
whereas in two cases WGA was applied directly on 5 l of coelomic fluid without DNA 
extraction. Although FISH and PCR experiments have been successfully performed with 
coelomic fluid samples, a CGH had not been previously achieved. A limited factor for 
not performing coelocentesis for early prenatal diagnosis is the poor quality and quantity 
of  DNA  obtained.  However,  overcoming  this  problem  with  WGA  and  managing 
successful application of a CGH on coelomic fluid samples would enhance the use of 
coelocentesis as a new technique of early prenatal diagnosis.  
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Chapter 2 
 
Materials and methods 
 
2.1 General 
 
Materials and methods that are specific for each chapter are written within each chapter 
separately. In this chapter all the materials and methods that were used in all or most 
chapters  are  described,  including  DNA  extraction,  single  cell  lysis  and  isolation  and 
whole genome amplification.  
 
2.2.1 DNA extraction from blood 
 
Generally, good quality DNA for positive controls and STR allele sizes was obtained 
from whole blood after a standard DNA extraction protocol. The materials related with 
DNA extraction are listed in appendix A2. For DNA extraction, 5ml of blood collected in 
ethylenediaminetetraacetic acid (EDTA) tubes were mixed with the same amount of low 
salt buffer TKM1 in a 14ml centrifuge tube. Then, 125 l of the detergent Igepal (Sigma, 
UK) was added in order to lyse the cells and the solution was mixed well and centrifuged 
at 2,200 rpm for 10 minutes. The supernatant was discarded and the remaining pellet was 
re suspended in 5ml of TKM1 and 125 l of Igepal, mixed and centrifuged at 2,200 rpm 
for 10 minutes. This was repeated a number of times until the redness of the pellet was 
reduced. The pellet was re suspended in 100 l of TKM1 and the sample was transferred 
to a 1.5ml microfuge tube (Eppendorf, UK). In the solution, 0.8ml of TKM2 and 50 l of 
10% sodium dodecyl sulphate (SDS; Sigma, UK) were added and mixed well in order to 
lyse the white blood cells. The sample was incubated at 55
oC for 30 minutes or longer 
until  the  lumps  had  gone.  Then  300 l  of  6M  NaCl  were  added,  mixed  well  and 
centrifuged at 12,000 for 5 min. The supernatant was transferred into two new 1.5ml 
microfuge tubes and the pellet was discarded. The DNA was precipitated by adding 1ml 
of 100% ice cold ethanol and mixing gently. The sample was centrifuged at 13,000 rpm 
for 10 minutes, the supernatant was discarded and the pellet was re suspended in 1ml of 
ice cold  70%  ethanol.  The  sample  was  centrifuged  for  5  minutes  at  10,000  rpm,  the   49 
supernatant was discarded and the pellet was left to air dry for 5 minutes. Finally, 50 l of 
TE buffer (10mM Tris; 1mM EDTA pH 8.0) was added to the sample.   
 
2.2.2 Culturing, collection and DNA extraction from skin fibroblasts 
 
DNA extracted from fibroblasts was used for molecular and cytogenetic experiments. 
Two trisomic fetal skin fibroblast cultures were provided from frozen cell stocks that 
grew in monolayer cultures at 37
oC. For cell collection, the cell culture medium was 
poured off and 5ml of prewarmed (37
oC) Hank’s medium was added to wash the cells. 
After a few seconds, the solution was substituted with 5ml of 0.25% trypsin/Versene 
solution at 37
oC and the flask was incubated at 37
oC for 5 minutes. During this period 
most of the cells were detached from the flasks and could be seen under an inverted 
microscope. A few drops of fetal calf serum were added in order to inactivate the trypsin 
and  the  cell  suspension  was  placed  into  centrifuge  tubes  and  spun  for  5  minutes  at 
1000rpm. Following centrifugation, most of the supernatant was discarded and 2ml of 
PBS was added in order to resuspend the pellet. The cell suspension could be used for 
DNA extraction, single cell isolation and slide preparation for FISH. 
 
For DNA extraction the cells were lysed by the addition of 2.5ml proteinase K solution 
and incubated at 37
oC for 30 minutes. Equal volumes of isopropanol were added to the 
tubes in order to precipitate the DNA and with the use of sterile inoculation loops the 
DNA  was  transferred  into  microcentrifuge  tubes.  The  DNA  was  centrifuged  for  5 
minutes at 10,000 rpm, the supernatant was discarded and the pellet was left to dry at 
room temperature for 5 minutes. The DNA was finally suspended in 200 l of TE buffer 
and stored at 4
oC. 
 
2.2.3 Lymphocyte and buccal cells collection 
 
Lymphocytes and buccal cells that were used for the projects had to be collected prior to 
single cell isolation and cell lysis. All the materials regarding cell collection, single cell 
isolation and cell lysis are listed in appendix A4. For lymphocytes, suspensions were   50 
obtained from normal individuals after fresh whole blood collection in lithium heparin 
tubes. Six ml of the collected blood was mixed with 6ml of saline (0.9% NaCl) solution 
in a 14ml centrifuge tube (blood/saline: 1/1). The mixture was transferred into another 
14ml centrifuge tube that contained  Ficoll Paque plus (Sigma, UK). The blood/saline 
solution was dropped gently in a way that it formed a layer on top of the Ficoll Paque 
plus without mixing it. The amount of blood/saline solution/Ficoll–Paque plus was 4/3. 
The  sample  was  centrifuged  at  1300  rpm  for  30  minutes  and  the  centrifuge  stopped 
slowly without the use of the brake. After centrifugation the lymphocytes formed a buffy 
coat in the middle of the tube and were transferred into a new 14ml tube. The tube was 
filled up with saline solution and the solution was mixed. The solution was centrifuged 
for another 15 min at 1300 rpm. The supernatant was discarded and the remaining pellet 
was dissolved in 2ml of saline solution. After dissolving the pellet the tube was filled up 
with  saline  and  the  solution  was  centrifuged  again  for  15  min  at  1300  rpm.  The 
supernatant  was  discarded  and  the  remaining  pellet  was  dissolved  in  2ml  of  saline 
solution. The cells were stored on ice for single cell isolation or for FISH experiments for 
a maximum of 16 hours.  
 
Buccal cells were collected from the buccal cavity by rubbing it with a sterile swab and 
transferred in a sterile 1.5ml tube with 1ml of phosphate buffer saline (PBS, Sigma, UK) 
and polyvinyl alcohol (PVA, Sigma, UK) (1g of PVA in 50ml of PBS) (Gibco, UK). The 
cells were stored for up to one day at 4
oC.  
 
2.3 Single cell isolation and cell lysis 
 
The single cell isolation protocol was different according to the type of cell lysis that was 
used. There were two single cell isolation protocols; alkaline (ALB lysis) and proteinase 
K (PK lysis). 
 
In order to isolate single cells, a small drop (~10 l) of the cell suspension was placed into 
a plastic Petri dish. For alkaline lysis, drops of dissociation buffer (DB; 140mM NaCl, 
0.2mM KCl, 0.04mM NaH2PO4 X 2H2O, 5.5mM glucose, 1.2mM NaHCO3, 0.02mM   51 
EDTA, and 0.01% (w/v) phenol red) (Sigma, UK) containing 1 mg/ml bovine serum 
albumin (BSA, Sigma, UK) were dropped onto another plastic Petri dish. Single cells 
were  picked  up  under  an  inverted  microscope  by  a  plastic  capillary  using  aspiratory 
micromanipulation
 and they were washed three times in the DB drops. The isolated cells 
were transferred by aspiration to a 0.5ml tube which contained 2.5 l of alkaline lysis 
buffer. The alkaline lysis buffer consisted of 200mM KOH (lysis 1, L1) or 200mM KOH 
and 50mM dithiothreitol (DTT, Sigma,  UK)  (lysis 2, L2) (table 2.1). The cells were 
incubated at  80
oC for at least 30 minutes and the cell lysis was completed by incubating 
the tubes that contained the cells at 65
oC for 10 minutes. 
 
For PK lysis, drops of PBS/PVA were dropped onto the plastic Petri dish. Similar to the 
alkaline lysis, single cells were picked up under the microscope
 by a plastic capillary 
using aspiratory micromanipulation
 and after washing three times in the PBS/PVA drops 
to ensure the single cell isolation, they were transferred by aspiration to a 0.5ml tube 
which contained 1 l of cold 17 M SDS (Sigma, UK) and 2 l of 125 g/ml proteinase K 
(Roche  Diagnostics,  USA)  (lysis  3,  L3)  (table  2.1).  The  lysis  was  completed  by 
incubating the mixture at 37
oC for 1 hour and then inactivating the enzyme at 95
oC for 15 
minutes in a PCR machine (Eppendorf, UK). The lysed cells where stored at 4
oC for 
immediate use or stored at  80
oC for use within a week (Table 2.1). 
 
A negative control sample was collected after each cell was isolated by touching the 
capillary to the last drop that contained the isolated cell and transferring the volume to a 
new tube containing one of the lysis buffers. The negative samples were stored at  80
oC 
and  used  directly  for  single  cell  PCR  for  the  DM  triplex  to  ensure  absence  of 
contamination. 
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Lysis 
method 
Isolation 
medium  Type of lysis  Characteristics 
L1  Dissociation 
buffer with BSA   Alkaline (200mM KOH)  Osmotic (burst the cell) milder 
without DTT in buffer 
L2  Dissociation 
buffer with BSA 
Alkaline (200mM KOH 
with 50mM DTT) 
Osmotic (burst the cell) 
stronger with DTT in buffer 
L3  PBS/PVA  Enzymatic (proteinase K)  Enzymatic lysis (digestion of 
proteins and free the DNA) 
Table 2.1: Summary of different lysis methods used for single cell lysis. This table 
summarises the three different lysis methods used; alkaline lysis without DTT, alkaline 
lysis with DTT and enzymatic lysis with the use of proteinase K. 
 
2.4 Whole genome amplification 
 
Two  different  methods  of  whole  genome  amplification,  the  isothermal  method  of 
multiple  displacement  amplification  (MDA,  Qiagen,  UK)  and  the  PCR based  method 
using  fragmentation  of  DNA  and  universal  primers  (GenomePlex,  Sigma,  UK),  were 
applied on genomic DNA and single cells before using these products for molecular or 
molecular  cytogenetic  analysis.  WGA  both  for  MDA  and  for  GenomePlex  was 
accomplished with the use of kits from companies. All the reagents and materials used 
for  MDA  and  GenomePlex  reactions  are  listed  on  appendix  A5.  A  total  of  seven 
protocols were produced (four protocols for MDA products and three protocols for the 
GenomePlex reactions) for the amplification of single cells and gDNA (table 2.2). 
 
2.4.1 MDA 
 
MDA amplification was achieved using the Repli g Midi kit (Qiagen, UK). For single 
cells, the MDA reaction took place after cell lysis from one of the previous mentioned 
lysis methods (L1, L2 and L3, section 2.3). The protocol followed was the one proposed 
by the company for gDNA. Briefly, 2.5 l of denaturation buffer (D1; 15% reconstituted 
DLB buffer) was added to the ~3 l of lysed product and incubated at room temperature 
for 3 minutes. Then 5 l of neutralisation buffer (N1; 10% of Stop solution) was added to 
mixture.  A  master  mix  of  10 l  dH2O,  29 l  Repli g  buffer  and  1 l  Repli g  DNA  53 
 
Protocol 
name 
DNA 
source 
Lysis 
Method 
WGA 
technique 
Denaturation 
of DNA  Neutralisation  Amplification 
method  Modifications 
P1  Single cell  L1, L2 or L3  MDA  2.5 l D1  5 l N1  30
oC for 6 
hours 
MDA company original 
protocol for gDNA 
P2  Single cell  L1  MDA  2.5 l D1  5 l N1  30
oC for 2 
hours 
2 hours incubation instead 
of 6 hours 
P3  gDNA     MDA  5 l D1  10 l N1  30
oC for 2 
hours 
2 hours incubation instead 
of 6 hours 
P4  Coelomic 
fluid 
L2 (from 
WGA kit)  MDA  3.5 l D2  3.5 l Stop 
solution 
30
oC for 2 
hours 
2 hours incubation, MDA 
company protocol for direct 
application on tissues 
P5  gDNA     GenomePlex 
WGA2 
95
oC for 4 
minutes     14 PCR cycles  WGA2 company original 
protocol 
P6  Single cell  L3 (from 
WGA kit) 
GenomePlex 
WGA4 
99
oC for 4 
minutes     25 PCR cycles  WGA4 company original 
protocol 
P7  Single cell  L1  GenomePlex 
WGA4 
99
oC for 4 
minutes  5 l N1  25 PCR cycles  WGA4 ALB L1 lysis, no 
incubation with PK enzyme 
Table 2.2: Protocols of DNA source and modifications of the WGA techniques. This table summarises all the different protocols of 
WGA applied for the molecular and a-CGH projects. Protocol P1 was used for the molecular project, protocols P2, P3, P6 and P7 
were used for the single cell a-CGH project and protocols P3, P4 and P5 were used for the coelomic fluid a-CGH project. 
 D1: denaturation buffer 1 
D2: denaturation buffer 2 
N1: Neutralisation buffer 1 
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polymerase for each sample was prepared and 40 l of the master mix was added to each 
sample. Finally the tubes were incubated at 30
oC for 6 hours (protocol 1, P1) or 2 hours 
(protocol  2,  P2).  The  reaction  was  terminated  by  heating  the  samples  at  65
oC  for  3 
minutes and storing them at 4
oC.  
 
For gDNA the initial DNA template used was 5 l. The protocol used (protocol 3, P3) 
was very similar to P2 with the only differences being double amount of D1 (5 l instead 
of 2.5 l) and N1 (10 l instead of 5 l) added to the DNA template and difference in the 
master mix (30 l including 29 l Repli g buffer and 1 l Repli g DNA polymerase instead 
of 40 l master mix which had an additional 10 l of dH2O). The incubation time for 
gDNA was 2 hours at 30
oC. 
 
For the prenatal chapter (chapter 5) direct amplification of 5 l coelomic fluid without 
previous DNA extraction was accomplished (protocol 4, P4). Briefly, 5 l of coelomic 
fluid  was  mixed  with  3.5 l  of  denaturation  buffer  D2  (5 l  of  1M  DTT,  55 l  of 
reconstituted buffer DLB) and incubated for 10 minutes on ice followed by 3.5 l of Stop 
solution.  A  master  mix  of  8 l  dH2O,  29 l  Repli g  buffer  and  1 l  Repli g  DNA 
polymerase for each sample was prepared and 38 l of the master mix was added to each 
sample. The tubes were incubated at 30
oC for 2 hours (protocol 4, P4) and the reaction 
was terminated by heating the samples at 65
oC for 3 minutes before storing them at 4
oC. 
 
2.4.2 GenomePlex 
 
Two  kits  were  used  for  amplification  of  DNA;  the  WGA2  kit  (WGA2;  Sigma,  UK) 
which was used for the amplification of gDNA and the WGA4 kit (WGA4; Sigma, UK) 
which was used for the amplification of single cells. 
 
With the WGA2 kit, 1 l of 10x DNA fragmentation buffer was added to 10 l gDNA in a 
0.5ml PCR tube. The mixture was first heated exactly for 4 minutes at 95
oC and then 
cooled on ice immediately. After brief vortexing and centrifugation to consolidate the 
products, 2 l and 1 l of 1x library preparation buffer and library stabilisation solution   55 
respectively were added to the sample. The mixture was heated at 95
oC for 2 minutes and 
cooled on ice. For OmniPlex library generation, 1 l of library preparation enzyme was 
added, the samples were vortexed and centrifuged briefly and incubated in a thermal 
cycler at 16
oC for 20 minutes, then at 24
oC for 20 minutes and finally at 37
oC for 20 
minutes. The reaction was terminated by heating the samples at 75
oC for 5 minutes and 
storing  at  4
oC.  For  the  PCR  amplification,  a  master  mix  consisting  of  7.5 l  of  10x 
amplification  master  mixes,  47.5 l  of  nuclease free  H2O  and  5 l  of  WGA  DNA 
polymerase per reaction was formed and 60 l of this master mix was added to each 
sample. The PCR amplification consisted of an initial denaturation step of 95
oC for 3 
minutes followed by 14 cycles with a denaturation step of 94
oC for 15 seconds and an 
anneal/extension step of 65
oC for 5 minutes. The samples were stored at 4
oC or  20
oC 
(protocol 5, P5). 
 
For single cells the GenomePlex Single Cell WGA Kit (WGA4) was used. The protocol 
used was very similar to P5 with the difference that an enzymatic lysis method was also 
included prior to DNA fragmentation (protocol 6, P6). For the cell lysis, 8 l of nuclease 
free H2O were added to the tube which contained the single cell in PBS/PVA solution in 
order for the volume to reach 9 l. A fresh lysis and fragmentation buffer solution were 
prepared (2 l of proteinase K solution and 32 l of 10x single cell lysis and fragmentation 
buffer) and 1 l was added to the tube. The mixture was vortexed and centrifuged briefly 
prior to incubation at 50
oC for 1 hour and then heated at 99
oC for four minutes. After that 
stage the protocol was identical to P5 with the exception of the final thermocycling step 
in which the products were first denatured at 95
oC for 3 minutes and then 25 cycles were 
performed  that  had  a  denaturation  step  of  94
oC  for  30  seconds  followed  by  an 
annealing/extension step of 65
oC for 5 minutes. 
 
A modified protocol for the GenomePlex Single Cell WGA Kit was also introduced in 
which the cell was lysed by the L1 method (protocol 7, P7). In this case the proteinase K 
solution was substituted by nuclease free water and the samples were not incubated at 
50
oC for 1 hour. A summary of the different protocols for WGA are listed on table 2.2.  
   56 
Chapter 3 
 
Molecular analysis of MDA products from single cells 
 
3.1 Hypothesis 
 
The hypothesis is that MDA can be used as a universal step prior to molecular analysis 
for PGD. 
 
 In order to address this hypothesis, the efficiency and accuracy of MDA as a method of 
WGA was measured on different cell types (buccal cells, lymphocytes, fibroblasts and 
blastomeres) and lysis methods (osmotic lysis L1 and L2 and enzymatic lysis L3) using 
two multiplex PCR protocols (DM I and CF) that had been optimised and applied in 
clinical PGD. The findings would be beneficial both for research and clinical PGD and 
could  also  be  useful  in  other  fields  where  the  DNA  is  limited.  The  advantages  and 
disadvantages of the use of MDA on single cells can be identified in order to obtain the 
best use of this technique in PGD. 
 
3.2 Introduction 
 
MDA seems to give the best results when the initial DNA template is from good quality 
gDNA compared to most PCR based techniques (Lasken et al., 2005). MDA superiority 
is due to greater genome coverage, less amplification bias and lower polymerase error 
rate. MDA’s big advantage over GenomePlex is the high molecular weight products that 
are produced. Thus, GenomePlex could not be used for single cell amplification prior to 
PCR due to the low molecular products that produces. So far studies with MDA on DNA 
sources  of  limited  amount  include  microbial  genomes  (Lasken,  2007),  bovine 
blastomeres  (Hirayama  et  al.,  2006),  blood  spots  (Dean  et  al.,  2002),  epidemiologic 
studies on buccal cytobrush (Moore et al., 2007) and forensic studies (Barber and Foran, 
2006).  MDA application on single cells for PGD have been reported both for clinical and 
research purposes (Ren et al., 2007; Renwick et al., 2006; Lledo et al., 2006; Burlet et al.,   57 
2006;  Hellani  et  al.,  2005).  The  main  advantage  of MDA  in  single  cells  is  the  final 
volume of DNA which is created and it can be used for PGH (Renwick et al., 2006), 
HLA  typing  (Hellani  et  al.,  2005)  and  for  multiple  tests  to  minimise  the  chance  of 
misdiagnosis  (Obradors  et  al.,  2008).  Although  all  the  WGA  methods  produce  large 
amounts of DNA, the PCR based WGA methods cannot be used in molecular analysis 
due to the short DNA products that are produced. This is because in single cell PCR there 
are only two copies of the genome and there is a high risk of the DNA being cut in the 
area that would be the target for PCR amplification. So in this chapter only MDA was 
used as a WGA method. 
 
The main disadvantage encountered with Phi29 polymerase is the requirement of a high 
quality of DNA in order to obtain best results (Hughes et al., 2005; Lage et al., 2003). 
Different groups have shown the only underrepresented regions of the genome are those 
in the proximity of the duplex ends which are usually abundant in degraded and damaged 
DNA (Panelli et al., 2006). MDA did not perform as expected in samples where the 
starting material was from lower molecular weight, such as paraffin embedded clinical 
samples and deteriorated forensic samples (Wang et al., 2004; Lage et al., 2003). 
 
In single cell studies the quality of DNA is largely dependent on the cell type and cell 
lysis used in order for MDA to have access to the DNA. In PGD different cell types such 
as buccal cells and lymphocytes are routinely used to design and optimise new PGD 
protocols prior to application to blastomeres (Thornhill et al., 2005). Buccal cells are 
easily  obtained  from  patients  and  are  larger  cells compared  to  lymphocytes  but  their 
DNA  is  considered  of  poor  quality  as  they  have  entered  the  phase  of  apoptosis 
(Piyamongkol et al., 2003).  The quality of the DNA is also dependent on the cell lysis 
used to make the DNA accessible to the polymerase. Two different lysis methods have 
been widely used in single cells; alkaline lysis (ALB) and enzymatic lysis (proteinase K 
lysis).  In this chapter three lysis buffers were used; proteinase K, a standard ALB and a 
modified ALB in which the DTT was excluded as it has been suggested to be harmful for 
DNA (Pierce et al., 2002). The different cell types and cell lysis were used in order to 
determine if and how MDA is influenced by these factors at the single cell level.   58 
 
The optimisation and use of MDA as a universal step in PGD for the amplification of the 
entire genome prior to any molecular analysis would probably be the most efficient and 
reliable  approach  for  PGD  evolution.  This  is  because  designing  multiplex  PCR  and 
optimising  the  reaction  at  the  single  cell  level  can  be  very  laborious  and  expensive 
(Obradors et al., 2008; Henegariu et al., 1997). Usually, a PGD test is specific to the 
family and months of work are needed for optimisation at the single cell level. 
 
Two widely used PGD  tests, which are also used as a model here, are for myotonic 
dystrophy type I (DM I) and cystic fibrosis (CF).  For DM I, the PGD protocol usually 
consists of a PCR product targeted on the specific Dystrophia myotonia protein kinase 
(DMPK) causative gene and two linked markers (less than 1CM apart) in the 19q13.2 
19q13.4 area (Kakourou et al., 2007). The reason for using two linked markers is in case 
of allele drop out (ADO) and total amplification failure (TAF) events. Diagnosis can also 
be based from indirect analysis of these markers rather than the direct detection of the 
mutation marker. In this project APOC2 and D19S112 dinucleotide short tandem repeat 
(STR) markers were chosen because they have already been used in our clinical PGD lab 
and they have high heterozygosity (85.2% and 86.3% respectively). In normal individuals 
the  heterozygosity  level  for  the  DM  (trinucleotide  repeat)  marker  is  72.9%  but  the 
pathogenic alleles are refractory to PCR since the expansion may include thousands of 
repeats (Kakourou et al., 2007). Interestingly, a crossover between the APOC2 and the 
DM  marker  has  been  described  even  though  they  are  considered  as  linked  markers 
illustrating  the  need  for  using  more  than  one  marker  as  confirmation  of  diagnosis 
(Kakourou et al., 2007). For the CF PGD test, the PCR product targets the p.Phe508del 
deletion, which represents the most common cystic fibrosis transmembrane conductance 
regulator (CFTR) gene mutation (a three basepair deletion) and gives a 94bp product for 
the normal allele and a 91bp for the mutant allele with the primers used in this project. 
Other STR markers used for the multiplex PCR are located in the introns or exons of the 
CFTR gene. Two dinucleotide STR markers chosen for this project were located in intron 
17 and 18 of the CFTR gene (IVS17TA and IVS18CA) and have been used in clinical 
PGD in our laboratory (figure 3.1).   59 
 
 
 
 
Figure 3.1: Location of markers on chromosomes 19 and 7. A: This diagram shows 
where and how the STR markers APOC2, DMPK and D19S112 are located and linked on 
chromosome 19. B: The dinucleotide repeats in intron 8 (IVS8CA) and 17 (IVS17TA) are 
shown and how they are located compared to the p.Phe508del mutation marker in the 
CFTR gene. 
 
3.3 Aims 
 
The aim of this study was to perform MDA on single cells and obtain reliable results 
from PCR. It was tested if different cells and cell types would have an affect on MDA at 
the single cell level. 
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3.4 Experimental Design 
 
The molecular results were separated in to two sections, preliminary and main results. 
Preliminary results include basic experiments such as measuring the concentration of the 
DNA  and  the  MDA  products,  determining  the  allele  sizes  obtained  from  the  gDNA, 
testing the negative samples to avoid contamination (negative control) and obtaining the 
results  from  MDA  products  where  the  starting  DNA  template  was  gDNA  (positive 
controls). In addition to these experiments, PCR was applied directly to single cells and 
to MDA products with different lysis methods. After the determination of the best lysis 
method, the main results include experiments with MDA products from different cell 
types.  Qualitative  analysis  of  the  results  was  also  performed  that  concentrate  on  the 
stutter patterns, the peak heights of the results, the ADO rate of the large/small alleles and 
the comparison of 25 and 40 PCR cycles. Figure 3.2 illustrates the experimental design of 
this project. 
 
 
Figure 3.2: Synopsis of the experimental design of this chapter. The diagram shows 
how molecular analysis was performed on single cell MDA products from different cell 
types and lysis methods. 
 
 The  experiments  involved  MDA  products  from  single  buccal  cells,  lymphocytes, 
fibroblasts and blastomeres that were lysed with the L1, L2 or L3 method (section 2.3), 
amplified with the P1 protocol (section 2.4.2, table 2.2) and subjected to triplex PCR. The 
analysis of the results was completed using specific measurements. These were the MDA 
amplification efficiency (MDA AE), the allele drop out (ADO), the total amplification 
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failure  (TAF)  and  the  accuracy  of  the  results.  The  MDA AE  was  calculated  as  the 
number of MDA products that generated a PCR product for at least one of the markers 
tested. The ADO rate was calculated as the percentage of heterozygous loci that appeared 
to be homozygous following PCR of MDA products whereas the TAF rate was calculated 
as the percentage of MDA products that completely failed to amplify by PCR at a given 
locus. The accuracy rate was measured as the percentage of MDA products that gave the 
expected allele size (EAS). In the following colour tables, EAS appears as a green box, 
ADO as blue and TAF as black. In a few cases a red box is shown which indicates that an 
unexpected  allele  size  appeared.  Cells  highlighted  in  black  indicated  that  the  MDA 
amplification had failed and so were excluded from post PCR analysis.  
 
3.5 Materials and methods 
 
3.5.1 DNA materials 
 
The DNA used for the molecular project was obtained from various sources. Two donors 
(A  and  B)  provided  blood  samples  from  which  DNA  was  extracted  and  single 
lymphocytes were collected and lysed as described in sections 2.2.1 and 2.2.3. The same 
individuals also provided buccal cells for single cell isolation and lysis. Skin fibroblast 
cultures that were grown in culture were obtained from two foetuses, one with trisomy 13 
and the other with trisomy 21 (named C and D respectively). Single blastomeres were 
obtained after disaggregation of embryos and their DNA was obtained after single cell 
isolation and cell lysis. The embryos used for this project were from PGS patients that 
were  non   transferable  due  to  chromosomal  abnormalities  found  in  clinical  work.  As 
reported from the embryologists that did the biopsy, all the blastomeres used for the 
molecular project were obtained from day 5 embryos that were previously frozen and 
their quality was validated from 2CC to 4BC. Single blastomeres were collected after 
disaggregation of the embryos using standard PBS/spreading solution (Mantzouratou et 
al.,  2009).  Embryo  handling  and  disaggregation  was  performed  from  Dr  Anna 
Mantzouratou and all the work was performed in a DNA free area which is specialised 
for single cell work. Table 3.1 summarises the number and the different types of cells   62 
isolated for this chapter. The DNA from the single cells was subjected directly to PCR or 
it was amplified with MDA prior to PCR analysis. 
 
From a total of 270 single cells isolated the majority were first amplified with MDA prior 
to  molecular  analysis.  A  total  of  75  MDA  products  derived  from  single  buccal  cells 
(donors A and B), 75 MDA products derived from single lymphocytes (donors A and B), 
20 MDA products derived from trisomic fibroblasts (C and D), 40 MDA products derived 
from single blastomeres, 50 single buccal cells and 50 single lymphocytes were used as 
the DNA source for the PCR reactions for the molecular project. 
 
DNA 
SOURCE  gDNA    Single cells 
    BUCCAL CELLS  LYMPHOCYTES  FIBROBLASTS  BLASTOMERES 
DONOR A  ￿ ￿ ￿ ￿  80  80  X  X 
DONOR B  ￿ ￿ ￿ ￿  25  25  X  X 
TRISOMY C  ￿ ￿ ￿ ￿  X  X  10  X 
TRISOMY D  ￿ ￿ ￿ ￿  X  X  10  X 
EMBRYOS 
(20) 
From parents: 
Not always  X  X  X  34 
Table 3.1: Summary of DNA source used. This table summarizes the DNA samples from 
various cell types for this chapter. The DNA from the parents of the embryos was not 
always available. Symbol “￿ ￿ ￿ ￿” was used to show that gDNA was obtained and symbol 
“X” was used to show that the specific types of cells were not obtained. 
 
3.5.2 DNA concentrations 
 
The DNA concentrations from the gDNA and MDA products were measured with the use 
of a spectrophotometer (ND 1000 UV Vis, NanoDrop, USA) and its computer program 
(ND 1000 software, NanoDrop, USA). 
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3.5.3 Ethical approval 
 
For  the  blastomeres  ethical  approval  was  obtained  from  the  Human  Fertilisation  and 
Embryology  Authority  (HFEA).  Written  consent  was  obtained  from  the  couples  who 
donated their embryos. 
 
3.5.4 Polymerase chain reaction 
 
Two  triplex  fluorescent  PCR  (F PCR)  reactions  were  applied  to  assess  the  MDA 
efficiency and accuracy to amplify single cells (Appendix A6). Both multiplex reactions 
had been previously optimised for direct application on single cells and have been used in 
clinical PGD in our laboratory (Kakourou et al., 2007; Moutou et al., 2004). Each of the 
forward primers was fluorescently labeled with either Fam, Ned or VIC dye. The details 
for each primer including the fluorescent label and the heterozygosity level are shown in 
table 3.4. The primer sequences are listed in appendix A, table A1. HIFI polymerase 
(Roche Diagnostics Ltd, UK), 10x HIFI fidelity buffer II (Roche Diagnostics Ltd, UK), 
dNTPs (Promega, USA), glycerol (Sigma, UK) and nuclease free H2O (Promega, USA) 
were used for the PCR reaction. All PCR Master mixes were prepared in a DNA free 
room with positive pressure inside a hood. All PCR reactions were carried out in an 
ABI9700 thermocycler (PE Applied Biosystems, UK). 
 
Loci  Type of 
sequence 
Forward primer 
label 
Region  Product size 
(bp) 
Heterozygosity 
DM1  Trinucleotide  VIC ®  19q13.3  120 203  72.9% 
D19S112  Dinucleotide  NED 
TM  19q13.3 19q13.4  117 142  86.3% 
APOC2  Dinucleotide  FAM ®  19q13.2  125 170  85.2% 
p.Phe508del  Specific  FAM ®  7q31.2  94    
IVS8CA  dinucleotide  NED 
TM  7q31.2  180 200  71% 
IVS17TA  dinucleotide  FAM ®  7q31.2  180 280  89% 
 
Table 3.2: Details of the primers used for chapter 3. This table summarizes the primers 
used for the two triplex PCR reaction, including the fluorescent label of the forward 
primer, the regions that amplify, the expected product size and the heterozygosity level.   64 
3.5.4.1 DM triplex 
 
The first multiplex PCR (DM triplex) was a triplex including three STR markers located 
in or around the area of the dystrophin (DMPK) gene (DM1, APOC2 and D19S112). The 
PCR reactions had a final volume of 25 l and consisted of 0.2mM dNTPs, 10% glycerol, 
1x HiFi fidelity buffer II containing 20mM MgCl2, 1.5 units HiFi Polymerase, primer sets 
of 0.2 M DM1, 0.3 M APOC2 and 0.3 M D19S112, and nuclease free H2O. For MDA 
products and gDNA 1 l was added to the mixture whereas in single cells the volume 
containing the DNA was estimated to be 3 l.  
 
The following conditions were used in the ABI9700 thermocycler for the DM triplex: 
Initial denaturation at 96
oC for two minutes followed by 94
oC for 15 seconds (96
oC for 
the first 10 cycles), annealing at 58
oC for 45 seconds and extension at 72
oC for one 
minute for 25 40 cycles. After a final elongation step at 72
oC for 7 minutes the samples 
were stored at 4
oC until used. For single cells and MDA products 40 cycles were used 
whereas  25  cycles  were  used  for  some  MDA  products  from  single  cells  in  order  to 
compare the difference in the cycle number. 
 
3.5.4.2 CF triplex 
 
The second multiplex (CF triplex) was a triplex containing three markers on the cystic 
fibrosis  transmembrane  conductance  regulator  (CFTR)  gene  (p.Phe508del,  IVS8CA, 
IVS17TA).  For  the  CF  triplex, the  reaction  for  single  cells  was  performed  as  a  split 
reaction because the last two markers interacted with each other. The reagents in the first 
round were similar to the DM triplex with the difference being the primer sets (0.2 M 
p.Phe508del, 0.6 M IVS8CA and 0.6 M IVS17TA). For the second round, 5 l of the 
PCR reaction from the first round was as the DNA template. The PCR reagents were only 
different in the primer sets where in one tube 0.2 M p.Phe508del and 0.6 M IVS8CA 
were added and in the other tube only 0.6 M IVS17TA was added. The PCR conditions 
in the first round included an initial denaturation at 96
oC for two minutes, 10 cycles with 
denaturation at 96
oC for 15 seconds, annealing at 51
oC for 45 seconds and extension at   65 
72
oC for one minute and a final elongation step at 72
oC for 7 minutes. For the second 
round  the  conditions  were  the  same  but  the  cycles  were  25  instead  of  10  and  the 
denaturation step was set at 94
oC instead of 96
oC. 
 
For gDNA and MDA products, the triplex reaction was separated from the beginning 
resulting in a duplex reaction (CF1) with the p.Phe508del and the IVS8CA markers and a 
singleplex reaction (CF2) with the IVS17TA marker. In the case of the duplex and the 
singleplex reaction (CF1 and CF2) the PCR reagents and conditions were identical to the 
ones used for the second round in the CF triplex. 
 
3.5.5 PCR analysis 
 
The PCR products were run on the ABI PRISM 310 genetic analyser (single capillary). 
Separations for each product were performed at 15,000 volt for 30 minutes, at 60
oC using 
the POP 6 sieving polymer (PE Applied Biosystems, UK) and 1 x genetic analyser buffer 
(PE Applied Biosystems, UK). Before the run, 1.5 l of the PCR product was mixed with 
12 l  of  formamide  (Sigma,  UK)  and  0.5 l  of  Genescan 500  ROX  size  standard  (PE 
Applied  Biosystems,  UK)  in  0.5  tubes  which  were  capped  with  rubber  septa.  This 
specific capping was necessary for the PRISM in order to have access to the sample 
through  the  capillary.  The  samples  were  then  denatured  at  95
oC  for  4  minutes  in  a 
Thermal  Reactor  (Hybaid,  UK)  and  transferred  to  the  ABI  PRISM  for  sequence 
detection.  As  one  of  the  primers  was  fluorescently labelled  at  the  5’  end  with  FAM 
(blue), VIC (green) or NED (black) the PCR products would be detected by the PRISM 
and the data were analysed using Genemapper analysis software version 3.5 (PE Applied 
Biosystems, UK). 
 
3.5.6 Statistical analysis 
 
Statistical analysis of the experiments was performed in order to compare the results. Chi 
square test was used to test the statistical difference between different cell types and cell 
lysis methods. For statistical analysis of the results the EAS was taken into account.   66 
 
3.6 Results 
 
3.6.1 Preliminary experiments  
 
3.6.1.1 DNA concentration 
 
The concentration of gDNA ranged between 0.9   1.3 g/ l. The concentration of the 
MDA products from single cells and gDNA was calculated to vary from 0.5 to 2 g/ l 
(absorbance ratio: 1.38 1.6). This range of  concentration included  all MDA products, 
even those in which PCR analysis showed a failure of MDA amplification in all the loci 
and the negative sample. The MDA products were not purified but used directly for PCR 
experiments. 
 
3.6.1.2 Allele sizes 
 
The  allele  sizes  from  each  DNA  sample  used  were  obtained  from  PCR  on  gDNA 
extracted from each individual. DNA from individual A and trisomy 21 (D) for the DM 
locus were the only fully informative markers. The p.Phe508del marker was the only non 
polymorphic marker and the same allele size is expected in all individuals lacking the 
p.Phe508del mutation. The results are shown in table 3.3.  For the blastomeres, in two 
cases (E1, E2 and F1, F2) parental DNA was available for comparison of alleles with the 
embryo  results  (EB  and  FB  embryos  respectively).  For  the  remaining  four  families 
gDNA was not available from the parents in order to confirm the expected allele sizes 
and so suggested sizes depended on comparison of results from blastomeres from the 
same embryo and from comparison of blastomeres from embryos from the same parents. 
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Table 3.3: True allele sizes after PCR of gDNA. The table shows the allele sizes on six 
markers of the two individuals (A and B), the two trisomic fibroblast cells (C and D) and 
from DNA from the parents (E1, E2, F1 and F2) of the embryos. Symbol (-) is used to 
show that PCR analysis was not done for the CF markers.  
 
3.6.1.3 Negative and positive controls for MDA 
 
During  single  cell  isolation,  for  each  cell  that  was  isolated  a  negative  control  was 
processed in order to check for contamination during the isolation process. All negative 
controls were subjected directly to PCR for the DM locus rather than being amplified first 
by MDA. This assessed the absence of contamination in a cost effective, reliable and fast 
way. None of the negative controls showed any relevant or irrelevant peaks indicating the 
absence of contamination in all the single cells collected. A negative PCR control was 
also included in each experiment where deionised nano pure H2O substituted DNA. All 
negative PCR controls showed no contamination. A negative MDA sample was subjected 
to PCR for the DM and the CF locus in order to check if any artefacts would appear from 
nonspecific DNA produced by the MDA reaction itself. Most of the artefacts produced 
were  less  than  120bp  long  and  their  peak  heights  were  very  low  (100  –  300  units) 
compared to the real peaks (500 – 9000 units) from the MDA products from the single 
cells.  For  each  PCR  experiment,  positive  controls  included  both  gDNA  and  MDA 
products from gDNA in order to confirm the accuracy and the efficiency of the reaction. 
Six  MDA  products  from  gDNA  of  individuals  A  and  B  were  produced  as  positive 
controls with 100% MDA AE, 100% EAS, 0% ADO and 0% TAF. 
  DM markers  CF markers 
  gDNA  APOC2  DM1  D19S112  Phe508  IVS8CA  IVS17TA 
A  152 154  140 155  123 132  94  180  200 250 
B  127 150  122  117 134  94  180  229 250 
C  127 150  122  139 141  94  180 182  245 285 
D  135 150  145 172  132 135  94  182 198  229 250 
E1  148 152  142 148  117 136          
E2  150 154  148 181  133 136          
F1  148 150  136 148  133          
F2  151 157  132 147  133            68 
3.6.1.4 Single cell PCR 
 
PCR for the DM triplex was applied to single lymphocytes and buccal cells as in clinical 
PGD workups. L1 (ALB lysis without DTT) and L3 (proteinase K lysis) methods were 
used.  The  results  are  shown  in  tables  3.4  and  3.5  and  figure  3.3.  The  cells  that  are 
highlighted in black were the ones where PCR did not work and were excluded from post 
PCR analysis. PCR efficiency was calculated to be 90.0% (27/30) for all cell types and 
lysis methods. PCR failure may be due to failure of the reaction but also due to loss of the 
cell during transfer. The results show that the L1 lysis method gave more accurate results 
compared to the L3 lysis method in both cell types (72.8% (59/81) compared to 65.1% 
(43/66) in buccal cells and 92.6% (75/81) compared to 47.0% (31/66) in lymphocytes). 
Chi square analysis showed that the results from the different lysis methods were not 
statistically different for the EAS in buccal cells (p= 0.169) but were on lymphocytes (p 
<0.001).  Lymphocytes  that  were  lysed  with  L1  lysis  provided  more  reliable  results 
compared to the other lysis/cell type combination.  Interestingly, lymphocytes lysed with 
the L3 method gave the worst results (47.0% accuracy, 24.2% ADO and 28.8% TAF) 
which indicated that enzymatic lysis was not suitable for lymphocytes. For buccal cells 
the  major  problem  that  L3  lysis  accounted  for  was  the  high  TAF  (19.7%,  13/66) 
compared to L1 lysis (9.9%, 8/81) rather than ADO where it is almost the same (15.1% 
(10/66)  and  17.3%  (14/81)  respectively).  In  lymphocytes  TAF  and  ADO  were  much 
higher when using L3 lysis (28.8% and 24.2% respectively) compared to L1 lysis (2.5% 
and 4.9% respectively). 
 
 
3.6.1.5 MDA using the L3 method 
 
Since L3 (proteinase K) lysis was shown to produce the most inaccurate results in single 
cell  PCR  only  five  MDA  products  from  single  lymphocytes  and  buccal  cells  were 
produced initially and applied on the DM and CF triplex. MDA products from buccal 
cells using the L3 lysis had 26.7% (8/30) accurate results, 20.0% (6/30) ADO and 53.3% 
(17/30) TAF. MDA products from lymphocytes using the  L3 lysis had 23.3% (7/30) 
accurate results, 3.3% (1/30) ADO and 70.0% (21/30) TAF. There was also one product   69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4: Triplex PCR on single buccal cells and lymphocytes after L1 or L3 lysis. The table shows the results from single cell PCR 
for the DM locus on buccal cells and lymphocytes comparing the different lysis methods and cell types. Green boxes represent the 
expected allele size (EAS) whereas blue boxes show allele drop out (ADO) and black boxes show total amplification failure (TAF). 
Lymphocytes lysed with L1 method (C) provided the best results. 
 
B:          Buccal L3 lysis 
  DM TRIPLEX 
 CELL NO.  APOC2  DM  D19S112 
       
A1       
A2       
A3       
A4       
A5       
A6       
A7       
A8       
A9       
A10       
A11       
A12       
A13       
A14       
A15       
A16       
A17       
A18       
A19       
A20       
A21       
A22       
A23       
A24       
A25       
A26       
A27       
A28       
A29       
A30       
C:   Lymphocytes L1 lysis 
  DM TRIPLEX 
 CELL NO.  APOC2  DM  D19S112 
       
A1       
A2       
A3       
A4       
A5       
A6       
A7       
A8       
A9       
A10       
A11       
A12       
A13       
A14       
A15       
A16       
A17       
A18       
A19       
A20       
A21       
A22       
A23       
A24       
A25       
A26       
A27       
A28       
A29       
A30       
A:        Buccal  L1 lysis 
  DM TRIPLEX 
 CELL NO.  APOC2  DM  D19S112 
       
A1       
A2       
A3       
A4       
A5       
A6       
A7       
A8       
A9       
A10       
A11       
A12       
A13       
A14       
A15       
A16       
A17       
A18       
A19       
A20       
A21       
A22       
A23       
A24       
A25       
A26       
A27       
A28       
A29       
A30       
D:   Lymphocytes L3 lysis 
  DM TRIPLEX 
 CELL NO.  APOC2  DM  D19S112 
       
A1       
A2       
A3       
A4       
A5       
A6       
A7       
A8       
A9       
A10       
A11       
A12       
A13       
A14       
A15       
A16       
A17       
A18       
A19       
A20       
A21       
A22       
A23       
A24       
A25       
A26       
A27       
A28       
A29       
A30         70 
 
 
 
Table 3.5: Summary of PCR analysis of single cells lysed with the L1 and L3 methods. Single buccal cells and lymphocytes from individual A with 
two lysis methods (L1 and L3) are compared using an optimised triplex PCR for single cells. Better results are obtained from lymphocytes L1 
lysis (92.6%) EAS) and worse results are obtained from lymphocytes L3 lysis (47%). This shows that cell lysis can play a key role according 
to the cell type that is used. 
  
a EAS; expected allele size 
 
bADO; allele drop out 
 
cTAF; total amplification failure 
 
dAll loci were homozygous. 
 
 
    Buccal cells L1 (n = 30) 
PCR-AE = 27/30 (90%)    Buccal cells L3 (n = 30) 
PCR-AE =22/30 (73.3%)    Lymphocytes L1 (n = 30) 
PCR-AE= 27/30 (90%) 
 
 
Lymphocytes L3 (n = 30) 
PCR-AE =22/30 (73.3%) 
Locus    EAS (%)
a  ADO (%)
b  TAF (%)
c    EAS (%)
a  ADO (%)
b  TAF (%)
c    EAS (%)
a  ADO (%)
b TAF (%)
c    EAS (%)
a  ADO (%)
b  TAF (%)
c 
APOC2    22/27(81.4)  1/27(3.7)  4/27(14.8)    16/22(72.7)  2/22(9.1)  4/22(18.2)    25/27(92.5)  1/27(3.7)  1/27(3.7)    17/22(77.3)  4/22(18.2)  1/22(4.5) 
DM    17/27(62.9)  6/27(22.2)  4/27(14.8)    13/22(59)  2/22(9.1)  7/22(31.8)    25/27(92.5)  1/27(3.7)  1/27(3.7)    6/22(27.3)  10/22(45.5)  6/22(27.3) 
D19S112    20/27(74.1)  7/27(25.9)  0/27(0)    14/22(63.6)  6/22(27.3)  2/22(9.1)    25/27(92.5)  2/27(7.4)  0/27(0)    8/22(36.4)  2/22(9.1)  12/22(54.5) 
                                 
TOTAL    59/81(72.8)  14/81(17.3)  8/81(9.9)    43/66(65.1)  10/66(15.1)  13/66(19.7)    75/81(92.6)  4/81(4.9)  2/81(2.5)    31/66(47)  16/66(24.2)  19/66(28.8)   71 
A: 
 
 
 
 
 
 
 
 
 
 
 
B: 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Electropherograms of single cell PCR for the DM triplex. The figures show 
how  the  electropherograms  look  like  after  single  cell  PCR  of  buccal  cells  (A)  and 
lymphocytes (B) for the DM triplex loci. The results on the left side were single cells 
lysed with L1 lysis whereas the results on the right side were single cells lysed with L3 
lysis. 
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size that did not match the expected allele sizes. The high TAF in both cell types was the 
inhibiting parameter that showed that L3 lysis may not be useful for MDA and no further 
experiments with L3 lysis were made for MDA reactions. The results are shown in table 
3.6 and figure 3.4. No statistical analysis was performed for MDA products and L3 lysis. 
 
 
 
 
 
Table 3.6: Triplex PCR on MDA products from single buccal cells and lymphocytes after L3 
lysis. This table shows the results from DM and CF triplex PCR on MDA products from 
five single buccal cells (A) and lymphocytes (B). The red box shows that an incorrect 
allele size was detected on the DM locus. Green boxes represent the expected allele size 
(EAS)  whereas  blue  boxes  show  allele  drop  out  (ADO)  and  black  boxes  show  total 
amplification failure (TAF). 
 
3.6.1.6 MDA using the L1 and L2 methods 
 
It has been suggested that DTT may not be beneficial for single cell lysis prior to PCR 
(Pierce et al., 2002). The effect of DTT in cell lysis prior to MDA was measured by 
comparing L1 and L2 lysis in lymphocytes and buccal cells. Tables 3.7 and 3.8 show the 
results of 80 MDA products.  Figures 3.5 and show the electropherograms of two cells 
after L1 and L2 lysis respectively. In buccal cells, MDA AE seems to be hampered by 
the addition of DTT (L2 lysis) in the lysis buffer but when excluding these cells the 
results showed a higher accuracy rate (53.6% (45/84) compared to 41.7% (45/108)) and 
lower TAF (23.8% (20/84) compared to 35.2% (38/108) whereas ADO was very similar 
(32.1% (18/56) and 30.6% (22/72)). A chi squared test showed that the lysis methods did 
not produce different results (p=0.101) but the MDA AE was much lower in the L3 lysis. 
For lymphocytes the L1 lysis method seemed to be beneficial for the MDA reaction since 
the  EAS  was  higher  and  the  TAF  was  lower  even  though  there  was  no  statistical 
difference (p=0.586). The ADO rate was similar for both lysis methods. This means that 
ADO was not influenced by the lysis method but the biggest difference was seen on the 
A:         MDA on  single Buccal cells L3 lysis 
  DM TRIPLEX  CF TRIPLEX 
CELL NO.  APOC2  DM  D19S112  phe508  IVS8CA IVS17TA 
             
A1             
A2             
A3             
A4             
A5             
B:        MDA on single  Lymphocytes L3 lysis 
  DM TRIPLEX  CF TRIPLEX 
CELL NO.  APOC2  DM  D19S112  phe508  IVS8CA IVS17TA 
             
A1             
A2             
A3             
A4             
A5               73 
TAF and the MDA AE. Results from L1 lysis were at least equal, if not beneficial, over 
L2 lysis for both cell types and so it was used in the following experiments. 
 
A: 
 
 
 
 
 
 
 
 
 
B: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Electropherograms of single cell MDA products after L3 lysis. The figures 
show the electropherograms of single buccal cells MDA (A) and single lymphocytes MDA 
(B) for the DM and CF triplex loci.  
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Table 3.7: PCR on MDA products from single buccal cells and lymphocytes after L1 and L2 
lysis. This table compares two different cell types (buccal cells and lymphocytes) and two 
lysis methods (L1 and L2) with the use of the two triplex PCR reactions. Green boxes 
represent the expected allele size (EAS) whereas blue boxes show allele drop out (ADO), 
black boxes show total amplification failure (TAF) and red boxes show inaccurate allele 
size.  The  inaccurate  allele  size  was  reported  when  the  alleles  obtained  from  the 
electropherograms did not match the expected alleles from the gDNA, so they could not 
be classified as ADO, EAS or TAF. 
B:                           Buccal Cells L2 lysis 
  DM TRIPLEX  CF TRIPLEX 
CELL NO.  APOC2  DM  D19S112  phe508  IVS8CA  IVS17TA 
             
A1             
A2             
A3             
A4             
A5             
A6             
A7             
A8             
A9             
A10             
A11             
A12             
A13             
A14             
A15             
A16             
A17             
A18             
A19             
A20             
A:                          Buccal Cells L1 lysis 
  DM TRIPLEX  CF TRIPLEX 
CELL NO.  APOC2  DM  D19S112  phe508  IVS8CA  IVS17TA 
             
A1             
A2             
A3             
A4             
A5             
A6             
A7             
A8             
A9             
A10             
A11             
A12             
A13             
A14             
A15             
A16             
A17             
A18             
A19             
A20             
D:                       Lymphocytes L2 lysis 
  DM TRIPLEX  CF TRIPLEX 
CELL NO.  APOC2  DM  D19S112  phe508  IVS8CA  IVS17TA 
             
A1             
A2             
A3             
A4             
A5             
A6             
A7             
A8             
A9             
A10             
A11             
A12             
A13             
A14             
A15             
A16             
A17             
A18             
A19             
A20             
C:                        Lymphocytes L1 lysis 
  DM TRIPLEX  CF TRIPLEX 
CELL NO.  APOC2  DM  D19S112  phe508  IVS8CA IVS17TA 
             
A1             
A2             
A3             
A4             
A5             
A6             
A7             
A8             
A9             
A10             
A11             
A12             
A13             
A14             
A15             
A16             
A17             
A18             
A19             
A20               75 
 
 
Table 3.8: Summary of PCR analysis on MDA products lysed with L1 and L2 methods. L1 and L2 lysis methods are being compared for 
effectiveness on MDA reaction on two cell types and using two multiplex PCR reactions. 
  
a EAS; expected allele size 
 
bADO; allele drop out 
 
cTAF; total amplification failure 
 
dAll loci were homozygote. 
 
 
 
 
    Buccal cells L1 (n = 20) 
MDA-AE = 18/20 (90%) 
 
 
Buccal cells L2 (n = 20) 
MDA-AE =14/20 (70%)    Lymphocytes L1 (n = 20) 
MDA-AE= 19/20 (95%) 
 
 
Lymphocytes L2 (n = 20) 
MDA-AE =20/20 (100%) 
Locus    EAS (%)
a  ADO (%)
b  TAF (%)
c    EAS (%)
a  ADO (%)
b  TAF (%)
c    EAS (%)
a  ADO (%)
bTAF (%)
c   EAS (%)
a  ADO (%)
b  TAF (%)
c 
APOC2    12/18(66.7)  3/18(16.7)  2/18(11.1)    11/14(78.6)  2/14(14.3)  1/14(7.1)    16/19(84.2)  2/19(10.5)  1/19(5.3)    17/20(85)  1/20(5)  2/20(10)
 
DM    2/18(11.1)  8/18(44.4)  7/18(38.9)    8/14(57.1)  5/14(35.7)  1/14(7.1)    10/19(52.6)  6/19(31.6)  2/19(10.5)    13/20(65)  6/20(30)  1/20(5) 
D19S112    7/18(38.9)  6/18(33.3)  4/18(22.2)    4/14(28.6)  7/14(50)  3/14(21.4)    16/19(84.2)  2/19(10.5)  1/19(5.3)    14/20(70)  5/20(25)  1/20(5) 
                                 
phe508    13/18(72.2)     5/18(27.8)    8/14(57.1)           6/14(42.6)    18/19(94.7)     1/19(5.3)    15/20(75)     5/20(25) 
IVS8CA    9/18(50)     9/18(50)    7/14(50)           6/14(42.6)    19/19(100)     0/19(0)    14/20(70)     6/20(30) 
IVS17TA    2/18(11.1)  5/18(27.8)  11/18(61.1)    7/14(50)  4/14(28.6)  3/14(21.4)    10/19(52.6)  9/19(47.4)  0/19(0)    11/20(55)  6/20(30)  3/20(15) 
                                 
TOTAL    45/108(41.7)  22/72(30.6)  38/108(35.2)    45/84(53.6)  18/56(32.1)  20/84(23.8)    89/114(78.1)  19/76(25)  5/114(4.3)    84/120(70)  18/80(22.5)  18/120(15)   76 
A: 
 
 
 
 
 
 
 
 
 
 
 
 
 
B: 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Electropherograms of single cell MDA products after L1 lysis. The figures 
show the electropherograms of single buccal cells MDA (A) and single lymphocytes MDA 
(B) after L1 lysis for the DM and CF triplex loci.  
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Figure 3.6: Electropherograms of single cell MDA products after L2 lysis. The figures 
show the electropherograms of a single buccal MDA (A) and a single lymphocyte MDA 
(B) after L2 lysis for the DM and CF triplex loci. For buccal cells the result A2 was used 
as no result was obtained from A1 buccal cell. 
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3.6.2 Main results 
 
3.6.2.1 MDA using L1 lysis - Comparison of different cell types 
 
MDA  using  L1  lysis  was  applied  to  50  buccal  cells,  50  single  lymphocytes  and  20 
fibroblasts prior to two multiplex PCRs for the DM and the CF loci. The results are 
shown in table 3.9. Electropherograms of the results of each cell type are shown on figure 
3.7 The average  ADO  rate was 31.0% (45/145) for buccal cells, 20.8% (35/168) for 
lymphocytes and 20.0% (18/90) for fibroblasts but with high inter locus variation (24.4   
45.5% for buccal cells, 14.6 – 29.2% for lymphocytes and 5.0 – 30% for fibroblasts). 
MDA products from buccal cells showed very high TAF (22.0%, 54/245) compared with 
lymphocytes (6.6%, 19/288) and fibroblasts (7.5%, 9/120). Finally, following MDA 1.2% 
(3/245)  and  0.3%  (1/288)  of  the  PCR  products  from  buccal  cells  and  lymphocytes 
respectively  had  an  allele  size  that  was  did  not  match  the  expected  allele  sizes  as 
determined from gDNA. A summary of the results is shown in Table 3.10. 
 
It can be concluded that MDA products from single lymphocytes and fibroblasts produce 
similar results (p=0.396) but significantly different from MDA products of single buccal 
cells (p<0.001 with both cell types). For clinical PGD however, diagnostic work ups prior 
to  blastomere  diagnosis  are  being  done  on  lymphocytes  or  buccal  cells  in  order  to 
optimise the PCR reaction. The best cell to do the work up would give comparable results 
to a blastomere. For this reason 34 blastomeres that were biopsied from 20 embryos and 
lysed with the same method (L1) were subjected to MDA prior to triplex PCR for the DM 
locus  (Table  3.9D).  CF  triplex  was  not  included  in  the  blastomeres  PCR  as  the 
heterozygosity level of IVS8CA and IVS17TA STR markers was not very high and so 
ADO events would have easily been misdiagnosed as EAS. The expected alleles of each 
embryo could only be based on the parental alleles and the results could not be 100% 
accurate unless the parents were fully informative for all the alleles. More markers could 
be  used  but  then  there  could  not  be  a  direct  comparison  with  buccal  cells  and 
lymphocytes. Unfortunately, gDNA from both parents was only available in the first 13 
blastomeres (named as EB and FB) and they were not fully informative for all loci (Table   79 
3.3, sample E1, E2, F1 and F2). For the rest of the blastomeres the results were based on 
comparing the allele sizes of blastomeres of the same embryos and blastomeres from 
siblings. The results are shown in table 3.9D. A comparison of the different cell types 
with blastomeres for the DM locus only is presented on table 3.11. Figure 3.8 shows the 
electropherograms of three blastomeres for the markers that it was tested. In two cases it 
cannot be concluded if a result was ADO or EAS and this was shown in the table as a 
green box with an X in the centre. These cases were excluded from post analysis. The 
embryos were expected to have chromosomal abnormalities as all the embryos were from 
PGS  cases.  MDA AE  was  not  calculated  for  blastomeres  as  three  markers  were  not 
considered to be enough to make a secure outcome. The MDA products that did not show 
any result at all at three loci were excluded from analysis. The analysis shows a clear 
similarity  of  blastomeres  with  lymphocytes  (p=0.904)  and  fibroblasts  (p=0.936). 
However, the results of the electropherograms were more close to buccal cells as bleed 
through  and  artefacts  were  present  in  most  of  the  results  which  made  the  diagnosis 
difficult.   80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.9: Comparison of different cell types with L1 lysis method (continued on the 
following page).  
A:                       Buccal Cells 
  DM TRIPLEX  CF TRIPLEX 
CELL NO.  APOC2  DM  D19S112  phe508  IVS8CA  IVS17TA 
             
A1             
A2             
A3             
A4             
A5             
A6             
A7             
A8             
A9             
A10             
A11             
A12             
A13             
A14             
A15             
A16             
A17             
A18             
A19             
A20             
A21             
A22             
A23             
A24             
A25             
             
B1             
B2             
B3             
B4             
B5             
B6             
B7             
B8             
B9             
B10             
B11             
B12             
B13             
B14             
B15             
B16             
B17             
B18             
B19             
B20             
B21             
B22             
B23             
B24             
B25             
B:                         Lymphocytes 
  DM TRIPLEX  CF TRIPLEX 
CELL NO.  APOC2  DM  D19S112  phe508  IVS8CA IVS17TA 
             
A1             
A2             
A3             
A4             
A5             
A6             
A7             
A8             
A9             
A10             
A11             
A12             
A13             
A14             
A15             
A16             
A17             
A18             
A19             
A20             
A21             
A22             
A23             
A24             
A25             
             
B1             
B2             
B3             
B4             
B5             
B6             
B7             
B8             
B9             
B10             
B11             
B12             
B13             
B14             
B15             
B16             
B17             
B18             
B19             
B20             
B21             
B22             
B23             
B24             
B25               81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.9: Comparison of different cell types with L1 lysis method. This table shows the 
results from DM and CF triplex PCR on MDA products from single buccal cells (A),  
lymphocytes (B) and fibroblasts (C). and the results from DM locus from MDA products 
from single blastomeres (D). Four red boxes are present in the results that indicate the 
detection of incorrect allele size. Green boxes represent the expected allele size (EAS), 
blue boxes show allele drop out (ADO) and black boxes show total amplification failure 
(TAF). In table D two green boxes that contain a cross (X) were excluded from post 
analysis because it was impossible to conclude if ADO was present or not. In blastomeres 
10  MDA  products  did  not  show  any  result  which  greatly  decreases  the  MDA-AE 
comparing to MDA products from other cell types. 
D:        Blastomeres 
  DM TRIPLEX 
 CELL NO.  APOC2  DM  D19S112 
       
EB1.1       
EB1.2       
EB2.1       
EB3.1       
EB3.2       
EB4.1       
       
FB1.1       
FB1.2       
FB2.1       
FB3.1       
FB3.2       
FB4.1       
FB4.2       
       
GB1.1       
GB1.2       
GB2.1       
GB2.2       
GB3.1       
GB3.2       
GB4.1       
       
HB1.1       
HB1.2       
HB2.1       
HB2.2       
HB3.1       
       
IB1.1       
IB1.2       
IB2.1       
IB2.2       
       
JB1.1       
JB1.2       
JB2.1       
JB2.2       
JB3.1       
C:                           Fibroblasts 
  DM TRIPLEX  CF TRIPLEX 
CELL NO.  APOC2  DM  D19S112  Phe508  IVS8CA  IVS17TA 
             
C1             
C2             
C3             
C4             
C5             
C6             
C7             
C8             
C9             
C10             
             
D1             
D2             
D3             
D4             
D5             
D6             
D7             
D8             
D9             
D10               82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.10: Summary of the results of single cell MDA products from different cell types with L1 lysis. The efficiency of single cell 
MDA on different cell types (buccal cells, lymphocytes and fibroblasts) was assessed.  The four cases where an inaccurate allele was 
present were excluded from post analysis because of the minimum impact on the final results (1.2% for buccal cells and 0.3% for 
lymphocytes).  
a EAS; expected allele size 
 
bADO; allele drop out 
 
cTAF; total amplification failure 
 
dAll loci were homozygote. 
 
 
 
 
  Buccal cells (n = 50) 
MDA-AE = 82% (41/50)    Lymphocytes (n = 50) 
 MDA-AE =96 % (48/50)    Fibroblasts (n = 20) 
MDA-AE = 100% (20/20) 
Locus  EAS (%)
a  ADO (%)
b  TAF (%)
c    EAS (%)
a  ADO (%)
b  TAF (%)
c    EAS (%)
a  ADO (%)
b  TAF (%)
c 
APOC2  26/41 (63.4)  10/41 (24.4)  4/41 (9.8)    39/48  (81.3)  7/48 (14.6)  2/48 (4.2)    18/20 (90)  1/20 (5)  1/20 (5) 
DM  19/41  (46.3) 10/ 22 (45.5)
  11/41 (24.3)    37/48 (77.1)  7/24 (29.2)  3/48 (6.3)    16/20 (80)  3/10 (30)  1/20 (5) 
D19S112  20/41 (48.8)  15/41 (36.6)  5/41 (12.2)    39/48 (81.3)  7/48 (14.6)  2/48 (4.2)    14/20 (70)  5/20 (25)  1/20 (5) 
                       
Phe508  36/41 (87.8)   
d  5/41 (12.2)    46/48 (96)   
d  2/48 (4.2)    18/20 (90)   
d  2/20 (10) 
IVS8CA  30/41 (73.1)   
d  11/41 (26.8)    46/48 (96)   
d  2/48 (4.2)    14/20 (70)  4/20 (20)  2/20 (10) 
IVS17TA  14/41 (34.1)  10/41 (24.4)  17/41 (41.4)    26/48 (54.2)  14/48 (29.2)  8/48 (8.4)    13/20 (65)  5/20 (25)  2/20 (10) 
                       
TOTAL  145/246 (59)  45/145 (31)  53/246 (21.6)    233/288 (81)  35/168 (20.8)  19/288 (6.6)    93/120 (77.5)  18/90 (20)  9/120 (7.5)   83 
 
Table 3.11: Summary of the results from MDA products from single blastomeres and comparison with other cell types. This table 
compares the results obtained from blastomeres with the results of other cell types for the same loci. MDA-AE was not calculated as 
the results only from DM triplex were not considered enough for reliable analysis. For EAS, ADO and TAF calculations 10 MDA 
products were excluded because no results were obtained for any of the three markers. This could not be reliable concluded if it was 
from TAF or MDA amplification failure. 
  
a EAS; expected allele size 
 
bADO; allele drop out 
 
cTAF; total amplification failure 
 
dAll loci were homozygote. 
  Blastomeres  (n = 34)    Buccal cells (n = 50)    Lymphocytes (n = 50)    Fibroblasts  (n = 20) 
Locus  EAS (%)
a  ADO (%)
b  TAF (%)
c    EAS (%)
a  ADO (%)
b  TAF (%)
c    EAS (%)
a  ADO (%)
b  TAF (%)
c    EAS (%)
a  ADO (%)
b  TAF (%)
c 
APOC2  23/24(95.8)  1/16(6.25)  0/24    26/41 (63.4)  10/41 (24.4)  4/41 (9.8)    39/48  (81.3)  7/48 (14.6)  2/48 (4.2)    18/20 (90)  1/20 (5)  1/20 (5) 
DM  15/24(62.5)  5/24(20.8)  2/24(8.3)    19/41  (46.3)  10/ 22 (45.5)
  11/41 (24.3)    37/48 (77.1)  7/24 (29.2)  3/48 (6.3)    16/20 (80)  3/10 (30)  1/20 (5) 
D19S112  20/24(83.3)  1/18(5.5)  3/24(12.5)    20/41 (48.8)  15/41 (36.6)  5/41 (12.2)    39/48 (81.3)  7/48 (14.6)  2/48 (4.2)    14/20 (70)  5/20 (25)  1/20 (5) 
                               
TOTAL  58/72(80.5)  7/58(12.1)  5/72(6.9)    65/123(52.8)  35/104(33.7)  20/123(16.2)    115/144(80)  21/120(17.5)  7/144(4.9)    48/60(80)  9/50(18)  3/60(5)   84 
A: 
 
 
 
 
 
 
 
 
 
 
 
 
B: 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Electropherograms of single cell MDA products after L1 lysis. The figures 
show  the  electropherograms  of  one  single  fibroblast  T13  MDA  (A)  and  one  single 
fibroblast T21 MDA (B) after L1 lysis for the DM and CF triplex loci.  
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Figure 3.6: Electropherograms of single blastomeres MDA products after L1 lysis. The figures show the electropherograms of  three 
single blastomeres MDA  after L1 lysis for the DM and CF triplex loci. The difficulty of the analysis was due to the many artefacts and 
bleed through present in the electropherograms. 
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3.6.2.2 Combined results of the triplex reaction. 
 
Triplex  PCR  is  used  in  clinical  PGD  in  order  to  produce  accurate  diagnosis  by 
overcoming problems such as ADO and TAF. For the DM and the CF triplex PCR, even 
if there was ADO or TAF in one marker, a secure diagnosis could be drawn for the 
embryo if the other two markers gave EAS. The diagnosis rate of PCR post MDA on 
different cell types was compared to single cell PCR without MDA. In clinical PGD 
diagnosis  can  be  made  when  2/3  markers  show  EAS.  Figure  3.3  demonstrates  the 
efficiency for diagnosis for each cell type lysed with L1 lysis for the DM triplex and 
compares  it  with  direct  triplex  on  single  cells.  In  the  case  of  MDA  products  from 
lymphocytes and buccal cells only the products from individual A were used. That was 
done in order to compare cells from the same individual and because individual B was 
not heterozygous for all loci (homozygous for the DM I locus). CF triplex was excluded 
from such comparisons as only one of the three markers was heterozygous. The figure 
shows that although single cell PCR gives higher EAS values overall there was a similar 
result when combing the results from the three markers.  
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Figure 3.8: Efficiency of diagnosis for DM triplex from different cell types with and without 
MDA. This figure compares the combined results from the triplex PCR on the DM locus on single 
cells and MDA products. Buccal cells show a lower efficiency of diagnosis with or without the 
MDA application. Blastomeres post MDA show greater efficiency of diagnosis over MDA 
products  from  single  buccal  cells  but  lower  compared  to  MDA  products  from  single 
lymphocytes and fibroblasts. This result is largely due to the low MDA-AE.   87 
3.6.3 Qualitative analysis 
 
3.6.3.1 MDA effect on stutter bands, preferential amplification and ADO 
  
F PCR analysis is mainly used for the detection of the allele length. Characteristic stutter 
patterns are associated with each STR locus. The examination of stutter bands and peak 
heights of the stutters is important in order to distinguish two alleles of similar size. This 
is because the additive effects of the stutter peaks alter the characteristic peak height 
ratios  at  that  locus.  The  effect  of  MDA  on  the  stutter  bands  and  peak  heights  was 
examined in order to conclude if these parameters should be considered for diagnosis. 
PCR  of  MDA  products  from  gDNA  retained  the  same  overall  stutter  pattern  as  that 
obtained  from  direct  PCR  of  gDNA.  Occasionally  the  stutter  peaks  were 
disproportionately high compared to the main peak (figure 3.4). Overall, complications of 
the stutter peak pattern were most pronounced in buccal cells. In some cases, involving 
MDA products from single cells, the pattern changed completely with the absence (figure 
3.5D) or the presence of extra (figure 3.6B) stutter peaks and with the presence of stutter 
peaks with higher amplitude than the main peaks. Preferential amplification (the ratio 
between two peak heights in a heterozygote locus being > 3 as described by Spits et al., 
2006) was very common (61.8% for the DM I locus) in MDA products from single cells 
(figure 3.6B). These findings may support the conclusion that diagnosis or haplotyping 
on MDA products from single cells cannot depend on peak height or stutter patterns. 
PCR  of  four  MDA  products  from  single  buccal  cells  and  lymphocytes  resulted  in 
inaccurate allele sizes (figure 3.7 and 3.8). However for figure 3.7B the inaccurate allele 
size could also be considered as an extreme form of a change of a stutter band in height 
and size in combination with ADO of the larger allele. Overall, in 58.1% (57/98) of the 
ADO events in MDA products from single cells, the larger allele was absent. However, 
when heterozygous loci involving alleles differing by only two base pairs were excluded 
from  the  calculations  the  ADO  rate  of  the  larger  alleles  was  calculated  to  be  50.6% 
(41/81). 
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Figure 3.9: Qualitative analysis of MDA from gDNA. Comparison of the PCR result 
from D19S112 marker obtained from gDNA (A) and MDA product from gDNA (B). It is 
obvious that the stutter pattern remains the same but the stutters were greatly enlarged 
and had the same size as the original peaks. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Comparison of PCR results of MDA products from different cell types 
with gDNA. This figure compares the PCR results from APOC2 and DM1 markers from 
gDNA (A), MDA product from gDNA (B), MDA product from a single lymphocyte (C)  
and MDA product from a single buccal cell (D). It is clear that the stutter pattern of the 
MDA products from the single lymphocyte and the buccal cell completely changes. ADO 
was also detected on this MDA product from this buccal cell.       89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Electropherogram from MDA buccal cells and gDNA for the D19S112 
locus. Image A is the result from gDNA which is compared to image B (shows an extreme 
form of preferential amplification) and image C (shows ADO of the large allele). Images 
B and C also show how complicated and noisy the stutter patterns can be post MDA. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Presence of inaccurate allele and ADO. Electropherogram comparing the 
PCR result from the MDA product from buccal cell A12 (B) and from gDNA (A) of the 
APOC2 marker. The MDA product has ADO of the large allele (154) and also displays 
an inaccurate allele (146). The inaccurate allele could also be explained as an extreme 
form of stutter pattern and peak height change.    90 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Presence of inaccurate allele size. This electropherogram comparing the 
PCR result from gDNA (A) and the MDA product from single buccal cell A5 on the 
D19S112 locus (B). The MDA product has ADO of the small allele and 3bp difference of 
the large allele compared to the gDNA result. 
 
3.6.3.2 Comparison of 25 and 40 PCR cycles on MDA products 
 
In single cell PCR, 35   40 cycles are usually needed for a sufficient amplification of the 
area  of  interest  whereas  for  PCR  on  gDNA  25 30  cycles  are  usually  enough  for 
analysable results. The number of optimal PCR cycles on MDA products from single 
cells was investigated. This was achieved by repeating PCR for the DM locus on 20 
MDA products from single lymphocytes and buccal cells with the difference of having 25 
PCR cycles instead of 40. The results were compared with PCR results on the same MDA 
products when using 40 cycles. In theory, a decrease of the PCR cycles could reduce the 
production of unspecific peaks and decrease the noise of the results.  
 
A comparison of the results obtained from 25 and 40 cycles on the same MDA products 
from single cells are shown on figures 3.9 and 3.10. These experiments were performed 
with cells with L1 lysis method. Overall, the reduction of the PCR cycles on the MDA 
products followed a very similar pattern. The main difference was that the peak height of 
the background noise, the stutter bands and the bleed through effect were decreased when 
fewer cycles were used. Bleed through effect is defined as the presence of excessive 
fluorescence of one labelled product being detected in the fluorescence of another dye   91 
because of overlapping wavelengths of the two dyes. An example of bleed through effect 
is when in multiplex PCR with three labelling dyes a PCR product that is labelled with 
VIC (green colour) is also detected in the analysis of the PCR product that is labelled 
with  FAM  (blue  colour).  An  example  of  bleed through  is  shown  on  figure  3.8A. 
Reducing the PCR cycles would also decrease the actual peak heights and this would 
increase the risk of misdiagnosis in case the peak height does not exceed 100 units (100 
units is the limit for identifying a real peak, Figure 3.9B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.9:  Comparison  of  results  of  the  same  MDA  product  after  different  PCR 
cycles. The electropherograms compare the DM triplex after 25 and 40 PCR cycles on 
MDA product from lymphocyte A13 (A: APOC2 locus, B: DM1 locus and C: D19S112 
locus). It was obvious that bleed-through and artefacts were more visible on the 40 PCR 
cycles but overall the stutter pattern remained the same. On diagram B, the large allele 
of the 25 PCR cycle was underrepresented compared with the 40 PCR cycles and could 
be misinterpreted as ADO. Bleed-through of the DM I labelled product to the APOC2 
electropherogram is detected. Blue colour: FAM label, Green colour: VIC label, Black 
colour: HEX label.   92 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Extreme presence of artefacts in more PCR cycles. Comparison of (A) 25 
and (B) 40 PCR cycles of DM locus on MDA products from buccal cell A7. ADO was 
present in both reaction but the 40 PCR cycles reactions exhibited too many artefacts 
that make the interpretation of the result unsecure and less clear. 
 
 
3.7 Discussion 
 
The limited amount of DNA is one of the greatest problems in a number of genetic tests, 
especially  in  PGD.  WGA  may  play  a  crucial  role  in  overcoming  this  problem  but 
accurate and detailed research has to be done in order to prevent inaccurate diagnosis. In 
the limited number of publications regarding single cell MDA and PCR analysis a large 
variation in the results has been reported although clinical application has already been 
performed.  In  this  project  MDA  amplification  from  the  minimum  amount  of  DNA 
available was assessed using two multiplex PCR reactions that have already been applied 
in clinical PGD (Kakourou et al., 2007; Moutou et al., 2004). The reason for choosing 
well established and efficient PCR reactions was to minimise the ADO and TAF events 
due to PCR inefficiency and concentrate on the potential of MDA. In most of the related 
work that has been done more than six PCR markers were analysed from each MDA 
sample. However, in this project it was considered that using two well designed PCR 
reactions could provide realistic and accurate conclusions. 
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Since the MDA reaction was first described by Lizardi et al. (1998) for circular DNA and 
later by Dean et al. (2002) for linear DNA it was tested in various DNA samples with 
different  DNA  quantity  and  quality.  When  the  starting  DNA  template  was  10ng  or 
greater, the results obtained were very promising, with more than 99% genome coverage 
(Dean et al., 2002; Paez et al., 2004). Even direct MDA on blood spots could give results 
similar to gDNA (Dean et al., 2003). Apart from genome coverage clear advantages over 
the PCR based WGA methods are the large DNA strands that are synthesized, the final 
DNA yield and the low amplification bias. The results from this project show that MDA 
of  gDNA  samples  were  100%  accurate  and  followed  similar  stutter  peak  patterns 
compared to direct gDNA. Sometimes the stutter peaks however could be higher than 
expected and have a similar peak height to the real peaks (figure 3.4). This occurrence, 
which was not consistent in all cases, probably occurred due to the high concentration of 
the PCR product on the ABI 310 genetic analyser rather being an MDA artefact.  
 
Testing at the single cell level is a much more challenging project as only two copies of 
the  DNA  template  are  available  and  new  parameters,  such  as  MDA AE  and  ADO 
complicate  the  results.  The  first  projects  that  concentrated  on  single  cell  MDA  were 
published in 2004 (Hellani et al., 2004; Handyside et al., 2004). 
 
Handyside  published  his  results  on  five  and  eleven  MDA  products  from  single 
lymphocytes  and  single  blastomeres  respectively.  The  results  were  based  on  a  very 
limited number of MDA products. MDA products from lymphocytes gave 100% MDA 
AE,  31%  ADO,  8%  TAF  and  2%  inaccurate  alleles  whereas  MDA  products  from 
blastomeres showed an overall 91% MDA AE and 16% ADO.  
 
Hellani et al. (2004) published the most controversial data on PCR with MDA samples 
from single cells. These results were based on 40 single lymphocytes that were lysed with 
proteinase K prior to MDA and digested and purified prior to PCR on 16 STR markers 
and a known mutation of the β globin gene. According to his findings, MDA AE was 
97.5%, TAF was 0.0% and overall ADO was 1.9% (10.3% for the β globin gene, 5.0% 
for D2S1338 STR marker and 0.0% for the rest 10 heterozygous STR markers). Our   94 
results are in complete contrast with Hellani’s findings since when using proteinase K 
lysis  prior  to  MDA  only  23.3%  of  the  results  gave  the  expected  allele  size  for 
lymphocytes. A year later Hellani’s group published the first clinical application of MDA 
in PGD (Hellani et al., 2005). Single cells this time were lysed using ALB lysis and not 
proteinase K, MDA AE was 97.8%, average ADO was 14.1% and TAF was 0.0%. For 10 
blastomeres that were used in two clinical PGD cases for thalassaemia and cystic fibrosis, 
MDA AE was 80.0% but ADO and TAF were absent. 
 
Since then a number of reports on single cell MDA and molecular analysis have been 
published even though it is a very specialized topic. Among them, the most important 
publications were from two groups, one from Belgium (Spits et al., 2006) that presented a 
detailed analysis from MDA products from single lymphocytes and one from the UK 
(Renwick 2006; Renwick et al., 2007) that evaluated and developed PGH. Renwick’s 
group could not be directly compared to our results since they use a completely different 
definition for ADO in their results. They consider ADO to be calculated as “the number 
of  alleles  that  failed  to  amplify  from  the  total  number  of  expected  alleles  at  the 
heterozygous loci and TAF was counted as two ADO events” whereas in our results and 
every other groups, ADO is considered as the random non amplification of one of the 
alleles present in a heterozygous sample (Ray and Handyside, 1996). Although TAF and 
ADO could have a similar nature of occurrence they should not be combined together 
since ADO can only be detected in heterozygous samples whereas TAF can be detected 
in all samples. By modifying Renwick’s calculations according to the analysis method 
that was used in this project for buccal cells an overall 38.8% ADO and 4.1% TAF were 
determined compared to 27.0% ADO that the group claimed. For blastomeres the EAS 
was 64.8% according to their results.  
 
Results from other groups are compared in detail with our results in the following pages 
(Glentis  et  al.,  2009).  Unfortunately,  most  of  the  other  published  work  was  mainly 
reporting application of MDA on clinical PGD. 
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3.7.1 Cell lysis 
 
Cell lysis is considered a crucial step for amplification by MDA as it enables exposure of 
the  DNA  making  it  accessible  to  the  Phi29  polymerase.  For  this  reason  specialized 
protocols on single cell lysis were preferred over the standard cell lysis protocol from the 
Repli G kit (Glentis et al., 2006b). From the two widely known lysis methods (alkaline 
and enzymatic), MDA produced much better results when the cells were lysed with ALB.  
Interestingly,  the  only  research  project  that  presented  results  for  MDA  single  cells 
following proteinase K lysis was in 2004 (Hellani et al., 2004). Proteinase K lysis showed 
slightly better results in buccal cells compared to lymphocytes prior to PCR irrespective 
of MDA application (tables 3.4 and 3.5). This could be explained by the different nature 
of the cells including their morphology and DNA compaction. It should be noted that 
proteinase K has been extensively used by our laboratory and others on single buccal 
cells prior to application of DOP PCR in research and clinical PGD m CGH analysis 
(Mantzouratou et al., 2008; Obradors et al., 2008; Wells et al., 2002). It seems that the 
lysis of a cell should first depend on the downstream application that will be followed 
and secondly on the type of cell. 
 
Two ALB lysis buffers (L1 and L2) were used with the only difference being the absence 
of DTT in L1. The two lysis buffers were compared in order to test if any variation would 
be detected from the results. Previous results from the Mayo clinic in the USA on MDA 
products from single fibroblasts showed excellent results when DTT was excluded from 
the  lysis  buffer  (Schowalter  et  al.,  2007).  The  same  MDA  products  from  single 
fibroblasts and blastomeres were sent to our laboratory from the Mayo group in 2007 and 
analysis of the two triplex PCR showed 100% accurate results with no ADO and TAF 
present (results not shown). Interestingly, the stutter pattern was similar to gDNA and no 
background artefacts were noticed. DTT has been shown to be necessary in single sperm 
studies as it reduces protamines by destroying disulphide bonds thereby allowing tightly 
packed DNA to become accessible to PCR primers. However, DTT may not be necessary 
for lysis of other cell types and its residual form may reduce PCR efficiency (Pierce et al., 
2002; Cui et al., 1989). Spits et al (2006) compared two lysis buffers which contained   96 
50 m and 100 m DTT and concluded that there was not a significant difference between 
the  two  buffers  although  a  small  difference  was  noticed  favouring  experiments  with 
50mΜ DTT. Schowalter et al (2007) concluded that DTT was not necessary for single 
cell MDA. Our experiments on the MDA reaction using a lysis buffer that contained DTT 
(50mM) on single buccal cells and lymphocytes showed a decreased MDA efficiency and 
accuracy on buccal cells and no difference on lymphocytes compared to cells that were 
lysed  without  DTT.  In  all  the  relative  literature  published  DTT  is  used  in  50 M  or 
100 M concentrations and volumes of 0.5 l to 2.5 l. It has been commented by other 
groups that ADO variation depends primarily on the cell type and the region of DNA that 
is amplified (Hellani et al., 2008; Burlet et al., 2006). Our results show that lysis also 
plays a crucial role in the ADO variation. 
 
3.7.2 Cell types 
 
Different cell types have been described previously for PGD workups and other studies at 
the single cell level (Renwick et al., 2007; Fiegler et al., 2007; Spits et al., 2006).There 
are crucial differences between the cell types that are chosen. Buccal cells are easy to 
obtain for genetic testing but their DNA is degenerate as these cells are already dead or 
they have started the process of apoptosis (Piyamongkol et al., 2003). Lymphocytes are 
very small cells (7 9 m diameter) which make the isolation more difficult compared to 
other cell types. Their nucleus is large and it encompasses most of the cell, the cytoplasm 
is tiny and the DNA is relatively dense (Loiko et al., 2006). The fibroblasts that were 
collected for this project were actively dividing cells isolated from culture flasks before 
confluence. The DNA may be similar to a blastomere or a carcinogenic cell that may be 
dividing and therefore may have double the amount of DNA template available for the 
MDA reaction. The blastomeres used for this study were obtained from embryos that 
were excluded from embryo transfer which make them very likely to have chromosomal 
abnormalities. The majority of PGD workups are done on lymphocytes (Hellani et al., 
2005;  Lledo  et  al.,  2007)  and  fewer  groups  have  reported  workups  on  buccal  cells 
(Obradors  et  al,.  2008;  Renwick  et  al.,  2006).  Our  results  show  a  clear  benefit  of 
lymphocytes and fibroblasts over buccal cells that can be explained by the superiority of   97 
DNA  quality  from  these  cell  types.  Blastomeres  have  comparable  results  with 
lymphocytes and fibroblasts but only when 10/34 cells that did not amplify at any locus 
were excluded. For two markers (APOC2 and D19S112) the ADO was relatively low 
(6.3% and 5.5% respectively) in contrast with the DM locus from which a 20.8% ADO 
rate was obtained. 
 
3.7.3 MDA-AE 
 
A marked difference in terms of MDA AE was observed between the MDA products 
from single buccal cells (82.0%) compared with lymphocytes and fibroblasts (96.0% and 
100% respectively). MDA AE for lymphocytes and fibroblasts in this study correlated 
with other studies (Lledo et al., 2007; Ren et al., 2007; Burlet et al., 2006;) but MDA AE 
for buccal cells yielded 100% in one publication (Obradors et al., 2008) and was not 
mentioned in another (Renwick et al., 2006). Since MDA AE has been calculated as the 
number of MDA products from single cells that would give at least one result for the 
tested loci, it is clear that the more loci that are used, the higher would be the MDA AE. 
However, it was our belief that if MDA would fail to amplify all six markers it would be 
enough to conclude that the amplification efficiency was so low that it was similar to 
MDA failure. Likewise, for MDA application on single blastomeres, MDA AE was not 
calculated because three markers located on the same chromosome were not considered 
enough to give a reliable result. As the blastomeres were obtained from embryos of PGS 
cases the chance of a chromosomal abnormality involving chromosome 19 was possible. 
It should be noted that MDA AE could not be tested by measuring DNA concentration 
since DNA measurements show DNA existence even in negative results (Renwick et al., 
2007; Spits et al., 2006). It is believed that MDA failure is mainly due to DNA quality of 
the single cell as it has been previously reported from various studies on gDNA samples 
of low molecular weight (Barber et al., 2006; Montgomery et al., 2005). 
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3.7.4 TAF and ADO 
 
The  biggest  difference  observed  on  MDA  products  from  buccal  cells  compared  to 
lymphocytes and fibroblasts was TAF. An average of 20.8% TAF was obtained from 
buccal  cells  compared  to  6.6%,  7.5%  and  6.9%  from  lymphocytes,  fibroblasts  and 
blastomeres respectively indicating that buccal cells may not be a suitable source of DNA 
to  facilitate  reliable  MDA  amplification.  DNA  degradation  could  explain  the  TAF 
difference between buccal cells and the other cell types studied. There is a large variation 
of TAF among different published results. Hellani et al. (2004, 2005, 2008) and Ren et al. 
(2007) indicated very low TAF for lymphocytes and blastomeres (zero up to 5%), Burlet 
et  al  (2006)  showed  a  5 15%  and  26 39%  TAF  for  lymphocytes  and  blastomeres 
respectively and Spits et al (2006) published an average of 9.2% TAF (61/600) on MDA 
products from single lymphocytes.  In our blastomere results, if the ten excluded cells 
were included in the analysis, the average TAF would increase to 34.2% from 6.9%. 
However, these cells were excluded from the analysis because it could not be determined 
if the alleles did not amplify due to MDA failure or due to actual TAF of the PCR post 
MDA. Renwick et al. (2006 and 2007) did not include TAF in their results but rather 
considered TAF as two ADO events. By analysing their data on MDA products from 
buccal cells with our parameters an overall 4.1% (3/72) of TAF was observed in the 
heterozygous loci (no information was given for the homozygous loci and so could not be 
included  in  the  analysis).  Obradors  et  al.  (2008)  did  not  detect  any  TAF  on  MDA 
products from single buccal cells. The results from these two groups are in contrast with 
our results which consider TAF as the largest problem encountered with MDA on single 
buccal cells. It should be noted that even in direct PCR on single buccal cells TAF has 
been calculated to be higher than the results published from these groups (Table 3.3; 
Sumita  et  al.,  2007;  Fassihi  et  al.,  2006).  According  to  our  results,  high  TAF  was 
expected  as  DNA  from  buccal  cells  is  considered  to  be  degenerated  and  this  could 
hamper MDA function. 
 
In our results ADO was calculated to be 31.0% for buccal cells, 20.8% for lymphocytes 
and 20.0% for fibroblasts. MDA products from blastomeres had an average of 12.1%   99 
ADO for the DM triplex. However, if the two inconclusive results were counted as ADO, 
blastomeres would have 15.6% ADO which would be very similar to the 17.5% and 
18.0%  ADO  of  lymphocytes  and  fibroblasts  for  the  DM  loci  respectively.  ADO  is  a 
phenomenon that has been associated primarily with limited DNA availability and less 
with poor quality of DNA as it is mainly abundant at the single cell level. The high inter 
locus variation observed shows that ADO also depends on the region of amplification. 
For buccal cells, Renwick et al. (2006) reported an average of 27.0% ADO although 
according to the actual definition of ADO their average rate rises to 38.8% for the results 
they presented. Having a universal presentation of the results would be helpful for the 
comparison  of  similar  research  projects.  Obradors  et  al.  (2008)  published  an  average 
ADO rate of 20%. Nevertheless, in the limited published papers regarding MDA and 
single buccal cells it seems that ADO varies greatly but is usually higher compared to 
MDA products from single lymphocytes. 
 
Regarding MDA on single lymphocytes, many more groups have published their data but 
the inconsistency of the results is even greater. Hellani et al. (2004), Lledo et al. (2006) 
and Ren et al. (2008) presented very small ADO (zero to 9%), Burlet et al. (2006) had an 
average  of  20%  ADO,  Spits  et  al.  (2006)  presented  an  average  of  26%  ADO  and 
Handyside et al. (2004) published an average of 31% ADO from a small number of MDA 
products.  Interestingly,  the  research  groups  that  have  published  high  ADO  rates  for 
lymphocytes experienced lower ADO rates on blastomeres (Glentis et al., 2009; Burlet et 
al., 2006) whereas the groups that show small ADO rates on lymphocytes had increased 
ADO in their clinical PGD cases with MDA (Ren et al., 2008; Lledo et al., 2006; Hellani 
et al., 2005) 
 
From the ADO results in 59.2% (58/98) of the total cases the larger allele was lost. 
However, considering heterozygous alleles that were more than 2bp apart, ADO of the 
larger  allele  occurred  in  50.6%  (40/81)  of  cases,  indicating  that  ADO  happened 
irrespective of allele size. In theory, ADO in MDA should happen irrespective of allele 
size  as  it  is  an  isothermal  amplification  with  effectively  no  upper  limit  on  strand 
extension length. However, this finding could be explained by the different stutter bands   100 
present in the MDA products. As stutter peaks were usually larger and different from the 
gDNA peaks for alleles that were very close together, ADO of the smaller allele may be 
present but “hidden” and confused with a stutter peak. Therefore in heterozygote samples 
that were 2bp apart, ADO was detected only in the larger allele (17/17). Similar concerns 
regarding confusion encountered from heterozygous alleles very close to each other have 
been reported previously following single cell MDA (Spits et al., 2006). According to 
this analysis it is very likely that some ADO events were confused with the stutter peaks 
in alleles with only 2bp difference due to the noise of the results. 
 
Overall from our TAF and ADO results we conclude that (a) although MDA increased 
the total amount of DNA prior to PCR it showed higher rates of ADO compared to direct 
single cell PCR (Moutou et al., 2004; Piyamongkol et al., 2002) and (b) the main problem 
of MDA of single cells of low quality was TAF and not ADO. Thus good quality DNA 
was  essential  for  robust  MDA.  The  results  from  some  groups  that  had  completely 
different outcomes from ours regarding TAF and ADO (Hellani et al., 2008; Hellani et al 
2004; Lledo et al., 2007; Lledo et al., 2006; Ren et al., 2007) give the impression that 
MDA should be considered as a favourable technique over direct PCR on single cells. In 
contrast, our results show that the advantage of MDA is that it produces large amounts of 
DNA  that  can  be  used  for  more  genetic  analysis  and  minimise  the  chance  of 
misdiagnosis. 
 
3.7.5 Inaccurate alleles, artefacts and bleed-through 
 
A total of four alleles (three from buccal and one from lymphocyte MDA products) of 
inaccurate size were detected (figures 3.7 and 3.8). At least one other study reported 
inaccurate allele size from PCR analysis after single cell MDA (Renwick et al., 2006) but 
most studies do not report the presence of incorrect alleles, confirming the accuracy of 
Phi29 polymerase (Dean et al., 2002). Contamination was excluded as an explanation of 
the presence of such alleles because it would likely account for inaccurate results on all 
three alleles of the triplex PCR. Although the data collected were very limited in order to 
make reliable conclusions it should be mentioned that MDA products from buccal cells   101 
had  three  times  more  inaccurate  allele  sizes  compared  to  lymphocytes.  The  main 
difference between the two cell types is the DNA quality which implies that this could 
play a role in the presence of inaccurate alleles. Another hypothetical explanation is the 
presence of chimeras that have been detected from DNA sequencing studies (Lasken and 
Stockwell, 2007).  
 
Whether the background noise of a result could be misunderstood as an incorrect allele 
would  need  further  investigation  but  depending  on  the  results  obtained  artefacts  and 
bleed through events could easily be distinguished from the real peaks. Bleed through 
could be minimised by diluting DNA from PCR product or use singleplex PCR (Sioban 
SenGupta,  personal  communication).  The  presence  of  background  noise  is  not  well 
understood but it is most likely that it begins due to traces of contaminating DNA or due 
to an undefined mechanism that does not require any template other than the primer 
population (Hutchison and Venter, 2006). Since the only available DNA comes from a 
single cell, even if a small amount of non specific DNA is produced, it would be easily 
detected. Some groups have managed to minimise the background noise by minimising 
the reaction volume to 60 600nl (Marcy et al., 2007; Hutchicon et al., 2005). However, 
that was technically impossible to do in our laboratory. The comparison of 25 and 40 
PCR cycles showed that artefacts and bleed through was diminished when fewer cycles 
were  used  but  still  existed.  However,  in  some  cases  the  real  peaks  were  also 
underrepresented (figure 3.7B large allele) and could be misdiagnosed as ADO. It was 
concluded that less PCR cycles minimise background noise but also increase the chance 
of misdiagnosis. 
 
3.7.6 Conclusion 
 
The  results  obtained  from  a  large  number  of  MDA  products  from  single  cells  from 
various  cell  types  gave  several  conclusions.  MDA  amplified  successfully  DNA  from 
single  cells,  in  the  majority  of  cases,  especially  on  cell  types  of  good  DNA  quality. 
Inaccurate alleles were found only in four cases but ADO and TAF were more often 
present compared to single cell PCR. As single cell PCR showed better results compared   102 
to  PCR  post  MDA  of  single  cells,  the  use  of  MDA  for  PGD  should  be  selected  for 
specific cases. The amount of DNA that is generated is the great advantage of MDA and 
could  be  helpful  to  minimise  misdiagnosis  by  using  direct  and  indirect  diagnosis 
(Obradors et al., 2008). Work up time for a specific genetic mutation could be minimised 
by  using  singleplex  PCR.  MDA  could  also  be  used  for  combination  of  molecular 
diagnosis with PGS (Obradors et al., 2008) or for the diagnosis of more than one genetic 
disorder. (Fiorentino et al., 2006). PGH can also be performed with MDA although from 
the results presented by Renwick et al. (2006 and 2007) a number of markers produced a 
very high ADO rate which means that PCR reactions for MDA should be well optimised. 
 
The preclinical evaluation in a limited number of cells (Ren et al., 2007; Lledo et al., 
2006)  was  considered  to  be  very  unreliable  as  high  ADO  and  TAF  could  lead  to 
misdiagnosis. According to our results, buccal cells were easy to obtain but were not 
favourable for MDA evaluation. The high variability of results presented from various 
groups demonstrates the need of more detailed research prior to the wide application of 
MDA to clinical PGD. The high background noise developed from the technique does not 
seem to influence PCR analysis but should be eliminated for other applications of MDA 
and single cells. More work should be done on single blastomeres for more reliable and 
accurate results. However, due to the difficulty of obtaining single blastomeres and in 
combination to the fact that too much work was done to optimise the reaction on other 
cell types it did not allow further experiments to be performed on single blastomeres.  In 
conclusion, MDA can be used as a universal step prior to molecular analysis for PGD. 
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Chapter 4 
 
Analysis of single cells by a-CGH 
 
4.1 Hypothesis 
 
The hypothesis of this chapter was that a CGH can accurately assess the chromosomes of 
a single cell. 
 
The difficulty of answering this hypothesis has mainly to do with the limited amount of 
DNA available and the sensitivity of a CGH. As WGA of single cells is necessary for a 
CGH  experiments,  uneven  amplification  of  the  genome  together  with  artefacts  and 
unspecific DNA formed by the amplification techniques would hamper the effectiveness 
and accuracy of a CGH.  
 
4.2 Introduction 
 
Five years after the development of metaphase CGH (Kalliomeni et al., 1992), the first 
approach of a CGH was published (Solinas Toldo et al., 1997). Two basic reasons for 
this evolution were the higher resolution that could be achieved and the automation of the 
analysis. A CGH has evolved very fast over recent years especially with the use of COT 
1 DNA that blocks repetitive sequences (Craig et al., 1997), dye swap experiments and 
the resolution increase with the use of oligo or tiling path BAC arrays. 
 
In PGS, aneuploidy screening of blastomeres is routinely performed by FISH (Baart et 
al., 2007) but m CGH has been applied (Wilton et al., 2001; Wells et al., 2002; Obradors 
et al., 2008). Both techniques have limitations (sections 1.5.5 and 1.5.6). An automated 
technique  that  could  provide  information  within  two  or  three  days  could  be  very 
beneficial. 
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Very few studies have been reported regarding single cell a CGH. The first approach was 
made in 2004 (Hu et al., 2004). Since then a limited number of groups have published 
their results (Hellani et al., 2004; Le Caignec et al., 2006; Feigler et al., 2007; Iwamoto et 
al., 2007; Fuhrmann et al., 2008). Each group used different array platforms (BAC arrays, 
SNP arrays, oligo arrays) and WGA methods (MDA, GenomePlex, DOP PCR, LA PCR) 
whereas some groups have concentrated on optimising the WGA technique and others the 
array platform. The maximum resolution from single cell a CGH has been claimed to be 
as  high  as  5MB  (Fuhrmann  et  al.,  2008)  but  in  the  first  clinical  PGS  case  that  was 
reported recently whole chromosome changes were considered (Hellani et al., 2008).  
 
4.3 Aims 
 
The aims of this chapter were to produce WGA (MDA and GenomePlex) products from 
various types of single cells (lymphocytes, fibroblasts and blastomeres) that can be used 
for accurate and reliable chromosomal analysis by a CGH. Application of good quality 
gDNA on a CGH can provide very high resolution analysis but at the single cell level 
high resolution analysis seems very difficult and challenging. 
 
A CGH could be very useful for the investigation of chromosomal abnormalities at the 
single cell level in different biological fields. PGS would benefit from analysis of all 
chromosomes  from  blastomeres  before  embryo  transfer.  A CGH  could  be  helpful  for 
PGS as it allows diagnosis within 2 3 days so the need of cryopreservation would be 
eliminated. Further applications of a CGH and single cells could be obtained for research 
purposes such as for the analysis of chromosomal imbalances in blastomeres. Similarly, 
the application of a CGH in single tumour cells could give more detailed information 
about  cancer  mechanisms  from  the  few  cells  that  actually  promote  chromosomal 
imbalances in tumours. 
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4.4 Experimental Design 
 
For the purposes of this study, two different WGA techniques were applied on single 
cells and the WGA product was applied on BAC array slides from different companies or 
institutions. The cells were initially lysed with L1 lysis (ALB lysis without DTT, table 
2.1) and amplified with MDA protocol P2. Alternatively, the cells were lysed with L1 or 
L3 lysis (proteinase K) and subjected to GenomePlex amplification (Section 2.4.2, table 
2.2). Single lymphocytes, blastomeres and fibroblasts were used for this study as well as 
gDNA for positive controls. The WGA products were purified using a DNA clean up kit 
and the DNA measured using a spectrophotometer. For MDA products, PCR analysis of 
the DM 1 locus was performed in order to confirm successful amplification. A CGH 
slides from three companies (Spectral Genomics, Array Genomics and BlueGnome) and 
two  institutions  (Sanger  Institute  and  Translational  Research  Laboratory,  TRL)  were 
used.  All  the  slides  were  BAC  arrays  with  various  resolutions  of  10MB  (about  400 
clones), 1MB (about 4000 clones) or tiling path (32000 clones). FISH experiments were 
performed  in  order  to  confirm  the  uniformity  of  the  fibroblasts  and  to  determine 
chromosome abnormalities in blastomeres. 
 
The results were separated into four sets of experiments. Experiments A were performed 
with the Sanger Institute slides. The results are presented separately because except for 
the  WGA  method,  the  arrays  were  run  at  the  Sanger  centre  by  another  person  and 
information  was  provided  (only  graphs  of  the  final results  and  not  analysis  data  like 
percentage  of  clone  inclusion  and  standard  deviation  for  autosomal  and  sex 
chromosomes). Experiments B  were performed  with gDNA  and MDA  products from 
gDNA which were used as positive control experiments and to demonstrate which slide 
was providing the best results. Experiments C were conducted with WGA products from 
single lymphocytes and fibroblasts and finally experiments D were performed with WGA 
from single blastomeres. Figure 4.1 summarises all the main experiments. Apart from 
Sanger arrays, all a CGH experiments were conducted by the author in the North Thames 
Regional Cytogenetic Laboratory, London. 
   106 
4.5 Materials and Methods 
 
4.51 Ethical approval 
 
For blastomeres and embryos, Human Fertilisation and Embryology Authority (HFEA) 
approval was obtained together with written consent from the couples for donation of 
their embryos for research purposes. 
 
 
4.5.2 Materials and DNA samples for a-CGH 
 
Various DNA samples were used for single cell a CGH experiments. Fourteen single 
lymphocytes, two single trisomic fibroblasts and five single blastomeres were subjected 
to  WGA  for  the  amplification  of  their  DNA  for  molecular  cytogenetic  downstream 
reactions.  MDA  from  control  DNA  as  well  as  non treated  DNA  with  known 
chromosomal abnormalities was used for control experiments. A single cell DOP PCR 
sample was provided by another student (Leoni Xanthopoulou) for one experiment. A 
total of 24 a CGH experiments were conducted with slides from different companies and 
institutions  (Sanger  Institute,  Spectral  Genomics,  Array  Genomics,  TRL  and 
BlueGnome)  
 
4.5.3 Cells and DNA treatment before a-CGH 
 
All lysis and WGA methods used for this chapter are described in sections 2.3 and 2.4. 
Single cells were lysed for DNA extraction prior to WGA. For MDA method L1 lysis 
(ALB lysis without DTT) was used. MDA protocol P2 (2 hours incubation) was used for 
the amplification of DNA from single cells whereas protocol P3 (protocol for gDNA) 
was used for DNA amplification of gDNA. For GenomePlex both L1 and L3 (proteinase 
K lysis) were used prior to amplification. The protocols that were used to amplify the   107 
 
Figure 4.1: Experimental design of the single cell a-CGH experiments. This figure presents a summary of the main experiments that 
were conducted in this chapter. Four sets of experiments were performed which are shown in different colours in the diagram. DNA 
was first amplified by WGA and purified and then applied to a-CGH after selection through PCR and concentration measurement.
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single  cells  were  P6  (proteinase  K  lysis  method)  and  P7  (alkaline  L1  lysis)  whereas 
gDNA was amplified with GenomePlex using protocol P5 (protocol for gDNA). All the 
DNA or WGA products were cleaned using Zymo research TM 25 clean up kit. After 
DNA  purification  the  DNA  concentrations  were  measured  using  a  spectrophotometer 
ND 1000  and  its  computer  program  ND 1000  software.  The  optical  density  (OD, 
260nm/280nm wavelength) was also scored for DNA purity. For pure DNA, OD should 
be 1.80. Numbers above 1.80 indicate the presence of RNA and numbers below 1.80 
imply  the  contamination  with  proteins.  In  order  to verify  that  MDA  amplification  of 
single cells had worked, all the single cell MDA products were subjected to PCR analysis 
for the DM I triplex (section 3.5.4.1). These markers were used only to determine that 
MDA correctly amplified the DNA from a single cell and the NanoDrop measurement 
was not due to unspecific DNA. The MDA products in which PCR had the most accurate 
genotypes were used for the a CGH experiments. PCR was not applied to single cell 
GenomePlex  products  because  the  technique  would  not  work  due  to  the  short  length 
products that are produced (section 3.2). In two MDA products from single blastomeres, 
PCR was also applied for detection of specific chromosomes and gender determination. 
The markers used were located on chromosome 5 (markers D5S1965, D5S2065, D5S656 
and  D5S346),  chromosome  7  (p.Phe508del  and  IVS8CA)  and  sex  chromosomes 
(amelogenin  gene).  The  PCR  reaction  for  the  markers  on  chromosome  7  is  already 
reported (section 3.5.4.2). For markers on chromosome 5, the reactions were performed 
in singleplex. All the markers had the forward primer labelled with FAM and 0.3 M of 
primers were used for each reaction. The rest of the reagents for the reaction and the 
conditions of the PCR are identical with the DM I triplex. The markers on the amelogenin 
gene were used for gender determination. PCR on a female sample would produce only 
one product (104 bp) and on a male sample two products (104 bp and 117 bp) due to the 
presence of the gene in X and Y chromosomes (Hellani et al., 2009). The forward primer 
of the amelogenin marker was labeled with FAM and 0.3 M of primers were used for the 
reaction. All the other reagents used for PCR were identical to the DM 1 triplex (section 
3.5.4.1)  and  the  reaction  conditions  were  identical  to  DM  I  triplex  apart  from  the 
annealing temperature which was 59
oC. 
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4.5.4 A-CGH 
 
Various microarray slides from different companies and research institutions were used; 
Sanger  Institute  (Cambridge  University),  Spectral  Genomics,  Array  Genomics,  the 
Translational  Research  Laboratory  (TRL)  (UCL)  and  BlueGnome.  For  each  slide  the 
optimised protocol from the company/institution was applied. 
 
4.5.4.1 Sanger Institute 
 
The  Sanger  Institute  developed  BAC  and  PAC  array  slides  for  prenatal  diagnosis 
(Rickman et al., 2005). The clones were previously amplified with DOP PCR. Four slides 
were hybridised on gDNA and MDA products from gDNA and single cells. The DNA 
and  MDA  products  were  produced  at  UCL  and  sent  to  the  Sanger  Institute  for 
hybridisation  and  analysis.  The  array  slides  (Rickman  et  al.,  2005)  and  the  protocol 
followed (Fiegler et al., 2003) have been previously published. 
 
4.5.4.2 Spectral Genomics 
 
The  Constitutional  Chip
TM  2.0  developed  by  Spectral  Genomics  (now  sold  to  Perkin 
Elmer, USA) is an a CGH platform that contains 434 BAC clones that are specific to 
known  constitutional  syndromes,  disorder causing  subtelomeric  regions  and  trisomies. 
Reagents used for this project are listed in Appendix A7. The labelling and hybridisation 
protocol used was provided from the company: Briefly, 1 g of each DNA sample was 
diluted in 50 l of nuclease free H2O and sonicated for 1 minute at 100 amplitude. The 
DNA was purified and eluted in 54 l of sterile water using the Zymo Research’s DNA 
clean and concentrator TM 5. Each sample was split into two tubes in order to label them 
with different dyes. Twenty  l of 2.5x random primer solution (Invitrogen) were added to 
each tube, the DNA was denatured at 100
oC for 5 minutes and immediately cooled on ice 
for  another  5  minutes.  Two  master  mixes  (one  for  each  dye)  were  prepared  which 
contained Spectral Labelling buffer 2.5 l X (4x number of experiments + 0.2), Cy3 dCTP 
or Cy5 dCTP 1.5 l X (4x number of experiments + 0.2) and Klenow fragment 1 l x (4 x   110 
number of experiments + 0.2). Five microlitre of the master mix was mixed with the 
DNA and the samples were incubated at 37
oC for 1 hour. The samples were denatured 
again at 100
oC for 5 minutes and cooled on ice for another 5 minutes; 5 l of the same 
master mix was added and incubated at 37
oC for another hour. Five  l of 0.5 M EDTA 
was added to each tube to stop the reaction. After labelling, the differentially labelled 
DNAs (test and reference) were mixed together and 45 l of Spectral Hybridisation Buffer 
I  was  added  together  with  6.45 l  of  5M  NaCl  and  65 l  of  isopropanol  in  order  to 
precipitate the DNA. The samples were incubated at room temperature for 20 minutes 
and centrifuged at full speed for 30 minutes. The supernatant was discarded, and the 
pellet was rinsed in 250 l of 70% ethanol. The samples were centrifuged for 3 minutes at 
full speed, the supernatant was discarded and the pellet was left to air dry for 5 minutes. 
The DNA was resuspended in 5 l of sterile water and incubated for 10 minutes at room 
temperature. After complete resuspension of the pellet, 12 l of Spectral Hybridisation 
Buffer II was added and the sample was incubated first at 72
oC for 10 minutes and then at 
37
oC for 30 minutes. Finally, 15 l of the DNA solution was applied on each sub array 
under a 22 x 22mm coverslip and the slide was incubated in a hybridisation at 37
oC for 
16 hours.  
 
For post hybridisation washes, the coverslips were removed from the slides by manually 
agitating the slides in 2xSSC/0.1% SDS and the slides were washed in the same solution 
for  15  minutes  at  45
oC.  The  slides  were  incubated  in  2xSSC/50%  formamide  for  15 
minutes at 45
oC and then in 2xSSC/0.1% SDS for 30 minutes at 45
oC. Finally the slides 
were washed in 0.2xSSC for 15 minutes at room temperature twice, and centrifuged at 
170g for 3 minutes to dry. 
 
4.5.4.3 Array Genomics 
 
Array Genomics is a French company that produces pre  and postnatal arrays. Each slides 
contains  950  BACs  printed  in  triplicate  in  two  separate  areas  allowing  dye swap 
hybridisations on the same slide. The clones are printed directly onto a 3D microscopic 
slide, without denaturation of the DNA. The clones cover most known micro deletion   111 
syndromes, telomeric regions and has a median resolution of 10MB. Three arrays were 
provided by Array Genomics and the reagents were supplied from Invitrogen and GE 
healthcare (dyes Cy3/Cy5). The protocol used was identical to the Spectral Genomics 
protocol (section 4.5.4.2). 
 
4.5.4.4 Translational Research Laboratory 
 
The Translational Research Laboratory (TRL, Institute for Women’s Health) developed 
an a CGH platform from the ‘Golden Path’ BAC clone set generated by CHORI (USA) 
and Genome Sciences Centre (Canada) (Mermaid 32K array). The 30,388 BAC clones 
were derived from the Human RPCI 11 and  13 libraries and the ‘CalTech’ Human BAC 
Libraries  (CIT D).  The  clones  were  amplified  using  MDA  (TempliPhi  kit,  GE 
Healthcare)  and purified using the Millipore MultiScreen PCR384 filter plates before 
printing onto slides using a QArray² robot. 
  
The Bioprime genomic labelling system was used to label the DNA. Briefly, 800ng of 
DNA or WGA product were used as a starting material and diluted in 21 l of dH2O. 
Twenty microlitres of random primers were added to the DNA and the samples were 
denatured at 95
oC for 15 minutes. This was followed by placing the samples on ice for 15 
minutes and then 5 l of dNTP/low dCTP mix, 2 l of Cy3 or Cy5 and 1 l of klenow 
fragment were added to each sample. The samples were incubated at 37
oC for 18 hours. 
After the reaction was finished 5 l of EDTA were added to stop the reaction and the 
tubes were stored at 4
oC.  
 
The  samples  were  purified  prior  to  the  precipitation  and  hybridisation  process  using 
Autoseq  G50  columns  following  a  standard  protocol.  Briefly,  the  columns  were  first 
vortexed for 30 seconds in order to resuspend the resin in the column and then the bottom 
closure was removed. The screw cap was loosened by one quarter of a turn, the columns 
were placed in a 1.5ml conical screw cap tubes and centrifuged at 5000rpm for 1 minute. 
The conical tubes that collected the supernatant were discarded and the columns were 
placed in new clean conical tubes. The labelled DNA was placed in the centre of the   112 
remaining resin ensuring that no product would be left in the walls of the tube. The 
columns  were  centrifuged  for  2  minutes  at  5000  rpm.  The  clean  labelled  DNA  was 
collected in the conical tubes and the columns were discarded. The incorporation of the 
dyes  in  the  DNA  was  measured  with  the  ND 1000  spectrophotometer  using  1.5 l  of 
labelled DNA.  
 
DNA precipitation was carried out by combining the reference and the test labelled DNA 
and adding 100 g of human COT 1 DNA, 30 l 3M NaOH pH5.2 and  825 l of absolute 
ethanol. The DNA was precipitated at  20
oC for 2 hours. After the precipitation step the 
samples  were  centrifuged  at  full  speed  for  30  minutes  at  4
oC,  the  supernatant  was 
removed and the pellet was dried in a heat block at 37
oC for 15 minutes. Hybridisation 
solution (50% formamide, 2% SDS, 10% dextran sulphate and 4 g/ l yeast tRNA) was 
prewarmed to 37
oC for a few minutes until it became clear and 85 l were applied to the 
dry DNA pellet. The samples were incubated at 37
oC and vortexed every 5 minutes until 
the pellet was completely dissolved. Once the  pellet was dissolved the samples were 
denatured at 70
oC for 5 minutes and re annealed for 1 hour at 37
oC. 
 
Ten millilitres of fresh pre hybridisation solution (25% formamide, 5xSSC, 0.1%SDS 
and 0.05g of BSA) was prepared and heated at 42
oC. The array was denatured on a heat 
block at 95
oC for 2 minutes and 200 l of pre hybridisation solution were placed on top of 
the array spots. This was covered with a 22x54mm coverslip and the array was incubated 
in a hybridisation chamber at 42
oC for one hour. The slides were rinsed in 0.1xSSC and 
dried by centrifugation at 170g for 2 minutes. 
 
The samples were applied on a 22x54mm coverslip avoiding any bubbles and the slides 
were carefully lowered onto the coverslip. The slides were inclubated in a hybridisation 
chamber at 42
oC for 16 hours. The post hybridisation washes were identical to Spectral 
Genomics protocol (section 4.5.4.2). 
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4.5.4.5 BlueGnome 
 
Two types of BlueGnome BAC array slides were used. The Cytochip 1MB V2 is an array 
of 6,000 BAC clones with a median of 565kb resolution of the human genome. The 
Cytochip prenatal Beta is a constitutional slide with 500 BAC clones that covers most of 
the known genetic imbalanced syndromes. Both types had two hybridisation areas for dye 
swap experiments.  
 
Fluorescent  labelling  of  test  and  reference  DNA  took  place  using  the  BlueGnome 
fluorescent labelling kit (BlueGnome, UK). Briefly 4 l containing 400ng of DNA were 
placed in a 0.2ml thin walled PCR tube. Cy3 and Cy5 labeling mixes where prepared as 
follows: Reaction buffer 10 l x (2 x number of experiments + 0.4), nuclease free H2O 
19 l  x  (2  x  number  of  experiments  +  0.4),  Primer  solution  10 l  x  (2  x  number  of 
experiments + 0.4), dNTP mix 5 l x (2 x number of experiments + 0.4) and Cy3 dCTP 
1 l x (2 x number of experiments + 0.4) or Cy5 dCTP 1 l X (2 x number of experiments 
+ 0.4). Once the labelling mixes were prepared, 45 l were added to the DNA and the 
samples were denatured at 94
oC for 5 minutes. Following denaturation the samples were 
immediately placed on ice for another 5 minutes. For the labelling reaction to take place 
1 l of klenow enzyme  was added to each tube and the samples were  incubated in a 
thermal cycler for 18 hours at 37
oC. Once the reaction had finished 5 l of EDTA was 
added to each sample to stop the reaction. The purification of the labelled DNA and the 
measuring of the dye incorporation were identical to the protocol followed by TRL slides 
(described in section 4.5.4.4). 
 
For precipitation, the tube was inverted twice to mix and precipitated in the dark for 2 
hours at  20
oC. After precipitation of labelled DNA, the samples were centrifuged at full 
speed for 15 minutes, the supernatant was discarded and the pellet was washed in 250 l 
of 70% ethanol. The samples were centrifuged again and the supernatant was discarded. 
Any remaining droplets were removed with a pipette and the samples were left to air dry 
for 5 minutes. The tubes containing a purplish pellet were stored in the dark at  20
oC until 
required.   114 
 
In a separate tube, 75 l of herring sperm DNA, 62.5 l of COT 1 DNA, 14 l of 3M 
sodium acetate pH 5.2 and 350 l of absolute ethanol per microarray experiment were 
mixed together  and precipitated for 2 hours at  20
oC. This mixture was used  for the 
formation of the hybridisation solution. Similar to the labelled DNA, after precipitation 
the samples were centrifuged at full speed for 15 minutes, the supernatant was discarded 
and the pellet was washed in 350 l of 70% ethanol. The samples were centrifuged again 
and the supernatant was discarded. Any remaining droplets were removed with a pipette 
and the samples were left to air dry for 5 minutes. 
 
Once  the  pellet  was  dried,  52.5 l  of  hybridisation buffer  (10%  dextran  sulphate)  per 
experiment was added and the tube was incubated at 75
oC in a hot block for 10 minutes. 
Ensuring that the pellet has completely dissolved, 25 l of the hybridisation solution were 
added to each labelled DNA pellet. The tubes were incubated for 10 minutes at 75
oC and 
flicked every couple of minutes to ensure that the pellet was completely dissolved. Once 
the  pellets  were  dissolved  the  samples  were  denatured  for  a  further  10  minutes.  The 
Cytochip  slides  were  incubated  in  100ml  PBS  solution  for  5  minutes  and  dried  by 
centrifugation at 1000 rpm for 3 minutes. Twenty two microlitres of the pre hybed DNA 
solution was applied on each sub array under a 22 x 22mm coverslip. Each array was 
placed in a hybridisation chamber and incubated at 37
oC for 16 hours. 
 
Formamide free washes were performed to remove any unbound labelled DNA from the 
Cytochip  slides.  The  coverslips  were  removed  from  the  Cytochip  slides  by  manually 
agitating  the  slides  in  2xSSC/0.05%  Tween20.  The  slides  were  washed  in  400ml  of 
2xSSC/0.05% Tween20 at room temperature twice for 10 minutes each. A third wash of 
the same solution at 60
oC for 5 minutes was performed and this was followed by a 1xSSC 
wash at 60
oC for 5 minutes. The slides were washed in 0.1xSSC solution at 60
oC for 5 
minutes and finally in 0.1xSSC at room temperature for 5 minutes. The slides were dried 
by centrifugation at 170g for 3 minutes. 
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4.5.4.6 Scanning and analysis 
The images were scanned using a ProScanArray HT Microarray Scanner (Perkin Elmer, 
Finland). The analysis of the images was performed with the use of the BlueFuse for 
microarrays software provided by BlueGnome for the Cytochip slides, the TRL slides 
and the Array Genomic slides. Analysis for Spectral Genomics was performed with the 
use of SpectralWare™ online software. The process order for all experiments was first 
normalization  and  then  exclusion.  For  Cytochip  arrays,  the  Cytochip  normalization 
software was used which has been designed by BlueGnome to provide best results for the 
company slides. The exclusion of the clones was performed by Cytochip normalization 
protocol. The software does not allow any changes to be made in the post processed 
results and combined results by fusion. The log2 threshold for amplification and deletion 
was set to +0.2999 and  0.2999 respectively. In a number of experiments, analysis was 
also performed with a different algorithm (prenatal algorithm) that is used to identify 
only whole chromosome changes. This algorithm is currently developed by BlueGnome 
but no further information was provided for the analysis method that is being performed. 
For the TRL 32K Mermaid arrays the Lowess 2D normalization method was used and 
clones were excluded when the confidence was less than 0.5 or replicates with SD were 
greater than 0.5. For the analysis of the Spectral Genomics and Array Genomics arrays, 
block lowess normalization method was used. No further information was provided for 
the Spectral Genomics analysis. For Array Genomics clones were excluded when the 
confidence was less than 0.3 or replicates with SD were greater than 0.1 or dye swap 
replicates with SD greater than 0.2. 
4.5.5 FISH experiments 
 
FISH experiments were used to examine chromosome abnormalities of human embryos 
from which blastomeres were used in the a CGH analysis and to score the fibroblasts in 
order to confirm the homogeneity of trisomies 13 and 21. DNA probes were all provided 
from Vysis UK and FISH solutions were provided by Sigma UK (Appendix A8).  
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4.5.5.1 Slide preparation for skin fibroblast and lymphocytes 
 
Lymphocytes  were  used  as  positive  controls.  Cell  suspensions  were  diluted  with  fix 
solution (three volumes of methanol and one volume of glacial acetic acid). With the use 
of a Pasteur pipette three drops of the cell suspensions were dropped on a clean moist 
slide from ~30cm height in order to spread the nuclei. With the use of a diamond marker 
a circle was engraved on the underside of the slide where the nuclei were spread. The 
slide was left to dry for two minutes and the slide was flooded with fix for 10 seconds. 
The fix solution was poured off, the slide was dried and 70% of acetic acid was added for 
a further 10 seconds. The slide was dried again and passed through an ethanol series 
(70%, 90% and 100%) for 5 minutes each. The slides were stored at 4
oC and were used 
within 30 days. 
 
 
4.5.5.2 Slide preparation for human embryos 
 
Prior to embryo spreading the slides were prepared as follows; they were first washed in 
methanol/HCl for a few seconds, left to dry, incubated in 10% poly l lysine solution for 5 
minutes, dried at room temperature and stored at 4
oC. A small circle was drawn on the 
underside of each slide with a diamond marker. A drop of spreading solution was placed 
on top of the circle. Another drop (of PBS) was placed in the outer corner of the slide. 
The embryos were transferred from the Petri dish to the PBS solution with the guidance 
of  a  dissecting  microscope  and  with  the  use  of  a  plastic  capillary  and  aspiratory 
micromanipulation.  The  capillary  was  first  primed  with  spreading  solution  and  then 
transferred the embryo to the drop of spreading solution. The lysis of the embryo was 
closely observed under the dissecting microscope and fresh spreading solution was added 
until complete lysis of the cells was achieved and the nuclei could be clearly seen without 
permitting  the  drop  to  dry.  Once  lysis  was  completed,  the  slide  was  left  to  dry  and 
incubated in PBS for 5 minutes and dehydrated through an ethanol series (70%, 90% and 
100%)  for  5  minutes  each.  The  slides  were  stored  for  up  to  two  weeks  at  room 
temperature.   117 
 
4.5.5.3 Slide pre-treatment 
 
The slides that contained the cells were first incubated in 1N HCl and 10mg/ml pepsin 
solution (Sigma, UK) at 37
oC for 20 minutes (embryos for 15 minutes) in order to make 
the DNA accessible to the probes. After the incubation, the slides were briefly washed 
once in double dH2O and once in PBS. The slides were fixed in 1% paraformaldehyde 
(Sigma, UK)/PBS for 10 minutes at 4
oC. After fixation, the slides were washed briefly 
once in PBS and twice in double dH2O and dehydrated through an ethanol series (70%, 
90% and 100%) for 5 minutes each (Harper et al., 1994). 
 
4.5.5.4 Probe preparation 
 
The probe mix consisted of probes for up to three chromosomes and buffer (CEP buffer 
for centromeric probes and LSI for locus specific probes). The total volume was always 
5 l per sample. Table 4.1 summarises all volumes for probe mixes. 
 
 
Probe mix  Amount  Buffer 
13(SG)/21(SR)  13/21:0.6 l  LSI: 4.4 l 
X(SG)/Y(SR)/18(SO)  2.5 l  CEP: 2.5 l 
13(SG)/21(SR)/15(SO)  13/21:0.6 l/ 15:0.5 l  LSI: 2.5 l 
1(SG)/ 5(SR)/19(SO)  1:0.6 l / 5:0.6 l / 19:0.6 l  LSI: 3.2 l 
 
Table  4.1:  Summary  of  probe mixes used  for FISH  on  fibroblasts  and  embryos.  A 
single round was used for the fibroblasts (chromsomes 13 and 21) and three rounds were 
used with each embryo. SG: spectrum green, SR: spectrum red and SO: spectrum orange. 
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4.5.5.5 Separate denaturation, hybridisation and post-hybridisation washes 
 
In case of separate hybridisation, 100 l of denaturation mix (70% formamide/2xSSC) 
was  added  to  the  slides,  covered  with  22x50  coverslips  and  incubated  at  75
oC  for  5 
minutes. The coverslips were removed and the slides were dehydrated in 70% ice cold 
ethanol for 5 minutes and then in 90% and 100% ethanol at room temperature for 5 
minutes each. The probe mix was denatured at 75
oC for 5 minutes and stored at 37
oC 
until the hybridisation step. Once the slides had dried, 5 l of probe mix was applied on 
the slide under a 13mm coverslip in the area where the circle was drawn. Rubber cement 
was applied around the coverslip and the slides were hybridised in a moist chamber at 
37
oC overnight. 
 
Once the hybridisation was complete, the coverslip and the rubber cement were gently 
removed and the slides were washed in the dark three times in 50% formamide/2xSSC at 
41
oC  for  5  minutes  each  and  then  3  times in 2xSSC  at  41
oC  for  5  minutes  each.  A 
4xSSC/0.05% Tween20 wash for 5 minutes followed and a final dehydration series (70%, 
90% and 100%) for 3 minutes each in the dark. After the slides were dried they were 
mounted in Vectorshield antifade medium counterstain (1.25ng/ml 4’, 6 diaminidino 2 
phenylindole (DAPI)) and stored in the dark at 4
oC. 
 
4.5.5.6 Co-denaturation, hybridisation and post-hybridisation washes 
 
In  co denaturation,  the  probe  mix  was  applied  on  the  slide  under  a  13mm  coverslip, 
denatured for 5 minutes at 75
oC and hybridised for 1 hour without the use of rubber 
cement.  After  hybridisation  the  coverslips  were  gently  removed  and  the  slides  were 
washed in 2xSSC/60% formamide at 41
oC for 5 minutes, followed by 2xSSC at 41
oC for 
5 minutes and finally with 4xSSC/0.05% Tween20 for 5 minutes at room temperature. 
The  slides  underwent  a  final  dehydration  series  and  were  mounted  in  Vectorshield 
antifade medium counterstain and stored in the dark at 4
oC. 
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4.5.5.7 Image analysis 
 
Fluorescent microscopy was achieved with the use of a Zeiss Axioskop microscope with 
chroma multi band pass TRITC/FICT/DAPI filter and single Spectrum Aqua filter. The 
same microscope with a built in Photometrics KAF 1400 cooled CCD (charged coupled 
device) camera was used to capture FISH images. SmartCapture software from Vysis was 
used to control the image capturing. The analysis was achieved using computer software 
(Digital Scientific, UK), that converted fluorescent intensities into a red, green or aqua 
colour for each signal. 
 
4.5.5.8 Re-probing of embryos 
 
In case of re probing, after analysis of the slides was completed, the coverslips were 
removed  and the slides  were washed at  room temperature in 4xSSC/0.05% Tween20 
twice  for  5  minutes  each  and  then  in  PBS  for  10  minutes  followed  by  dehydration 
through an ethanol series. The slides were exposed to light during these washes in order 
for the old probe to fade. After dehydration the same slide could be used again. 
 
4.6 Results 
 
4.6.1 DNA and WGA product concentration and quality validation  
 
Concentrations of all the DNA and WGA products prepared for the array experiments are 
presented  in  table  4.2.  PCR  on  the  MDA  products  certified  that  the  reaction  was 
successfully performed (table 4.3). The presence of DNA of the MDA products was not 
detected  by  running  an  agarose  gel  because  even  negative  MDA  samples  produce 
unspecific  DNA  that  cannot  be  clearly  distinguished  from  other  MDA  products.  An 
example of how single cell MDA products appear on agarose gels and how they are 
compared with gDNA and gDNA MDA products is illustrated on Appendix A9, figure 
A1. For lymphocytes and fibroblasts the true alleles were already obtained from chapter 3 
(table 3.5) and so the MDA products that were used for the a CGH experiments were the   120 
ones  that  had  the  most  accurate  genotype.  For  blastomeres  the  expected  alleles  were 
unknown and so the MDA reactions’ performance was based on the presence of alleles. 
In one case of a single blastomere MDA product, three alleles were detected in two loci 
(DM1 and APOC2) and two alleles on the third locus (D19S112) which implied either 
contamination  or  trisomy  19  (table  4.3).  Although  MDA  incubation  time  of  Phi29 
polymerase was decreased to two hours in this project (protocol P2) from six (protocol 
P1) no difference was observed in the PCR results. For GenomePlex products, molecular 
analysis was not performed as the presence or absence of alleles would only depend on 
where the DNA was cut at the first step of the reaction. Measuring the concentration of 
the  GenomePlex  products  was  the  only  validation  for  the  amplification  efficiency  of 
GenomePlex. 
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DNA template  WGA method   protocol  DNA conc. 
(ng/ l)  OD 
No WGA  220  1.8  gDNA male normal 
(Promega)  MDA P3  497  1.85 
No WGA  190  1.8  gDNA female normal 
(Promega)  MDA P3  363  1.86 
gDNA 46, XY der(3)+ 
(3;15)(p24.3;q13)  No WGA  121  1.81 
No WGA  67  1.78  gDNA from cultured 
fibroblast T13  MDA P3  171  1.87 
No WGA  89  1.77  gDNA from cultured 
fibroblast T21  MDA P3  258  1.86 
Single Fibroblast T21   MDA P2  60  1.86 
Single Fibroblast T13  MDA P2  190  1.83 
Single lymphocyte male 1  MDA P2  67  1.74 
Single lymphocyte male 2  MDA P2  40  1.83 
Single lymphocyte male 3  MDA P2  180  1.86 
Single lymphocyte male 4  GenomePlex P6  11  1.42 
Single lymphocyte male 5  GenomePlex P6  17  1.62 
Single lymphocyte male 6  GenomePlex P6  146  1.77 
Single lymphocyte male 7  GenomePlex P7  224  1.85 
Single lymphocyte female 1  MDA P2  123  1.81 
Single lymphocyte female 2  MDA P2  33  1.54 
Single lymphocyte female 3  MDA P2  73  1.83 
Single lymphocyte female 4  GenomePlex P6  299  1.85 
Single lymphocyte female 5  GenomePlex P6  155  1.82 
Single lymphocyte female 6  GenomePlex P7  283  1.79 
Single lymphocyte female 7  GenomePlex P7  231  1.86 
Single blastomere 1  MDA P2  166  1.84 
Single blastomere 2  MDA P2  251  1.86 
Single blastomere 3  GenomePlex P7  43  1.83 
Single blastomere 4   MDA P2  234  1.79 
Single blastomere 5  GenomePlex P7  6  1.46 
 
Table 4.2: DNA samples prepared for the array experiments. The DNA concentration 
and the OD are displayed. Some samples with low DNA concentration were excluded 
from the experiments. Conc.: Concentration, OD: optical density. 
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Table 4.3: PCR validation of MDA reaction with PCR. This table presents the PCR 
results of the DM 1 triplex reaction of MDA products from single cells before a-CGH. 
MDA products from single lymphocyte male 2, and single lymphocytes female 1 and 2 
were excluded from a-CGH experiments because ADO and TAF were present. 
 
4.6.2 Results from Sanger Institute a-CGH slides 
 
The  first  a CGH  experiments  that  were  performed  for  this  project  were  from 
collaboration with the Sanger Institute. Four a CGH experiments were conducted. The 
test and reference samples used for a CGH are shown in table 4.4. The results obtained 
from these experiments were not promising. The only robust result obtained was from 
gDNA and inconclusive results were presented from all WGA products, even when MDA 
was applied using gDNA. The DOP PCR amplified single cell that was hybridised to the 
Sanger Institute arrays was also used in a different project regarding single cell m CGH 
and the result confirmed a trisomy 21 (figure 4.2). 
 
 
 
 
MDA products/Markers  APOC2  DM1  D19S112 
Single Fibroblast T13  127 150  122  139 141 
Single Fibroblast T21  135 150  145 172  132 ADO 
Single lymphocyte male 1  152 154  140 155  123 132 
Single lymphocyte male 2  152 ADO  ADO 155  123 132 
Single lymphocyte male 3  152 154  140 155  123 132 
Single lymphocyte female 1  127 150  122  ADO 134 
Single lymphocyte female 2  127 150  TAF  117 ADO 
Single lymphocyte female 3  127 150  122  117 134 
Single blastomere 1  152  122  123 141 
Single blastomere 2  150  128 146  117 
Single blastomere 4   135 150 154  128 146 181  117 130   123 
Experiment  
number  Test sample  Amplification 
method 
Reference 
sample  Result 
A1  Fibroblast gDNA 47,XX+21  No amplification  47,XY+21 
A2  Fibroblast gDNA 47,XX+21  MDA, P3  Inconclusive 
A3  Single Fibroblast T21  MDA, P2  Inconclusive 
A4  Single Fibroblast T21  DOP PCR 
Normal male 
gDNA 
Inconclusive 
 
Table  4.4:  Sanger  Institute  a-CGH  experiments.  This  tables  shows  the  test  and 
reference DNA used for each experiment as well as the result from the analysis. 
 
 
 A: 
 
 
 
 
 
 
 
 
 
 
B: 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Graphs of the result from experiment A1. The diagrams present the result of 
experiment  A1,  where  a  trisomy  21  was  detected  from  gDNA.  (A):  Results  from  all 
chromosomes, (B): detail analysis on chromosome 21. Only clones on chromosome 21 
show an increase of the log2 channel1/channel2 ratio and the spots are highlighted in 
green. 
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4.6.3 A-CGH results with gDNA and MDA products from gDNA 
 
Prior to single cell a CGH, experiments using gDNA and MDA products from gDNA 
were performed in order to assess the efficiency and the quality of different slides. Table 
4.5 shows all the experiments made with the different a CGH slides together with the test 
and reference samples used in each case. 
 
Exper. 
No 
Array slide 
Company 
Test DNA 
(gDNA) 
Reference 
DNA (gDNA) 
Spots 
analysed   Result 
B1  Spectral Genomics 2.0
TM Normal male  Normal female  93.69 %  Y chr. amplif. 
B2  Spectral Genomics 3.0
TM 46, XY der(3) + 
(3;15)(p24.3;q13)  Normal female  96.58 % 
  Sex mismatch 
B3  Array Genomics prenatal Normal male  Normal female  87.34 %  Y chr. amplif. 
B4  Array Genomics prenatal Trisomy 13 male  Trisomy 21 
female  56.65 %  21,X chrom. 
del. /13 amplif. 
B5  Mermaid 32K (TRL)  Normal male  Normal female  78.26 %  Sex mismatch 
B6 
Cytochip prenatal 
(BlueGnome) 
46, XY der(4) + 
(4;5)(q35.1;p14.3) Normal female  99.85 %  Sex mismatch, 
chr. 5 amplif. 
B7 
Cytochip 1MB 
(BlueGnome) 
MDA P3 Normal 
male 
MDA P3 
Normal female  99.81 %  Sex mismatch 
 
Table 4.5: A-CGH experiments with gDNA and WGA products from gDNA. This table 
presents  the  a-CGH  experiments  performed  with  gDNA,  indicating  the  source  of  the 
array slides, the test and reference DNA, the number of clones analysed and the result 
obtained from the array. Chr.: chromosome, Amplif.: amplification. 
 
The  Spectral  Genomics  constitutional  chips  2.0
TM  slide  failed  to  show  a  clear  sex 
mismatch even with gDNA samples and only Y chromosome amplification was detected 
(figure 4.3). An upgrade version of Spectral Genomics 2.0
TM slide (Spectral Genomics 
3.0
TM), was also tested by using an abnormal gDNA as test sample (46, XY der(3) + 
(3;15)(p24.3;q13))  and  a  normal  female  as  a  reference  sample.  Although  a  clear  sex 
mismatch was detected, this experiment failed to show any chromosomal changes on 
chromosomes 3 and 15 (figure 4.4). 
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A:  B: 
 
 
 
 
 
 
 
 
 
 
 
 
C:  D:  E: 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Spectral Genomics 2.0 ™ experiment B1 Ideograms. The figure shows the 
ideograms from all chromosomes (A) and detail on chromosomes Y (B), X (C), 1 (D) and 
7 (E) after analysis of a-CGH images with SpectralWare ™. No chromosomal imbalance 
was detected on chromosome X despite the 2:1 ratio in the test and reference DNA. The 
image for the X chromosome is similar to chromosomes 1 and 7 where the ratio was 1:1. 
A small deletion is seen on chromosome Y but only 2/12 clones exceed the threshold 
level. 
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Figure 4.4:  Spectral Genomics 3.0 ™ experiment B2 Ideograms. A clear sex mismatch 
was observed from the analysis of this experiment (A: Graph for all chromosomes, B: 
chromosome X, C: chromosome Y). However, no chromosome imbalance was detected 
for chromosomes 3 and 15 (D).   127 
Two slides were used from Array Genomics. In the first experiment, normal male was 
hybridised  against  normal  female  gDNA.  Similarly  to  Spectral  Genomics,  the  Y 
chromosome showed a clear amplification but the X chromosome did not exceed the log2 
ratio  threshold  for  deletion.  In  the  second  experiment,  gDNA  extracted  from  the 
embryonic fibroblast cell lines was used. A male sample with trisomy 13 (47, XY +13) 
was  hybridised  against  a  female  sample  with  trisomy  21  (47,  XX  +21).    Four 
chromosomal imbalances were expected to be scored. The analysis showed amplification 
on chromosome 13 and deletion on chromosomes 21 and X although they were not strong 
enough to exceed the desired log2 intensity ratio threshold for imbalance. None of the 
clones representing the Y chromosome were included in the analysis so no conclusion 
could  be  made  for  that  chromosome.    Generally,  the  experiment  had  low  clone 
representation (56.65%) (figure 4.5). In order to exclude mosaicism as a cause of low 
log2 Ch1/Ch2 ratio for chromosomes 13 and 21, FISH experiments were done on the 
embryonic fibroblast cells for these chromosomes which confirmed the uniformity of the 
fibroblast cells (figure 4.6). 
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Figure  4.5:    Array  Genomics  experiment  2 
ideograms.  Figure  A  shows  the  result  from 
Array Genomics a-CGH slide. Only 56.65% of 
the  clones  were  included  in  the  analysis.  No 
clones were included for the Y chromosome and 
only  two  clones  for  the  chromosome  21.  A 
deletion  for  chromosome  X  and  amplification 
for  chromosome  13  (Figure  B)  was  scored 
correctly.   129 
 
A:          B: 
 
 
 
 
 
 
 
 
 
Figure 4.6:  Fibroblast FISH analysis. FISH analysis for fibroblasts with trisomy 13 (A) 
and  21  (B).  Two  hundred  cells  from  each  cell  line  were  counted  to  confirm  trisomy 
uniformity and to exclude mosaicism. Uniformity for T13 line: 97% (194/200), uniformity 
for  T21:  91%  (182/200).  Probes  for  chromosome  13:  Spectrum  Green,  probes  for 
chromosome 21: Spectrum Red. 
 
 
The TRL Mermaid 32K BAC array was tested on good quality gDNA using normal male 
and female as test and reference samples respectively. The result showed a clear sex 
mismatch (SD of autosomes: 0.116, SD of X chromosome: 0.218, SD of Y chromosome: 
0.502) (figure 4.7). The experiments with these arrays were not performed as dye swap 
because the cost would increase considerably. Analysis with different software developed 
from the TRL group was also performed (figure 4.7E).  
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Figure 4.7: TRL Mermaid arrays experiment B5.  These figures show the result of the 
Mermaid arrays after hybridisation of good quality gDNA. A clear sex mismatch was 
detected. A: Graph of all chromosomes after analysis with BlueFuse software, B, C and 
D:  Ideograms  of  chromosomes  1,  X  and  Y  respectively,  E:  Analysis  with  a  different 
software.  
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The BlueFuse Cytochip prenatal Beta slide was tested on gDNA. The 1MB Cytochip 
slides were routinely used in the north Thames Regional Cytogenetic laboratory. The 
sample used as test DNA was shown to have chromosomal imbalance (46, XY der(4) + 
(4;5)(q35.1;p14.3)) with the use of the 1MB a CGH slides and so a replicate experiment 
was performed with the Cytochip prenatal slide in order to compare the slides (figure 
4.8). A very clear sex mismatch was obtained and also the imbalance on chromosome 5 
was  spotted  (SD  of  autosomes:  0.058,  SD  of  X  chromosome:  0.137,  SD  of  Y 
chromosome:  0.314,  SD  of  chromosome  5:  0.124).  However,  the  deletion  on 
chromosome 4 was not detected with the prenatal slide, which was identified with the 
1MB slide. This experiment showed a great sensitivity of Cytochip slides over the other 
a CGH slides but also the limitations of using prenatal slides over 1MB slides. 
  
The efficiency of MDA was assessed with the use of the Cytochip 1MB slide (experiment 
B7). This was performed in order to see if MDA products from initial good quality DNA 
could  be  used  for  a CGH.  The  initial  concentration  of  DNA  was  20ng  for  test  and 
reference DNA and both of them were amplified using MDA P3 protocol (section 2.4, 
table 2.2), MDA for gDNA, two hours incubation). The analysis of this result is shown in 
figure  4.9.  A  clear  sex  mismatch  was  detected  but  also  high  background  noise  was 
produced by MDA (SD of autosomes: 0.133, SD of X chromosome: 0.225, SD of Y 
chromosome:  0.926).  This  resulted  in  a  number  of  individual  clones  to  exceed  the 
threshold  log2  intensity  ratio  of  ch1/ch2  which  would  normally  be  considered  as 
chromosomal  aberrations.  Most  of  these  clones  were  located  close  to  the  end  of 
chromosomes.  Some  regions  of  the  genome,  like  the  1p36.6  region,  were  repeatedly 
shown as imbalanced when Cytochip slides were used with WGA products (other results 
demonstrate this on graphs from experiments C7 and C8 and from chapter 5). The more 
profound outcome regarding this experiment was that the resolution of a CGH dropped 
with MDA as amplification or deletion of individual clones would be considered as an 
artefact and the theoretical 1MB resolution could not be achieved. 
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Figure 4.8: Cytochip prenatal ideograms of a-CGH experiment B6. The graph (A) and 
the ideograms of chromosomes X (B), Y (C), 4 (D) and 5 (E) show the result of gDNA 
hybridisation  on  the  Cytochip  prenatal  slides.  Sex  mismatch  is  detected  as  well  as 
duplication in the proximal end of chromosome 5p but no deletion on chromosome 4q is 
identified. The duplication on chromosome 5p but also the deletion on chromosome 4q 
was detected when using the Cytochip 1MB a-CGH slides (ideograms F and G).   133 
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Figure 4.9: Cytochip 1MB ideograms from experiment B7 (MDA product from gDNA). 
The figures show the result after analysis of MDA product from good quality DNA on 
1MB a-CGH slide with BlueFuse analysis software. A: Graph of the whole genome. B, C, 
D, E and F: Detailed ideograms of chromosomes 1, 9, 12, X and Y.  A clear sex mismatch 
is  seen  but  many  individual  clones  on  all  chromosomes  would  erroneously  show 
amplification or deletion. These regions are usually located in the chromosome arms.   134 
4.6.4 A-CGH results with WGA products from single lymphocytes and fibroblasts 
 
Following the experiments with gDNA, nine experiments were conducted with WGA 
products from single lymphocytes and fibroblasts. MDA protocol P2 and GenomePlex 
protocols P6 and P7 were used to amplify the DNA of the single cells. A CGH slides 
from Spectral Genomics, Array Genomics, TRL and BlueGnome were used. Table 4.6 
lists all the experiments conducted with single cell lymphocytes and fibroblasts.  
 
Exper no.  Array slide  Test DNA (single 
cell WGA)  Reference DNA  Spots 
analysed  Result 
C1 
Spectral Genomics 
2.0
TM  
lymphocyte female 7 
– P7 
Single lymphocyte 
male 7 – P7    76.75%  No 
imbalance 
C2 
Spectral Genomics 
2.0
TM  
fibroblast, T13 male   
P2 
Single fibroblast, 
T21 female – P2  19.38%  inconclusive 
C3 
Array Genomics 
prenatal 
fibroblast, T13 male   
P2 
Single fibroblast, 
T21 female – P2  39.25%  inconclusive 
C4  Mermaid 32K (TRL) lymphocyte male 7 – 
P7 
Single lymphocyte 
female 7 –  P7  63.53%  No 
imbalance 
C5  Mermaid 32K (TRL) lymphocyte female 5 
– P6 
Single lymphocyte 
male 6 – P6  15.30%  Inconclusive 
C6 
Cytochip 1MB 
(BlueGnome) 
lymphocyte male 3 – 
P2 
Female gDNA, No 
WGA  66.47%  Sex 
mismatch 
C7 
Cytochip prenatal 
(BlueGnome) 
lymphocyte male 3 – 
P2 
Single lymphocyte 
female 1 –  P2  57.79%  Sex 
mismatch 
C8 
Cytochip prenatal 
(BlueGnome) 
lymphocyte male 7 – 
P7 
Single lymphocyte 
female 7 – P7  86.14%  Sex 
mismatch 
C9 
Cytochip prenatal 
(BlueGnome) 
lymphocyte male 6 – 
P6 
Single lymphocyte 
female 5 –  P6  88.69%  Sex 
mismatch 
 
Table  4.6:  Experiments  performed  with  WGA  products  from  single  lymphocytes  and 
fibroblasts. This table summarises all the experiments with WGA products from single 
lymphocytes and fibroblasts together with their results. T21: Trisomy 21, T13: Trisomy 
13. 
 
Unfortunately only the BlueGnome Cytochip 1MB and prenatal slides managed to show 
the expected results. Spectral Genomics, Array Genomics and Mermaid a CGH slides 
failed to show any reliable result from three different methods of amplification. Results 
from these a CGH slides are shown in figures 4.10, 4.11 and 4.12. 
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Figure  4.10:  Spectral  Genomics  constitutional  2.0™  experiment  C1.  These  figures 
show the result from MDA product from single lymphocytes with the Spectral Genomics 
a-CGH  slides.  Graph  A  shows  that  only  a  partial  deletion  (two  clones  only)  of 
chromosome Y is observed. (B): Chromosome 1, (C): Chromosome 7, (D): Chromosome 
X and (E): Chromosome Y ideograms are displayed. 
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Figure 4.11: Array Genomics prenatal slide result of experiment C3. The ideograms of 
seven chromosomes from the analysis of MDA products from single fibroblasts on Array 
Genomics slide are displayed. Although four chromosomal imbalances were expected to 
be detected, only chromosome X produced a true result. Only one clone was included for 
the Y chromosome and three from chromosome 21. Generally, the experiment had many 
artefacts and so the result was inconclusive. Ideograms of chromosomes X (A), Y(B), 13 
(C), 21 (D), 10 (E), 17 (F) and 18 (G) are shown. 
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Figure  4.12:  TRL  Mermaid  array  slides  of  experiment  C4.  This  figure  shows  the 
ideograms from the single lymphocyte cell amplified with GenomePlex (P7 protocol, ALB 
lysis). No clear difference could be observed for any chromosomes, not even for the Y 
chromosome where the DNA ratio between test and reference was 1:0. The SD was high 
for all chromosomes (average SD for autosomes: 0.235). A: Graph of the result. B, C and 
D: Ideograms of chromosomes 1, X and Y respectively. E: Analysis with other software 
than BlueFuse.   138 
The BlueGnome Cytochip 1MB slide was used to test MDA product from single male 
lymphocytes against good quality female gDNA. The results are shown in figure 4.13. 
Although the MDA products produced very high background noise (SD for autosomes: 
0.642, SD for X chromosome: 0.577, SD for Y chromosome: 0.914, clones included: 
66.47%, median between replicates: 0.06), a clear amplification on chromosome Y and 
deletion on chromosome X was observed. The imbalance of the sex chromosomes could 
not be identified with the use of BlueFuse Cytochip analysis as it is not programmed to 
obtain results with high SD.  Analysis with a different algorithm (prenatal algorithm, 
currently being developed by BlueGnome)  was performed in order to  avoid the high 
background noise and detect whole chromosome changes (figure 4.13F). In this graph the 
X  chromosome  appeared  as  amplified  and  the  Y  chromosome  as  deleted  due  to  the 
reverse order of the top and bottom sub array by mistake. Due to the background noise it 
was concluded that only large/whole chromosome changes could be detected. In order to 
minimise the background noise in the following experiments single cells were used as 
reference DNA and were amplified in a similar way as test DNA. 
 
The  three  following  experiments  were  done  using  the  BlueGnome  Cytochip  prenatal 
slides  instead  of  the  1MB  slides.  That  was  done  in  order  to  further  decrease  the 
background  noise.  Even  though  the  resolution  would  be  decreased  the  clones  were 
expected  to  be  enough  to  detect  large/whole  chromosome  changes.  In  each  of  these 
experiments the test and the reference DNA were male and female single lymphocytes 
were amplified with a different WGA method. In the first experiment MDA P2 protocol 
was  used  for  WGA  whereas  in  the  other  two  experiments  GenomePlex  P6  and  P7 
protocols were used. That was done to compare the two WGA techniques and to see if 
cell lysis would play a crucial role in the result. A sex mismatch was expected to be 
detected in each experiment (4.14 and 4.15). 
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Figure 4.13: BlueGnome Cytochip 1MB slide of experiment C6. The figures show the 
analysis  of  MDA  product  from  single  lymphocyte  (male)  against  high  quality  gDNA 
(female) using the Cytochip 1MB slide. Figure A shows the graph of the entire genome. 
Figures B and C show the ideograms of chromosomes 1 and 20 in which the majority of 
clones  are  shown  as  amplified  or  deleted.  Figure  D  and  E  show  the  ideograms  of 
chromosomes  X  and  Y  where  the  majority  of  clones  were  detected  as  deleted  and 
amplified  respectively.  Graph  F  shows  the  analysis  of  the  result  with  the  prenatal 
algorithm which shows sex mismatch result in opposite orientation due to the mistake in 
the analysis software.   140 
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Figure 4.14: BlueGnome Cytochip prenatal slide Ideograms of experiment C7 (MDA 
P2  protocol).  These  figures  present  the  result  from  MDA  products  from  single 
lymphocytes (test and reference DNA) on a Cytochip prenatal slide. Graph A shows the 
result of the entire genome, figures B and C the ideograms of chromosomes 1 and 20. 
Although the background noise was high sex mismatch could be detected as the vast 
majority  of  clones  for  chromosome  X  and  Y  appeared  as  deleted  and  amplified 
respectively  (D and E). Many individual  clones would exceed the threshold ratio for 
chromosome imbalance (A), such as region 1p36.  
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Figure  4.15:  BlueGnome  Cytochip  prenatal  results  of  experiments  C8  and  C9 
(GenomePlex P6 and P7 protocols).  Figures A- E: Graph of Cytochip prenatal slide of 
single cell GenomePlex products with P6 protocol (proteinase K lysis) and ideograms of 
chromosomes 1, 20, X and Y respectively. Figures F-J: Graph of Cytochip prenatal slide 
of single cell GenomePlex products with P7 protocol (ALB L1 lysis) and ideograms of 
chromosomes 1, 20, X and Y.  Both results have decreased background noise compare to 
MDA products. GenomePlex with ALB lysis had more noisy results but clearer results for 
sex mismatch.   142 
Among the three results the experiment with the MDA products had the highest SD and 
the highest median between replicates (SD for autosomes: 0.243, SD for X chromosome: 
0.205,  SD  for  Y  chromosome:  0.293,  clones  included:  57.79%,  median  between 
replicates: 0.13) compared to the GenomePlex products lysed with Proteinase K (SD for 
autosomes: 0.127, SD for X chromosome: 0.142, SD for Y chromosome: 0.128, clones 
included: 86.14%, median between replicates: 0.08) and the GenomePlex products lysed 
with  ALB  (SD  for  autosomes:  0.168,  SD  for  X  chromosome:  0.179,  SD  for  Y 
chromosome:  0.382,  clones  included:  89.22%,  median  between  replicates:  0.07). 
Although only one result per WGA protocol was obtained which was not very secure for 
conclusions, GenomePlex with ALB lysis was considered to provide the most desired 
outcome compare to the other methods.  
 
Generally, from the single cell a CGH results only Cytochip prenatal and 1MB resolution 
slides managed to show at least sex mismatch difference even though the background 
noise was very high. Cytochip prenatal slides decreased the background noise but would 
only  be  reliable  for  whole  chromosome  changes.  Analysis  with  a  different  algorithm 
could be the key for more secure outcomes. 
 
4.6.5 A-CGH results with WGA products from single blastomeres 
 
Following  the  single  cell  a CGH  project  with  lymphocytes,  the  application  of  single 
blastomeres to a CGH was tested. The WGA products were applied on the BlueGnome 
Cytochip 1MB slide in order to see if any chromosomal abnormalities could be detected. 
Although the Cytochip prenatal slides provided lower background noise, the 1MB slides 
were preferred because there was a higher chance to detect a chromosome abnormality 
whereas  analysis  with  a  different  algorithm  could  help  to  overcome  the  noisy 
background. A total of five blastomeres were obtained from three embryos. The first 
embryo  was  from  a  PGD  case  for  fragile  X  syndrome,  where  male  embryos  were 
excluded from transfer. A blastomere was biosied from a day 5 embryo of high quality 
(4AA) and MDA was applied (protocol P2). The rest of the embryo was disaggregated 
and the blastomeres were fixed on a poly lysine slide by Dr Anna Mantzouratou and   143 
FISH  was  applied  for  chromosomes  13,  21,  15,  18,  X  and  Y  and  no  chromosomal 
abnormality was detected. The result of the a CGH experiment is shown on figure 4.16 
(experiment D1). The result suffered from very high noise (SD for autosomes: 0.840, SD 
for  X  chromosome:  0.884,  SD  for  Y  chromosome:  1.034,  clones  included:  71.30%, 
median between replicates: 0.06) but sex mismatch could be detected when analysed with 
the prenatal algorithm. 
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Figure  4.16:  BlueGnome  Cytochip  1MB  slide  result  of  experiment  D1  (Embryo  1, 
blastomere 1, MDA). The results were very noisy (Graph A). High SD was obtained for 
all  chromosomes,  like  chromosomes  1  (B)  and  17  (C)  although  a  clear  deletion  and 
amplification of chromosomes X and Y respectively was also obtained with the original 
analysis (D and E). Analysis with the prenatal algorithm showed a clear chromosomal 
change on chromosomes X and Y (F).    144 
The second embryo was obtained from a PGS case where FISH analysis on a single 
blastomere during the clinical case resulted in one signal for chromosome 21 and two for 
chromosomes 13, 18, 15, 16 and 22. The quality of the embryo was also reported to be 
low by the embryologists (2CC). After exclusion from transfer, two blastomeres were 
biopsied, one of them was subjected to MDA  (protocol 2) and one was subjected to 
GenomePlex (protocol 7, ALB lysis). The rest of the embryo was spread on a poly L 
lysine coated slide for FISH. The MDA product was subjected to PCR for the DM triplex 
and ensured that the reaction amplified the DNA successfully (table 4.7). Other markers 
on various chromosomes were used as well for confirmation of the a CGH results (table 
4.7).  Unfortunately,  robust  GenomePlex  amplification  for  single  cells  could  not  be 
confirmed  with  PCR  and  the  success  of  the  reaction  only  depended  on  the  DNA 
concentration of the product (43ng/ l, table 4.2). As reference DNA, a single female 
lymphocyte was used which was amplified in the same way for each experiment.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.7: PCR analysis with 10 markers on five chromosomes for blastomeres. This 
table summarises the results obtained from analysis at 10 loci on the MDA products from 
blastomeres prior to a-CGH. Three alleles were found in two markers of chromosome 19 
for embryo 3, blastomere 1 and a-CGH confirmed a trisomy for this chromosome. Only 
one marker (D5S656) did not show any results for both MDA products even though it 
worked on the positive control.  
Markers/Samples  Embryo 2, Blastomere 1  Embryo 3, Blastomere 1 
   Allele sizes 
Chromosome 5     
D5S1965  180/ 206  205 
D5S2065  214  214 
D5S656  -  - 
D5S346  251  251 
Chromosome 7     
p.Phe508del  94  94 
IVS8CA  185  182 
Chromosome 19     
APOC2  150  135 /150 /154 
DM1  128/ 146  128 /146 /181 
D19S112  117  117/ 130 
Sex chromosomes     
Amelogenin  104  104/ 110   145 
For the D2 experiment the background noise produced by the MDA product was very 
high (SD for autosomes: 0.693, SD for X chromosome: 0.676, SD for Y chromosome: 
0.728, clones included: 49.35%, median between replicates: 0.15) and analysis with the 
prenatal algorithm was also performed which revealed an amplification for chromosome 
5 (47, XX +5) (figure 4.17). This time the prenatal algorithm was applied without the use 
of dye swap and each sub array was considered as a different experiment in order to 
confirm reproducibility of the results. For the GenomePlex product the hybridisation was 
very poor (31.31%) which also resulted in high background noise (SD for autosomes: 
0.333, SD for X chromosome: 0.293, SD for Y chromosome: 0.374, median between 
replicates:  0.22).  Although  analysis  with  the  prenatal  algorithm  was  performed  no 
chromosome imbalance was detected (figure 4.18).  
 
Follow up FISH analysis for the same six chromosomes characterised the embryo as 
chaotic whereas a third round of FISH for chromosomes 1, 5, and 19 failed due to poor 
hybridisation. PCR analysis on the MDA product was also performed with a total of 
seven markers on chromosomes 5, 7, X and Y (table 4.6). Interestingly none of the four 
markers for chromosome 5 had three alleles.  Thus the PCR results could not confirm or 
reject the presence of trisomy 5. One allele was detected for the amelogenin gene which 
confirmed the result of a CGH that the embryo was female. 
 
The third embryo was from the same cohort as the second embryo. FISH analysis from 
the PGS case on a single blastomere resulted in one signal for chromosomes 13, 16 and 
21 two signals for chromosomes 15 and 22 and three signals for chromosome 18. Again, 
the quality of the embryo was low (2CB). After exclusion from transfer, two blastomeres 
were biopsied, one of them was subjected to MDA (protocol 2) and one was subjected to 
GenomePlex (protocol 7, ALB lysis). Similarly to the previous experiment, the rest of the 
embryo was spread on a poly L lysine coated slide for FISH and the MDA product was 
subjected  to  PCR  for  the  DM  triplex.  FISH  analysis  on  the  same  six  markers 
characterised the embryo as aneuploid/chaotic mosaic with monosomy 21 due to meiotic 
error (90% monosomy for chromosome 21). PCR for DM locus on MDA product created 
suspicions of trisomy 19 as two of the three markers presented three alleles (table 4.6).   146 
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Figure  4.17:  BlueGnome  Cytochip  1MB  slide  result  of  experiment  D2  (Embryo  2, 
blastomere  1,  MDA).  The  figures  show  the  a-CGH  analysis  from  blastomere  2  after 
MDA. Graph (A) shows the result of the entire genome. Figures B, C, D and E show the 
ideograms of chromosomes 1, 5, X and Y chromosomes respectively. The majority of 
clones of chromosome 5 were seen as amplified. Analysis with the prenatal algorithm 
was done separately on each sub-array which demonstrated the reproducibility of the 
result  (F).  The  application  of  the  prenatal  algorithm  showed  a  clear  chromosomal 
change on chromosomes 5 (F) on both sub-arrays.   147 
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Figure  4.18:  BlueGnome  Cytochip  1MB  slide  result  of  experiment  D3  (Embryo  2, 
blastomere  2,  GenomePlex).   The  figures  show  the  analysis from  blastomere  3  after 
GenomePlex. Due to very poor hybridisation only 31.31% of the clones were used for the 
analysis  which  makes  the  result  very  unreliable.  No  chromosomal  imbalances  were 
obtained  for  any  chromosomes.  A:  Graph  of  the  entire  genome.  B,  C,  D  and  E: 
Ideograms of chromosomes 1, 5, X and Y. F: Analysis with the prenatal algorithm. 
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The  results  from  the  a CGH  experiment  are  shown  on  figure  4.19  (experiment  D4). 
Unfortunately, the GenomePlex amplification failed (concentration of product = 6ng/ l) 
and so results only from the MDA product were obtained. The analysis with the prenatal 
algorithm was necessary due to the high background noise (SD for autosomes: 0.519, SD 
for  X  chromosome:  0.511,  SD  for  Y  chromosome:  0.861,  clones  included:  49.73%, 
median between replicates: 0.14). A trisomy on chromosome 19 was detected in both sub 
arrays (47, XX +19). Trisomy 19 was also confirmed from the PCR analysis on the DM 
locus but analysis of the sex chromosomes showed that the blastomere was male (table 
4.7). Additionally, the majority of clones on chromosome 1 were detected as amplified 
which  implied  that  there  was  an  imbalance  for  this  chromosome  (figure  4.19D). 
However,  the  analysis  with  the  prenatal  algorithm  did  not  detect  any  imbalance  for 
chromosome 1. A third round of FISH for chromosomes 1, 5 and 19 on the rest of the 
embryo failed due to poor hybridisation which could have given some information for 
chromosome 1 in the rest of the blastomeres. Unfortunately, there were not any STR 
markers for chromosome 1 that could be used for PCR analysis on the MDA product. 
Table 4.8 summarises all the results form a CGH, FISH results from clinical PGS and 
follow up results and PCR on markers on chromosomes 5, 7, 19, X and Y. 
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Figure  4.19:  BlueGnome  Cytochip  1MB  slide  result  of  experiment  D4  (Embryo  3, 
blastomere 4, MDA). Graph A show the analysis from the first blastomere after MDA of 
embryo 3. Detail analysis of chromosomes 1, 19, X and Y are displayed on figures B, C, 
D  and  E  respectively.  Analysis  with  the  prenatal  algorithm  detected  amplification  of 
chromosome  19  for  both  sub-arrays.  However,  most  clones  of  chromosome  1  were 
detected as amplified which increased the probability of a trisomy 1. 
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Exper 
no. 
Test 
DNA 
Ref. DNA 
(single cell)  WGA  a-CGH 
result 
Clinical 
PGS 
FISH on rest 
of embryo 
PCR 
analysis 
D1  Embryo 1 
blast. 1 
Lymphocyte 
female  MDA  46, XX  Not 
performed 
No 
abnormality 
detected 
Not 
performed 
D2  Embryo 2 
blast. 1 
Lymphocyte 
female  MDA  47,XX+5 
D3  Embryo 2 
blast. 2 
Lymphocyte 
female 
GenomePlex  poor 
hybridisation 
Monosomy 
21  Chaotic 
Female,  
No trisomy 5 
detected 
D4  Embryo 3 
blast. 1 
Lymphocyte 
female  MDA  47,XX+19  Chaotic  Chaotic/ 
monosomy 21 
Male, 
Trisomy 19 
 
Table 4.8: Summary of results obtained from WGA products from single blastomeres.  
This table compares the results obtained from a-CGH with the results from FISH and 
PCR. Direct comparison cannot be performed with FISH because different chromosomal 
abnormalities can be obtained from blastomeres of the same embryo. However, a trisomy 
19 detected by a-CGH was confirmed by PCR. 
 
 
4.7 Discussion 
 
A CGH  is  a  very  advanced  technique  with  great  potential  for  both  research  and 
diagnostic  purposes.  However,  application  of  single  cells  on  a CGH  has  technical 
limitations. Very few studies on single cell a CGH have been published due to these 
problems. The most profound problem is the background noise which makes analysis 
more complicated. In this project, two different WGA techniques were used to amplify 
the entire genome from a single cell and applied to BAC a CGH slides. Wherever it was 
possible, opposite sex of test and reference samples were chosen as a positive control. 
Most  of  the  experiments  were  performed  using  the  BlueGnome  Cytochip  1MB  or 
prenatal slides as these were the ones that showed the best results on gDNA and single 
cell  experiments.  Two  lysis  methods  were  performed  prior  to  GenomePlex;  one  was 
proteinase K lysis as obtained from the manufacturers’ instructions and one was L1 lysis 
which was found to perform better than MDA (chapter 3). 
 
In  the  first  application  of  single  cell  a CGH,  a  different  platform  and  amplification 
method was used (Hu et al., 2004). The limitations of this project were that although   151 
expected  trisomies  were  detected  from  fibroblast  cell  lines,  the  result  depended  on 
comparing  the  intensity  ratios  from  the  aneuploid  and  the  euploid  chromosomes.  An 
additional problem was the inability to perform correct analysis for the Y chromosome, 
even though correct results were obtained for the X chromosome. Hellani et al. (2004) 
reported  single  cell  a CGH  using  MDA  and  the  Spectral  Genomics  1MB  a CGH.  In 
contrast to the results obtained from this project with the Spectral Genomics array slides, 
a  trisomy  21  was  detected  even  though  only  half  of  the  clones  of  chromosome  21 
exceeded the Ch1/Ch2 ratio threshold. In the following years four more groups published 
their  results  (Le  Caignec  et  al.,  2006;  Fiegler  et  al.,  2007;  Iwamoto  et  al.,  2007; 
Fuhrmann et al., 2008). In these projects different WGA techniques, slide resolution and 
array platforms were used but all the results were promising. The resolution analysis from 
these papers ranged from 34MB up to 2 3MB. Very recently the first clinical application 
of PGS using a CGH was published concentrating only in whole chromosome changes 
(Hellani et al., 2008). All these papers are discussed and compared with the results from 
this project. 
 
4.7.1 A-CGH platforms 
 
Three major different types of a CGH platforms have been constructed from different 
companies. The main difference is the DNA probes that bind on the glass slide which can 
be DNA from chromosome specific DNA libraries, BAC probes or oligonucleotides (25 
85) synthesized in situ. Currently all these platforms have been used for single cell a 
CGH but most of the published work is based on BAC a CGH slides.  Each platform has 
advantages and disadvantages while the most promising results are from oligonucleotide 
and SNP arrays with the crucial advantage being the reduced background noise. In the 
first published paper in 2004 (Hu et al., 2004) chromosome specific DNA libraries were 
used and this was followed by four papers using BAC array platforms (1MB and 100K 
tiling path) (Hellani et al., 2004; Le Caignec et al., 2006; Fiegler et al., 2007; Fuhrmann 
et al., 2008) and two with oligonucleotide array platforms (Iwamoto et al., 2007; Hellani 
et al., 2008). 
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A different platform is  not the only  factor affecting the outcome of single  cell array 
experiments. Even when using slides from the same platform from a different company 
the  results  can  vary.  An  example  is  the  results  obtained  from  this  project  where  the 
Spectral  Genomics  constitutional  slides,  the  Array  Genomics  prenatal  slides  and  the 
BlueGnome  Cytochip  prenatal  slides  had  a  very  similar  manufacturing  principle  and 
resolution but different outcome from the same WGA products. Differences could exist 
from the way each company amplifies the DNA from the BAC probes. Slides from the 
Sanger Institute and BlueGnome used DOP PCR for their BAC probes whereas TRL 
used MDA. No information was given by Spectral Genomics and Array Genomics about 
the amplification method of the target DNA. Spotting techniques, probe diameter and 
distance between spots could also play a role in the result. A big difference was noted in 
the probes spotted from the TRL tiling path arrays and the other companies as in the 
Mermaid 32K arrays the spots were much smaller and closer to each other. In addition 
the  results  from  the  Cytochip  1MB  slides  had  higher  SD  compared  to  the  Cytochip 
prenatal slides where the spots were larger and the distance between them greater. The 
fact that results from the same arrays but from a different batch could lead to different 
results makes clear that small differences during array fabrication could lead to diverse 
results (Wells et al., 2008). 
 
Fuhrmann et al. (2008) showed how a modified BAC a CGH platform could provide high 
resolution analysis with single cells. The idea was based on the fact that BAC clones and 
WGA products from single cells would be contaminated by micro quantities of bacterial 
DNA and this resulted in unspecific hybridisation on the array slide. Although the normal 
BAC  array  slide  could  not  even  detect  whole  chromosome  changes,  the  modified 
platform  which  consisted  of  highly  purified  BAC  clones  was  able  to  identify 
chromosomal gain or loss as small as 4.4MB. Additionally, the exclusion of BAC clones 
with high GC content (>45%) was found to further improve single cell a CGH results. 
This  paper  would  be  of  great  value  for  further  single  cell  a CGH  research  and  high 
resolution analysis. Unfortunately, in this project it was not possible to manipulate the a 
CGH slides and so the research was focused only on comparing slides from different 
companies in order to obtain the best result for single cell a CGH.    153 
 
4.7.2 WGA method for test and reference DNA 
 
So far most WGA techniques have been applied to single cell DNA amplification prior to 
a CGH  including  DOP PCR,  MDA,  GenomePlex  and  LA  adaptor  PCR.  The  WGA 
techniques could mainly be separated in to MDA and PCR based. The main advantage of 
the  PCR  based  WGA  is  that  they  produce  less  non specific  DNA  and  minimise  the 
background noise. The results from the Cytochip prenatal and 1MB slides showed that 
SD of log2 ratio was higher for the MDA products (0.42 1.3) compared to GenomePlex 
products  (0.38  –  0.4).  Similar  findings  were  obtained  from  the  literature  where  Le 
Caignec et al. (2006) used MDA and reported an SD of 0.84 – 1.13, whereas Fiegler et al. 
(2007) used GenomePlex and Fuhrmann et al. (2008) used LA adaptor PCR and obtained 
SD of 0.14  0.24 and 0.23  0.36 respectively from their experiments. Another advantage 
of the PCR based techniques is that they do not under  or over  amplify regions close to 
the chromosome ends. The graphs in figure 4.14 show a gain or loss in the chromosome 
ends  in  the  MDA  products  whereas  this  was  not  observed  in  the  experiments  with 
GenomePlex amplified DNA (figure 4.15). This artefact was more obvious in the 1MB 
slide compare to the prenatal slide probably due to the higher density of probes in the 
telomeric regions. 
 
The big advantage of MDA is the production of large DNA molecules that can be used 
for molecular analysis when the MDA technique has correctly amplified the DNA and so 
PCR could confirm a result obtained from a CGH.  In this project a trisomy 19 was 
confirmed with the use of PCR on the DM locus and also a blastomere shown to be 
female  from  a CGH  was  shown  to  be  male  with  the  use  of  PCR  markers  on  the 
amelogenin gene. A different approach could not be used in case of blastomeres in order 
to confirm the result and so if another WGA method was used instead confirmation of the 
results would not be feasible. In cases of single cell a CGH from cell lines or tumour 
cells FISH analysis on other cells could confirm the array result. Unfortunately, most of 
the high molecular weight products and the hyper branched structures produced by MDA 
are probably discarded during DNA purification as the DNA could be reduced up to 1/3   154 
of  the  initial  volume  after  DNA  clean  up.  As  this  could  influence  the  result  of  an 
experiment, a single cell a CGH research project is being carried out currently in UCL 
Centre  for  PGD  that  excludes  the  DNA  clean up  step  (Thalia  Mamas,  personal 
communication). Mild DNA digestion could also provide a solution to this problem. A 
modified  version  of  MDA,  named  restriction  and  circularization aided  rolling  circle 
amplification  (RCA RCA),  could  be  used  as  an  advanced  technique  to  overcome  the 
difficulty  of  amplification  at  the  chromosome  ends  but  it  would  also  hamper  the 
advantage of MDA for molecular analysis. 
 
GenomePlex was used because the company provided an optimised protocol for single 
cells, and also good genome coverage and low amplification bias was obtained from 
other  published  work  (Arneson  et  al.,  2008).  A  single  cell  a CGH  paper  was  also 
published with the use of GenomePlex (Fiegler et al., 2007). As cell lysis was shown to 
play  a  crucial  role  in  the  result  of  the  molecular  project  the  L1  lysis  was  used  in  a 
modified protocol for GenomePlex. Unfortunately, the two lysis methods could only be 
compared from two experiments (Figure 4.13) which was not enough to make secure 
outcomes. Nevertheless, from the results obtained alkaline lysis was shown to increase 
the background noise but sex mismatch was also clearer. Generally, the main drawback 
of GenomePlex regardless of the lysis method was that only 70% of the cells managed to 
amplify  (table  4.2).  Unfortunately,  none  of  the  GenomePlex  products  from  single 
blastomeres showed an array result although better results than the MDA products were 
expected. More experiments would be needed in order to make a secure result about the 
reaction’s amplification efficiency. 
 
Another factor related to the amplification method of the DNA has to do with the WGA 
that was used to enrich the DNA of the BAC probes prior to fabrication on the slide. 
Generally, the same amplification method for the DNA probes and the test and reference 
DNA  should  be  avoided  as  it  would  increase  the  background  noise  (Nigel  Carter, 
personal communication). In the results presented in this chapter one experiment was 
conducted  which  used  the  same  WGA  as  the  one  used  to  enrich  the  target  DNA 
(experiment 4) but inconclusive results were obtained due to high SD. For the TRL slides   155 
MDA  was  used  to  enrich  the  target  DNA  and  so  the  same  method  was  avoided  for 
amplification of test and reference DNA. Similarly, the optimised protocol from the TRL 
group uses GenomePlex as the WGA method for test and reference DNA (Chris Jones, 
personal communication). However, the first published paper on single cell a CGH used 
DOP PCR both for target DNA and for test DNA (Hu et al., 2004). 
 
A controversial aspect related to WGA has to do with the reference sample. Different 
groups have reported reference DNA being amplified with the same method as the single 
cell (Hellani et al., 2004) or gDNA amplified with the same method (Fuhrmann et al., 
2008) or gDNA without amplification (Fiegler et al., 2007). The idea that reference DNA 
should be similar to the test DNA is based on the fact that the artefacts produced during 
WGA would be minimised. A very well presented paper regarding WGA on gDNA from 
small quantities showed how background noise increased when reference DNA was from 
different the test DNA (Knijnenburg et al., 2007). Two different groups with results on 
single  cell  a CGH  concluded  that  the  SD  was  decreased  when  gDNA  was  used  as 
reference. In this project, in the one experiment (experiment C4) gDNA was used as 
reference but due to the very high SD obtained, in the following experiments similar 
DNA to test sample was used. A direct comparison to see if reference DNA would make 
a difference in the result was not obtained. However, by comparing this result with single 
blastomere a CGH experiments SD was again very high. 
 
4.7.3 Analysis method and maximum resolution 
 
Due to the high SD, analysis could not be based on results from individual clones but 
rather on the clustering and normalising data from many spots in order to detect gain or 
loss at a specific region. This was achieved with the use of a different algorithm provided 
by BlueGnome, which diminished the resolution to whole chromosome changes. In every 
single  cell  a CGH  published  paper  some  kind  of  clustering  of  results  has  been  done 
which resulted in minimising the resolution of the array experiment. Fuhrmann et al. 
(2008) reported high resolution (4.4 MB) analysis but further analysis with qPCR showed 
that these were not single chromosome changes (4 7 copies). Another group claimed that   156 
SNP array analysis on MDA products from single cells could be similar to gDNA results 
with a 2 3MB smoothing (Iwamoto et al., 2007). In addition, Fiegler et al. (2007) claimed 
to have identified a previously unknown 8.3MB deletion from a stable cell line even 
though no confirmation of the result was performed. Finally, Le Caignec et al. (2006) 
reported a maximum 34MB resolution, but this abnormality was already known and the 
analysis focused separately in this region of the genome. The same group reported that if 
60 clones in a row were consequently amplified or deleted a chromosomal imbalance 
would be detected without previous knowledge. With the use of 1MB array slides though, 
this would mean a resolution of 60MB which is bigger than the whole of chromosome 21. 
Generally,  as  discussed  by  Wells  et  al.  (2008) single  cell  a CGH  work  may  only  be 
reliable for whole chromosome changes. With this respect, the prenatal slides would be 
more useful and cheaper for PGS. 
 
The results obtained from this project were analysed with two ways. First the analysis 
was  performed  with  BlueFuse  Cytochip  analysis  and  secondly  with  the  use  of  the 
prenatal  algorithm.  With  BlueFuse  Cytochip  analysis  most  of  the  clones  appeared  as 
amplified or deleted due to the high SD. The analysis could only be done by looking at 
the ideograms of each chromosome separately and making assumptions about the ploidy 
according to if the majority of the clones were above or below zero of log2 intensity 
ratio. As a robust and clear result cannot be based on assumptions, the use of the prenatal 
algorithm  was  used  for  the  blastomeres  where  the  karyotype  was  unknown.  For  the 
experiments C6 C9 with normal lymphocytes the only shift in the majority of the clones 
was observed for chromosomes X and Y. For blastomere D1, both Cytochip ideograms 
and analysis with prenatal algorithm showed the same result, which was a male normal 
blastomere.  For  experiments  D2  and  D4  however,  the  results  obtained  from  the  two 
analysis methods were different. In D2, analysis with ideograms showed an amplification 
of chromosomes 5 and Y. Analysis with the prenatal algorithm confirmed amplification 
on  chromosome  5  but  not  for  chromosome  Y.  Molecular  analysis  showed  that  the 
blastomere  was  female  unless  ADO  was  present  but  did  not  confirm  the  trisomy  on 
chromosome 5. Experiment D3 was not considered reliable as the majority of the clones 
were  excluded  from  analysis.  Finally,  Cytochip  analysis  of  experiment  D4  created   157 
suspicions for amplification of chromosomes 1, 19 and Y and deletion for chromosomes 
8,  13,  14  and  16.  The  prenatal  algorithm  only  confirmed  the  amplification  of 
chromosome 19 although more chromosomal imbalances were expected as the embryo 
was  characterised  as  chaotic.  Molecular  analysis  also  confirmed  amplification  of 
chromosome  19  but  also  showed  the  presence  of  chromosome  Y  in  the  test  sample. 
Ideally, more markers should be used in order to confirm the blastomeres a CGH result 
but it was clear that the prenatal algorithm failed to show the correct karyotype of the 
blastomere.  
 
4.7.4 Conclusion 
 
Overall, the results obtained from this project showed how difficult it is to analyse single 
cells by a CGH. The experiments with single lymphocytes and the Cytochip prenatal 
slides managed to show better results with less false positives regardless of the WGA 
method used. Generally, all the slides apart from BlueGnome Cytochip 1MB and prenatal 
failed  to  show  any  reliable  result.  The  single  lymphocytes  with  Cytochip  1MB 
(experiment  C6)  showed  that  even  such  a  noisy  result  could  be  analysed  when  the 
prenatal algorithm was used. In the single blastomere a CGH experiments, the karyotype 
was unknown and more markers on different chromosomes should have been used in 
order  to  confirm  the  results.  The  prenatal  algorithm  this  time  was  shown  to  have  a 
misdiagnosis  on  at  least  one  chromosome  (chromosome  Y,  experiment  D4).  If  more 
markers were used on the MDA product for chromosomes 1, 8, 13, 14 and 16 a more 
reliable outcome could have been made. The aims of this project were not met entirely as 
more results will be needed for optimisation of the technique. However, the fact that sex 
mismatch was detected with the Cytochip 1MB and prenatal slide is promising for future 
development of single cell a CGH. From the literature it is clear that it is only matter of 
time until reliable single cell a CGH will be applied widely for research and diagnostic 
purposes. The first clinical PGS a CGH case has already been reported (Hellani et al., 
2008). The key to the success will be a combination of a highly reliable and optimised 
array platform for single cells (Furhmann et al., 2008) and an optimised WGA method for   158 
single cells. As shown by Iwamoto et al. (2007) the a CGH result was largely dependent 
on the quality of amplification products. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   159 
 
Chapter 5 
 
A-CGH analysis of coelomic fluid 
5.1 Hypothesis 
 
The hypothesis of this chapter is that aneuploidy can  be detected in coelomic fluid using 
a CGH. 
The  DNA  collected  from  coelomic  fluid  is  considered  to  be  degenerate  and  of  low 
quantity which is one of the biggest limitations for considering coelocentesis as a new 
technique of prenatal diagnosis. However, if reliable diagnosis by a CGH from DNA 
extracted from coelomic fluid can be achieved then this would be a step forward to use 
coelocentesis as an early prenatal diagnosis technique. 
 
5.2 Introduction 
 
Coelocentesis  has  rarely  been  applied  clinically  (Makrydimas  et  al.,  2004).  The  big 
advantage of this technique is that prenatal diagnosis can be performed very early, from 
the 5
th to the 11
th week of gestation (Jauniaux et al., 2003). The benefit of having an early 
prenatal diagnosis is that the parents can be reassured much earlier if the fetus is normal. 
In  the  case  of  an  affected  fetus  they  can  have  a  safer  termination  of  pregnancy 
(Makrydimas et al., 2002). Early diagnosis also has the potential for stem cell therapy to 
be  performed  before  the  11
th  week  where  the  fetus  is  immunologically  intolerant 
(Jouannic et al., 2006; Makrydimas et al., 2004). Coelocentesis is not a difficult technique 
to learn and only induces minimal discomfort to the mother (Jauniaux et al., 2003). As 
coelocentesis does not require puncture of the placenta or the amniotic sac, the risk of 
directly injuring the fetus or the placenta is very low (Jauniaux et al., 2003; Jurkovic et 
al., 1993). 
 
Coelocentesis  has  also  many  limitations.  One  of  the  most  important  drawbacks  is 
information on the fetal loss rate. One group reported a 25% (Ross et al., 1997) fetal loss 
in contrast to the 2% fetal loss reported by a different group (Makrydimas et al., 2002)   160 
even though similar techniques were used. Further investigation has to be done to resolve 
this  issue.  Another  limitation  of  coelocentesis  is  contamination  by  maternal  blood 
(Jouannic  et  al.,  2006).  Many  studies  have  found  coelomic  fluid  samples  to  be 
contaminated with maternal DNA which implies that coelocentesis would need further 
improvement for clinical application (Jauniaux et al., 2003; Jouannic et al., 2006). In 
order to avoid contamination in the current studies the first 0.2ml of coelomic fluid that is 
collected are discarded and a new needle and syringe is used for the extraction of the pure 
sample (Jauniaux et al., 2003). 
 
The most profound problem related to coelocentesis is that the samples collected contain 
little DNA within poor quality. A recent study has shown that the density of the coelomic 
fluid cells ranges from zero to ten cells per microlitre which makes a maximum amount 
of DNA available for diagnosis to be 60ng from 1ml coelomic fluid (Jouannic et al., 
2008). FISH experiments have shown that the DNA quality present in the coelomic fluid 
cells  is  poor,  as  most  cells  are  degenerate  (George  Makrydimas,  personal 
communication). Although up to 4ml of coelomic fluid can be aspired by coelocentesis 
there is a suggestion that extracting more than 1ml would increase the risk of fetal loss 
(Eric Jauniaux, personal communication). 
 
A limited number of studies have been performed on coelomic fluid samples. Jauniaux et 
al. (2003) published a successful QF PCR analysis for chromosomal abnormalities of 
chromosomes X, Y, 18 and 13 but the maternal contamination was found to be in the 
majority  of  the  samples.  In  contrast  Jouannic  et  al.  (2006)  used  real time  PCR  and 
obtained  a  58%  diagnosis  when  using  stringent  criteria.  FISH  analysis  of  11 
chromosomes on interphase nuclei from coelomic fluid samples has also been reported 
(Chatzimeletiou et al., 2005). 
 
 
5.3 Aims 
 
 
The aim of this project was to perform successful molecular cytogenetic analysis by a 
CGH with DNA from coelomic fluid samples. The challenge of this project was the low   161 
quantity and quality of DNA available. For this reason, WGA had to be considered in 
order  to  produce  reliable  and  robust  results.  MDA  and  GenomePlex  were  used  and 
compared as WGA techniques for DNA amplification of the coelomic fluid samples. The 
optimisation of coelomic fluid samples on a CGH could be beneficial if coelocentesis 
would  ever  be  considered  and  applied  as  an  early  form  of  prenatal  diagnosis.  The 
application of WGA direct on coelomic fluid without previous DNA extraction was also 
considered  in  order  to  investigate  if  a  minimum  amount  of  coelomic  fluid  could  be 
extracted for molecular cytogenetic analysis. 
 
For  this  project,  DNA  was  extracted  from  coelomic  fluid  samples,  and  amplified  by 
MDA  or  GenomePlex.  Coelomic  fluid  was  aspired  from  pregnant  women  that  were 
having  termination  of  pregnancy  (TOP)  for  social  reasons  or  evacuation  of  retained 
products of conception (ERPC) in case of miscarriage. Contamination of the sample and 
sample sex was tested with the use of PCR (DM I triplex) and FISH (sex chromosomes) 
respectively. A total of 20 a CGH experiments were performed with five coelomic fluid 
samples. 
 
5.4 Experimental design 
 
Coelomic  fluid  was  collected  using  coelocentesis  from  women  just  before  they 
underwent TOP or ERPC. Maternal blood and a small piece of placenta were collected 
with each coelomic fluid sample. The DNA was extracted from coelomic fluid and MDA 
or GenomePlex was applied to 5 l of the extracted DNA. In one case MDA was applied 
directly on 5 l of coelomic fluid, without DNA extraction. The amplified products were 
used for molecular analysis using the DM triplex locus. The same molecular tests were 
applied on DNA extracted from the maternal blood and the results were compared in 
order to check for contamination. FISH was applied on the placenta in order to detect the 
fetal sex and this was used for sex mismatch experiments on a CGH. The WGA products 
from  the  coelomic  fluid  samples  were  applied  on  a CGH  slides.  Any  abnormalities 
detected  were  confirmed  with  FISH  analysis  on  the  placenta  sample.  Figure  5.1 
summarises the experimental design.   162 
 
 
Figure 5.1: Summary of experimental design for the coelomic fluid study. This diagram shows how the experiments of this chapter 
were designed in order to make a valid conclusion. After collection of samples (coelomic fluid, maternal blood and placenta) a series 
of experiments were done in order to determine which coelomic fluid samples were pure, what was the fetal sex and finally to do a-
CGH analysis. Any abnormalities detected were compared with FISH analysis from the placenta samples. TOP: termination of 
pregnancy; ERPC: evacuation of retained products of conception.
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5.5 Materials and Methods 
 
5.5.1 Ethical approval 
 
For the this chapter ethical approval was obtained from the University College London 
Hospitals  Committee  on  the  Ethics  of  Human  Research  and  all  women  gave  written 
consent after receiving complete information about the procedure. 
 
5.5.2 Coelocentesis and tissues collection 
 
Coelocentesis was performed by Professor Eric Jauniaux in University College London 
Hospital.  The  procedure  took  place  immediately  before  TOP  or  ERPC  under  general 
anaesthesia.  The  gestational  age  was  determined  by  ultrasound  measurement  of  the 
crown–rump  length.  For  the  coelomic  fluid  collection,  the  external  genitalia  and  the 
vagina  were  cleaned  with  an  antiseptic  solution  and  coelomic  fluid  was  collected  by 
transvaginal puncture under ultrasound guidance using a 20G needle. The first 0.2 0.4ml 
of the coelomic fluid were discarded in order to avoid maternal contamination and the 
next 0.2 3ml were collected with a new 20G needle in 2ml syringes. Together with the 
coelomic fluid sample, maternal blood was collected for contamination check and also 
placenta tissue after TOP or ERPC was obtained for confirmation of the results. 
 
5.5.3 DNA extraction 
 
The  coelomic  fluid  was  transferred  to  1.5ml  microcentrifuge  tubes,  kept  on  ice  and 
transferred immediately to the main lab for DNA extraction using the Puregene genomic 
DNA  purification  kit  (Gentra  Systems,  USA)  (Appendix  A3).  The  protocol  followed 
from the kit was one for DNA extraction from 50 l body fluid for low cell numbers. 
Briefly  the  coelomic  fluid  was  centrifuged  at  8,000rpm  for  10  minutes  in  order  to 
concentrate the samples and the supernatant was discarded leaving a white pellet and 
~50 l  of  fluid.  A  maximum  of  1ml  coelomic  fluid  was  used  for  DNA  extraction. 
Following  that,  250 l  of  Cell  lysis  solution  was  mixed  well  with  the  CoF,  1.5 l  of   164 
proteinase K (20mg/ml) was added and the sample was incubated at 55
oC for 1 hour to 
complete lysis. After that, 1.5 l of RNase A solution (Gentra Systems, USA) was added 
and the samples were incubated at 37
oC for 30 minutes. The samples were cooled on ice 
for 1 minute and 100 l of protein precipitation solution was added to the lysate. The 
sample was vortexed for 20 minutes, incubated on ice for 5 minutes and centrifuged at 
full speed for 3 minutes. The supernatant containing the DNA was transferred to a clean 
1.5ml tube while the protein pellet content was discarded. For DNA precipitation, 300 l 
of 100% isopropanol and 0.5 l of glycogen solution (Gentra systems, USA) was mixed 
gently with the DNA and incubated at room temperature for 5 minutes. The sample was 
centrifuged at full speed, the supernatant was discarded and the DNA was washed in 
300 l of 70% ethanol. The DNA was centrifuged again at full speed, the supernatant was 
discarded and the DNA was left to air dry for 5 minutes. The DNA was hydrated in 20 l 
DNA hydration solution at 65
oC for 1 hour and stored at  20
oC. For DNA extraction of 
blood, the protocol was as described in section 2.2.1. 
 
5.5.4 WGA, PCR and DNA concentrations 
 
WGA for a CGH analysis and PCR using the DM I locus was performed with MDA or 
GenomePlex. WGA methods and protocols are described in section 2.4. Protocols P3 
(MDA on gDNA) and P5 (WGA2, GenomePlex on gDNA) were applied to the reference 
samples and the DNA extracted from the coelomic fluid samples whereas protocol P4 
(MDA on coelomic fluid) was applied directly to coelomic fluid without previous DNA 
extraction. The triplex DM 1 PCR reaction was applied to DNA extracted from maternal 
blood and MDA products from the  coelomic  fluid samples. The DM 1 protocol was 
described in section 3.5.4.1. Measuring the DNA concentration was performed only for 
the  WGA  products  that  were  used  for  a CGH  experiments  after  sample  purification. 
DNA purification and concentration method are described in section 4.5.3. 
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5.5.5 DNA and tissue materials collected 
 
All the DNA and the tissue materials collected for this project are summarised in table 
5.1.  The  table  includes  the  coelomic  fluid  reference  from  TOP  and  ERPC  samples 
collected, the fetus age, the amount of coelomic fluid collected, the collection of maternal 
blood and placenta tissue and the method of WGA used to amplify the coelomic fluid. 
 
CoF sample 
reference 
Weeks of 
pregnancy 
Amount of coelomic 
fluid Collected 
Maternal blood and 
Placenta collected 
Method of WGA 
applied to 
coelomic fluid 
TOP samples 
CoF1  9W 5D  1ml  ￿  MDA 
CoF2  9W  2ml  ￿  MDA 
CoF3  9W 2D  4ml  ￿  MDA, 
GenomePlex 
CoF4  9W 4D  4ml  ￿  MDA 
GenomePlex 
CoF5  10W 5D  2ml  X  MDA 
CoF6  8W 3D  2ml  ￿  MDA 
CoF7  6W 5D  1ml  ￿  MDA, 
GenomePlex 
CoF8  6W 4D  1ml  ￿  MDA, 
GenomePlex 
CoF9  9W  1.5ml  ￿  MDA 
ERPC samples 
CoF10  11W 3D  2ml 
 
Maternal blood 
only 
MDA, MDA direct 
of CF, 
GenomePlex 
CoF11  8W  2ml 
  ￿  MDA, 
GenomePlex 
CoF12  8W  2ml  ￿  MDA 
CoF13  9W  4.5ml  ￿  MDA 
 
Table  5.1:  Details  of  the  coelomic  fluid  and  other  materials  collected.  This  table 
summarises all DNA and tissue materials collected for this project. Sign “￿” is used to 
show that maternal blood and placenta were collected and sign “X” is used to show that 
maternal blood and placenta were not collected or WGA was not performed. 
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5.5.6 Fluorescent in Situ Hybridisation 
 
5.5.6.1 Touch preparation 
 
FISH experiments were applied on placental tissue in order to obtain the fetal gender and 
to  confirm  results  from  a CGH  analysis.  Placental  tissue  was  collected  after  TOP  or 
ERPC from women that also provided the coelomic fluid. The placenta samples were 
either  used  directly  or  were  frozen  at   80
oC  for  up  to  two  weeks  prior  to  touch 
preparations. The placenta was washed three times in Hank’s media (HBSS) on a Petri 
dish and any non embryonic material was removed with the use of a scalpel in order to 
avoid contamination. The slides were prepared by washing first in ethanol for 5 minutes, 
then in methanol for 10 minutes and finally in fix solution (3 volumes of methanol in 1 
volume of acetic acid) for 30 minutes. After the slides were dried, a small piece of tissue 
was dapped and spread along each slide. Seven slides were produced from each placental 
tissue and were stored at 4
oC. 
 
5.5.6.2 Probe preparation 
 
The probe mix consisted of probes for up to three chromosomes and buffer (CEP buffer 
for centromeric probes and LSI for locus specific probes). The total volume was always 
5 l per sample. Table 5.2 shows all volumes for probe mixes. 
 
Probe mix  Amount  Buffer 
X(SG)/Y(SR)/18(SA)  2.5 l  CEP: 2.5 l 
13(SG)/21(SO)/15(SA)  13/21:0.6 l/ 15:0.5 l  LSI: 2.5 l 
 
Table 5.2: Summary of probe mixes used for the prenatal project. One or two rounds of 
FISH  experiments  were  conducted  with  each  slide  after  touch  preparations.  SG: 
spectrum green, SR: spectrum red and SA: spectrum aqua. 
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5.5.6.3 FISH methods 
 
All the FISH methods regarding denaturation (co  and separate), hybridization and post 
hybridisation washes and image analysis interpretation have been described in sections 
4.5.6 
 
5.5.7 Molecular cytogenetic analysis by a-CGH 
 
Molecular cytogenetic analysis by a CGH was performed for the analysis of the coelomic 
fluid  samples.  Slides  from  BlueGnome  (prenatal  slides  and  1MB  slides),  the  TRL 
Mermaid 32K array slides and Spectral Genomics constitutional slides were used for this 
project. As reference material, WGA products amplified in the same method as the test 
samples and opposite sex were used. The initial DNA that was used for WGA was 10ng. 
The methods for a CGH, labelling, hybridization, scanning and analysis are described in 
detail in section 4.5.4. All the experiments apart from the ones with the 32K mermaid 
slide were performed in dye swap. 
 
5.6 Results 
 
5.6.1 Molecular analysis for contamination 
 
The first experiments focused on distinguishing which samples were contaminated with 
maternal blood and which were pure. As coelocentesis is not yet a validated technique 
and  the  amount  of  coelomic  fluid  cells  is  very  limited,  even  a  small  amount  of 
contamination could have a great effect on the outcome of the experiment. Only pure 
samples would be analysed by a CGH. Coelomic fluid has a clear yellowish colour. The 
transparency is usually lost when the fluid is contaminated with blood and the colour may 
become light or dark yellow. The blood could be either from the mother or the fetus. 
Blood contamination was also physically observed during the DNA extraction protocol,   168 
in the first step that the samples were centrifuged for 10 minutes at 6,000 rpm. After 
centrifugation the coelomic fluid cells were usually observed as a small tiny white pellet 
Sometimes  the  pellet  was  not  seen  probably  done  to  the  very  small  amount  of  cells 
present. A red spot was also present in all the samples when the colour was not clear and 
this confirmed the blood contamination of the coelomic fluid samples. 
 
 In  order  to  determine  if  the  samples  were  contaminated  by  maternal  blood,  a 
contamination  check  was  performed  using  PCR  analysis  of  three  STR  markers  on 
chromosome  19  (DM  triplex  reaction).  PCR  analysis  was  performed  on  the  MDA 
products and the results were compared with the alleles obtained from the maternal DNA 
after DNA extraction from blood. Although it could not be proved which samples were 
contaminated as the paternal DNA was not available, it was easy to find samples that 
were free of contamination. Pure samples were considered in samples where one allele 
was identical to the mother and a second that was not the same. The results are shown on 
table 5.3. 
 
From the results presented in this table it was shown that TOP samples CoF 3, CoF 4, 
CoF 7, CoF 8 and ERPC sample CoF 10 had a clear colour. CoF 9 sample did not show 
any results which could be because of MDA failure or because no cells were available. 
CoF 11 sample was considered either contaminated or the fetus had trisomy 19 as three 
alleles were present at two loci. For CoF 10 where the MDA product was derived directly 
from  5 l  of  coelomic  fluid  without  DNA  extraction, PCR  analysis  revealed  identical 
alleles with the CoF 10 MDA sample (result not presented on table 5.3). In samples CoF 
1, CoF 2, CoF 5, CoF 6, CoF 12 and CoF 13 the PCR alleles were identical to the 
maternal  DNA  and  were  excluded  from  further  experiments  because  it  could  not  be 
concluded if they were contaminated or not. 
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Samples  DM I triplex  CoF Colour 
  APOC2  DM  D19S112   
TOP samples 
       
CoF 1 MDA sample  139   150  140   146  114   122  Light Yellow 
CoF 1 Maternal DNA  139   150  140   146  114   122   
CoF 2 MDA sample  135   150   155  122 – 140  117  Light Yellow 
CoF 2 Maternal DNA  135   150  122 – 140  117   123   
CoF 3 MDA sample  135   152  138   145  128  Clear 
CoF 3 Maternal DNA  135   154  138   145  120   128   
CoF 4 MDA sample  155   161  122  149  130   133  Clear 
CoF 4 Maternal DNA  151   161  122   131  133   
CoF 5 MDA sample  152   154  122   140  171  121   133  Light Yellow 
CoF 5 Maternal DNA  152   154  140 – 171  121   133   
CoF 6 MDA sample  129   150  144   151  123   136  Dark Yellow 
CoF 6 Maternal DNA  129   150  144   151  123   136   
CoF 7 MDA sample  152   155  133   139  128   135  Clear 
CoF 7 Maternal DNA  155  122   139  128   135   
CoF 8 MDA sample  148   155  119   132  120   130  Clear 
CoF 8 Maternal DNA  148   152  119  120   141   
CoF 9 MDA sample           Clear 
CoF 9 Maternal DNA  135   150  146   154  117   
ERPC samples 
       
CoF 10 MDA sample  151   156  123   170  117   133  Clear 
CoF 10 Maternal DNA  156  123  129   133   
CoF 11 MDA sample  139   151  140   150   154  117 – 122   128  Light Yellow 
CoF 11 Maternal DNA  135 – 139   151  140   154  117   122   
CoF 12 MDA sample  150  140   155  122   133  Dark Yellow 
CoF  12 Maternal DNA  150  140   155  122   133   
CoF 13 MDA sample  148 – 154  122   180  123  Dark Yellow 
CoF  13 Maternal DNA  148 – 154  122   180  123   
 
Table 5.3: Allele sizes of CoF samples and maternal DNA. The table summarises the 
PCR results of the three loci of the DM triplex reaction from all the MDA products of 
CoF DNA and the maternal DNA.  The CoF colour shows the colour of the samples prior 
to DNA extraction.   170 
 
5.6.2 FISH analysis 
 
The gender determination of the fetus was necessary in order to conduct sex mismatch 
experiments with a CGH. The probe mix contained probes for chromosome X, Y and 18. 
The results are shown on Table 5.4 and Figure 5.2. FISH experiments were not done for 
CoF 10 because a karyotype had already been performed which revealed that the embryo 
was a male with trisomy 21 (47, XY + 21). For CoF 11 two X chromosomes, one Y 
chromosome and three 18 chromosomes were identified. These findings, together with 
the molecular analysis on chromosome 19 increased the suspicions that the sample was 
triploid (69, XXY). 
 
Placenta tissue samples of  Fluorescent signals  Result 
  X  Y  18   
CoF3  2  0  2   Female 
CoF4  1  1  2  Male 
CoF7  2  0  2  Female 
CoF8  2  0  2  Female 
CoF11  2  1   3  Male 
 
Table 5.4: Fluorescent signals for chromosomes X, Y and 18 from the placenta tissue 
samples: This table summarises the number of fluorescent signals obtained after FISH 
analysis on the placenta tissue samples so that the sex of the fetus could be determined. 
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Figure 5.2: FISH analysis of placenta samples for chromosomes 18, X and Y. These 
figures  show  the  results  of  the  placenta  samples  obtained  in  order  to  determine  the 
gender of the fetus. A: placenta of CoF 3, B: placenta of CoF 4, C: placenta of CoF 7, D: 
placenta of CoF 8 and E: placenta of CoF 11. From FISH analysis it was concluded that 
samples CoF 3, CoF 7 and CoF 8 were female whereas CoF 4 was male. CoF 11 was 
chromosomally  abnormal  as  three  chromosomes  18,  two  chromosomes  X  and  one 
chromosome  Y  was  detected.  Spectrum  aqua:  chromosome  18,  Spectrum  Green: 
chromosome X and Spectrum red: Chromosome Y. 
 
5.6.3 DNA concentration 
 
The DNA concentrations of the coelomic fluids and the WGA products are listed in table 
5.5. The literature (Jouannic et al., 2008) reports that zero to ten fetal cells are present per 
microlitre of coelomic fluid which means that the maximum DNA that could be obtained 
from a DNA extraction would be 60ng of DNA (6pg of DNA per cell x 10,000 cells 
maximum present in 1ml of coelomic fluid). Since the DNA extracted from the coelomic 
fluid was diluted in 20 l of hydration solution the maximum concentration expected from 
was 1.5ng/ l. However, from the results obtained, the DNA concentration of coelomic 
fluid was much more than what was expected. DNA from cell free DNA (cfDNA) that is   172 
present in CoF could be the reason for increasing the final DNA yield. Similar results 
have  been  found  by  Jouannic  et  al.  (2008).  Nevertheless,  it  was  very  likely  that 
measuring DNA concentration at such low quantities could produce incorrect results. 
Measuring DNA concentration by running a gel could provide more accurate results but 
this was not ideal due to the limited DNA that was available. In one case MDA was also 
applied to half the amount of DNA (2.5 l instead of 5 l) extracted from the CoF 10.  
 
The DNA concentration from the MDA and GenomePlex products was measured after 
DNA purification. The optical density (OD) was scored to show the DNA purity. Due to 
the limited number of a CGH experiments that could be conducted because of the high 
costs of the technique five samples were used for a CGH analysis. CoF 3 sample was 
excluded from the analysis mainly due to the poor amplification by MDA. 
 
Sample  gDNA  MDA  GenomePlex 
    Amplification 1  Amplification 2  
  ng/µl  OD  ng/µl  OD  ng/µl  OD  ng/µl  OD 
CoF 3  13  1.82  32  1.24        85  1.97 
CoF 4  11  1.44  130  1.81        108  1.92 
CoF 7  16  1.26  190  1.8        328  1.96 
CoF 8  9  1.71  100  1.81        184  1.90 
CoF 10  6  1.68  83  1.82  98  1.89  33  1.72 
CoF 10 cells        89  1.77             
CoF 11  21  1.8  122  1.78        66  1.68 
control male  20  1.80  462  1.80        527  1.89 
control female  20  1.80  458  1.84        475  1.83 
 
Table 5.5: DNA concentration of CoF samples and their WGA products. This table 
summarises the results from the CoF samples after DNA extraction and after WGA (MDA 
and GenomePlex). In CoF 10, MDA amplification was performed twice and also direct 
amplification of the same sample without DNA extraction was performed. OD: optical 
density. 
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5.6.4 A-CGH analysis 
 
For the a CGH experiments BAC a CGH slides of different resolution (10MB, 1MB and 
100KB) from different companies (BlueGnome, TRL and Spectral Genomics) were used. 
For the TOP samples the termination was done for psycho social purposes and so there 
was  no  previous  indication  for  chromosomal  imbalances  to  be  present.  Thus,  the 
experiments  were  mainly  focused  on  which  slides  and  amplification  method  would 
provide the best results.  
 
5.6.4.1 A-CGH analysis of CoF 4 
 
CoF 4 DNA was amplified with MDA and GenomePlex. The GenomePlex sample was 
applied to a Cytochip 1MB and a Cytochip prenatal slide. The MDA product was applied 
to a Cytochip 1MB, a Cytochip prenatal slide and a TRL 32K Mermaid array slide. The 
results from the Cytochip arrays are shown on figure 5.3 for the MDA products and 
figure 5.4 for the GenomePlex products. For the experiments the control DNA used was 
normal female amplified with a similar method to the test DNA. A CGH analysis was not 
performed with the mermaid 32K array due to very poor hybridisation (21.4% probe 
inclusion).  From  the  results  obtained,  it  was  easy to  detect  sex  mismatch  in  all  four 
experiments  but  the  MDA  samples  produced  much  nosier  results  compared  to  the 
GenomePlex  products  (table  5.6).  The  GenomePlex  CoF  4     Cytochip  prenatal  slide 
experiment was the only one where no single spot exceeded the theoretical log2 threshold 
ratio for amplification or deletion apart from the sex chromosomes. In contrast, MDA 
samples produced many artefacts especially in regions close to the chromosome ends 
which minimised the resolution analysis to whole/large chromosome changes.   174 
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Figure 5.3: A-CGH analysis of CoF 4 MDA products. These graphs compare a-CGH results from two identical test and reference 
MDA samples applied in high and low resolution slides from BlueGnome.  A: CoF 4 MDA sample – Cytochip 1MB, B: CoF 4 MDA 
sample- Cytochip prenatal slide. Although a large number of individual clones show false positive results, it is obvious that only the 
majority of the clones for chromosomes X and Y are seen as deleted and amplified respectively which certifies the sex imbalance of 
test/reference DNA.   175 
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Figure 5.4: A-CGH analysis of CoF 4 GenomePlex products. These graphs compare a-CGH results from two identical test and 
reference samples amplified with GenomePlex with high and low resolution slides from the same company A: CoF 4 GenomePlex 
sample – Cytochip 1MB, B: CoF 4 GenomePlex sample- Cytochip prenatal slide. The results are much clearer compared to the MDA 
samples and sex mismatch can easily be detected on both arrays. No false positives were detected with the Cytochip prenatal array.  176 
  CoF 4 MDA  CoF 4 GenomePlex 
  Cytochip 
1MB 
Cytochip 
prenatal 
Cytochip 
1MB 
Cytochip 
prenatal 
SD for autosomes  0.212  0.203  0.094  0.070 
SD for chromosome X  0.179  0.220  0.168  0.126 
SD for chromosome Y  0.927  0.552  0.731  0.497 
Median between replicates  0.08  0.08  0.08  0.07 
Clones included (%)  81.26  98.87  94.20  100 
 
Table 5.6: Summary of results of the a-CGH with CoF 4. The table presents useful 
analysis measurements of the CoF 4 a-CGH experiments. CoF 4 GenomePlex produces 
much lower SD compared to MDA products. 
 
5.6.4.2 A-CGH analysis of CoF 7 
 
Three experiments were conducted with CoF 7. A CoF 7 MDA sample was hybridised 
against a normal MDA male sample on a Cytochip 1MB slide. Two a CGH experiments 
were conducted with GenomePlex products from CoF 7. One Cytochip prenatal and one 
Cytochip 1MB slides was used for the experiments. Reference sample was normal male 
amplified in the same way.  The results are presented in table 5.7 and figure 5.5. The 
MDA sample produced very noisy results compared to the GenomePlex products.  The 
CoF 7 GenomePlex sample produced results with very small SD even though a clear 
difference on the X chromosome was not as clear as in the 1MB slide (figure 5.6). 
 
  CoF 7 MDA  CoF 7 GenomePlex 
  Cytochip 1MB  Cytochip 1MB  Cytochip prenatal 
SD for autosomes  0.297  0.073  0.043 
SD for chromosome X  0.313  0.144  0.096 
SD for chromosome Y  0.662  0.501  0.180 
Median between replicates  0.07  0.07  0.07 
Clones included (%)  95.33  95.57  98.22 
 
Table 5.7: Summary of results of the a-CGH with CoF 7. The table presents useful 
analysis measurements of the CoF 7 a-CGH experiments. The Cytochip prenatal -CoF 7 
GenomePlex experiment was the only that did not produce false positive results.   177 
A: 
 
 
 
 
 
 
B: 
 
 
 
 
 
 
C: 
 
 
 
 
 
 
 
Figure 5.5: A-CGH analysis of CoF 7 MDA and GenomePlex products. The ideograms 
present the a-CGH results of CoF 7 WGA products with Cytochip 1MB and prenatal 
slides. A: CoF 7 MDA sample – Cytochip 1MB, B: CoF 7 GenomePlex sample- Cytochip 
1MB slide and C: CoF 7 GenomePlex sample- Cytochip prenatal slide. The reduction of 
noise is clear in the GenomePlex products. In all a-CGH experiments sex mismatch could 
be identified but with the MDA sample, analysis with the prenatal algorithm would be 
needed  for  better  identification  of  the  imbalance.  For  the  Cytochip  prenatal  array, 
lowering the threshold for amplification would be necessary for the identification of the 
chromosome X amplification.   178 
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Figure  5.6:  Ideograms  of  Chromosome  X  from  a-CGH  experiments  with  CoF  7. 
Detailed ideograms of chromosome X from a-CGH experiments on CoF 7 (from figure 
5.5).  A:  MDA  sample  -1MB  array,  B:  GenomePlex  sample  –  1MB  array  and  C: 
GenomePlex sample – prenatal array. Although a clear amplification is detected in the 
1MB slides in both MDA and GenomePlex products, an imbalance is not seen in the 
centromeric region on the prenatal slide. 
 
5.6.4.3 A-CGH analysis of CoF 8 
 
Four experiments were conducted with CoF 8. Figure 5.7 compares the results from the 
first two experiments. DNA of CoF 8 was amplified with GenomePlex and hybridised in 
two array slides; a Cytochip prenatal slide and a 32K Mermaid array slide. Table 5.8 
summarises the analysis data. In the other two experiments a CoF 8 GenomePlex and 
CoF  8  MDA  products  were  applied  on  two  Spectral  Genomics  constitutional  slides 
(figure  5.8).  Unfortunately,  no  data  were  obtained  with  SpectralWare™  analysis 
software. The reference sample was a normal male sample amplified in a similar way to 
the test samples.   179 
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Figure 5.7: A-CGH analysis of CoF 8 GenomePlex products with Cytochip prenatal and Mermaid 32K slides. The ideograms 
compare  the  a-CGH  results  of  CoF  8  GenomePlex  products  with  Cytochip  prenatal  slide  and  32K  Mermaid  slide.  A:  CoF8 
GenomePlex sample – Cytochip prenatal slide, B and C: Detailed ideograms of chromosomes X and Y respectively from the Cytochip 
prenatal  slide.  D:  CoF  8  GenomePlex  sample-  32K  Mermaid  array;  E  and  F:  Detailed  ideograms  of  chromosomes  X  and  Y 
respectively from the 32K Mermaid slide. The sex mismatch was identified with both arrays even though it was not so strong to exceed 
the log2 threshold ratios for the amplification of the X chromosome. The reference sample was a GenomePlex normal male sample.   180 
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Figure 5.8: A-CGH analysis of CoF 8 GenomePlex and MDA products Spectral Genomics constitutional slides. The ideograms 
compare the a-CGH results of GenomePlex and MDA CoF 8 products using the Spectral Genomics constitutional slides. A: CoF8 
GenomePlex sample – Spectral Genomics Constitutional slide. B and C: Ideograms of chromosomes X and Y respectively from the 
GenomePlex product. D: CoF 8 MDA sample- Spectral Genomics Constitutional slide; E and F: Ideograms of chromosomes X and Y 
respectively from the MDA product. Only the experiment with the GenomePlex product identified the chromosome X amplification.   181 
  CoF 8 GenomePlex 
  Cytochip prenatal  Mermaid 32K 
SD for autosomes  0.071  0.212 
SD for chromosome X  0.095  0.214 
SD for chromosome Y  0.220  0.579 
Median between replicates  0.07  0.31 
Clones included (%)  98.81  67.35 
 
Table 5.8: Summary of results of the a-CGH with CoF 8. This table presents the data 
provided by the analysis of Cytochip prenatal and the Mermaid 32K arrays by BlueFuse 
software. There is a large difference in these results although the same samples were 
hybridised. Both arrays detected an Y chromosome deletion and weak amplification of 
chromosome X. 
 
When CoF 8 was amplified with GenomePlex, sex mismatch was detected with all array 
slides, even though most clones did not reach the log2 ratio threshold for amplification of 
the X chromosome. No mosaicism was detected in the placenta sample after FISH. The 
copy number changes in the X chromosome were based on the location of the majority of 
spots on the graph which were located towards the amplification region rather than being 
detected by the software program. Only Y chromosome deletion could be detected with 
the MDA product and the Spectral Genomic slides. 
 
5.6.4.4 A-CGH analysis of CoF 10 
 
In contrast to the TOP samples, chromosomal abnormalities were expected in the ERPC 
samples. For CoF 10, the karyotype of the embryo was found to be 47, XY+21 after CVS 
analysis that was performed clinically. For this reason FISH analysis was not performed 
on  the  placenta.  Six  a CGH  experiments  were  performed  with  CoF  10  MDA  and 
GenomePlex products. In the first experiments the MDA sample was hybridised against a 
normal female control on a Cytochip 1MB slide and a Mermaid 32K array slide. Another 
MDA sample was produced in which the initial DNA source was 5 l of MDA CoF 10 
(re MDA CoF 10). This MDA sample was hybridised on a Mermaid 32K array slide.   182 
This experiment was done in order to conclude if MDA could reliably be re amplified as 
it  has  been  previously  suggested  by  other  groups  (Alan  Thornhill,  personal 
communication). The result was compared with the previous experiment with the 32K 
Mermaid array. The results are presented in figures 5.9 and 5.10. For the 32K Mermaid 
arrays, dye swap was not performed; Cy3 was used for the reference DNA and Cy5 for 
the test DNA. 
 
From  the  result  obtained  from  MDA  CoF  10  on  the  Cytochip  1MB  slide  it  can  be 
concluded that overall a CGH analysis can be performed in DNA extracted from 1ml 
CoF and be able to detect whole chromosome changes or chromosomal imbalances of at 
least 50MB, which is the amount of DNA in chromosome 21. It should be noted that the 
DNA  concentration  found  after  DNA  extraction  of  the  coelomic  fluid  was  12ng/ l 
(260/280 = 1.68) which was the smallest amount of DNA from all the samples (table 5.5). 
From this result an imbalance on chromosome 21 was obtained together with artefacts 
located all around the genome but preferentially in the chromosome ends. Amplification 
of the region 1p36 that was detected in this experiment was also abundant in the other 
experiments  discussed  in  chapter  4  (figure  4.9  (experiment  B7)  and  figure  4.14 
(experiment C7)). Analysis of the same sample with the 32K Mermaid arrays did not 
produce equivalent results but still imbalances on chromosomes 21, X and Y could be 
identified. Analysis of the re MDA CoF 10 only included 23.3% of clones and so an 
outcome  could  not  be  concluded.  Table  5.9  summarises  the  data  obtained  from  the 
analysis of these experiments.   183 
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Figure  5.9:  A-CGH  analysis  of  CoF  10  MDA  products  with  Cytochip  1MB  slides.  The  graph  (A)  and  the  ideograms  for 
chromosomes 21 (B), X (C) and Y (D) show the analysis of a-CGH of the sample CoF 10 that was known to be male with trisomy 21. 
A-CGH analysis with Cytochip 1MB slide can correctly predict the result even though the experiment cannot be trustful for small 
chromosome changes as a number of clones scattered on the graph would exceed the threshold for amplification/deletion.   184 
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Figure 5.10: A-CGH analysis of CoF 10 MDA products with 32K Mermaid slides. Graph A shows the results of a-CGH of CoF 10 
MDA product that was applied to a 32K Mermaid slide and the ideograms B, C and D show the detailed result for chromosomes 21, X 
and Y respectively. The result is much more nosier compared to the Cytochip 1MB experiment but still the majority of the clones of 
chromosome 21 are detected as deleted.  Graph E shows the a-CGH result of an MDA sample that used as DNA source the MDA 
sample CoF10 in which no reliable outcome can be considered due to the poor hybridisation.   185 
  CoF 10 MDA  CoF 10 re-MDA 
  Cytochip 1MB  Mermaid 32K  Mermaid 32K 
SD for autosomes  0.174  0.471  0.467 
SD for chromosome X  0.137  0.451  0.478 
SD for chromosome Y  0.815  0.557  0.386 
SD for chromosome 21  0.215  0.828  1.012 
Median between replicates  0.05  0.51  0.7 
Clones included (%)  99.3  59.9  23.3 
 
Table 5.9: Summary of results of the a-CGH with CoF 10 MDA products. This table 
presents the data analysis from three a-CGH experiments performed with CoF 10 MDA 
product and CoF re-MDA product. The CoF 10 re-MDA-Mermaid 32K array contained 
only 23.3% of the clones for analysis so the result was not considered reliable. High SD 
of the CoF 10 MDA- Mermaid 32K array was also present compared to the CoF 10 
MDA-Cytochip 1MB experiment. 
 
Molecular  cytogenetic  analysis  of  the  GenomePlex  CoF  10  was  performed  with  the 
Cytochip prenatal slide. The result presented in figure 5.11 shows that SD was very low 
when using GenomePlex and only one spot exceeded the log2 ratio for chromosomal 
abnormality for chromosome 21. Different analysis settings should be used for detection 
of trisomy 21 by the software programme. Details of the data obtained are summarised on 
table 5.10. 
 
As  MDA  CoF  10  showed  the  best  results  with  the  Cytochip  1MB  slide,  the  next 
experiment was to produce an MDA sample from which the initial DNA template would 
be 2.5 l of CoF 10 DNA, rather than 5 l that was used in the previous amplification. 
That experiment was done in order to conclude if even less CoF DNA would be enough 
for  successful  a CGH  analysis.  The  sample  that  was  produced  was  hybridised  to  a 
Cytochip  1MB  slide,  exactly  the  same  way  as  the  first  experiment  (figure  5.8).  The 
analysis of this a CGH showed a similar pattern with the first experiment but with higher 
background noise which made the analysis more difficult. However, analysis with the 
prenatal algorithm provided by BlueGnome showed a clear trisomy 21. The graphs of the 
result are presented on figure 5.12.   186 
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Figure 5.11: A-CGH analysis of CoF 10 GenomePlex products with the Cytochip prenatal slides. Graph A shows the results of a-
CGH of CoF 10 GenomePlex product that was applied to a Cytochip prenatal slide. Ideograms B, C and D show the detailed results 
for chromosomes 21, X and Y respectively. Lowering the log2 threshold ratio for amplification/ deletion would be necessary for the 
identification of detection of imbalances for chromosomes 21 and X.   187 
The final experiment that was performed with CoF 10 sample was to test if a CGH could 
be  successfully  performed  in  minute  amounts  of  DNA  from  CoF  samples,  without 
previously having DNA extraction. MDA was applied directly to 5 l of CoF 10 without 
previous DNA extraction. MDA protocol 4 (P4) was used with an alkaline lysis. The 
maximum  amount  of  DNA  expected  to  be  present  was  from  50  cells  (because  a 
maximum  of  10  cells/ l  has  been  reported  for  coelomic  fluid).  The  MDA  product 
contained 89ng/ l of DNA. The MDA sample was hybridised against a normal male 
MDA sample on a Cytochip prenatal slide and the slide was analysed with the BlueFuse 
Cytochip protocol and with the prenatal algorithm. The result is shown on figure 5.13. 
 
  CoF 10 
GenomePlex 
CoF 10 half 
amount MDA 
CoF 10 direct 
MDA 
  Cytochip prenatal  Cytochip 1MB  Cytochip prenatal 
SD for autosomes  0.071  0.366  0.520 
SD for chromosome X  0.098  0.360  0.499 
SD for chromosome Y  0.198  1.050  0.698 
SD for chromosome 21  0.060  0.319  0.365 
Median between replicates  0.03  0.05  0.08 
Clones included (%)  99.1  98.56%,  99.26%, 
 
Table 5.10: Summary of results of the a-CGH with CoF 10 MDA and GenomePlex 
products. This table summarises the results of three experiments with CoF 10 sample. 
The  SD  of  the  CoF  10  direct  MDA  –  Cytochip  prenatal  experiment  was  the  highest 
among all the experiments with CoF 10 which indicates the low amplification efficiency 
of MDA when applied directly to CoF. 
 
Unfortunately, the experiment did not give the expected result. The background noise 
was very high even though a prenatal slide was used. In the PCR for the DM triplex good 
results were obtained which means that direct application of CoF samples with MDA is 
feasible for molecular analysis. However, application of this MDA product for analysis 
by a CGH was only enough to detect 1:2 changes (X chromosome) and 1:0 changes (Y 
chromosome)  but  not  2:3  changes  (chromosome  21).  Further  investigation  would  be 
needed for optimisation of direct amplification with MDA of CoF samples.   188 
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Figure 5.12: A-CGH analysis of CoF 10 MDA product from 2.5µl of DNA with the Cytochip 1MB slide. A: Graph presenting the 
result of the MDA product from 2.5µl of CoF10 DNA applied on Cytochip 1MB slide. The result has higher SD compared to the 
experiment where double amount of DNA was used for MDA amplification. Thus, identification with trisomy 21 is more difficult 
without the use of the prenatal algorithm.  B: The same result analysed with the prenatal algorithm showing that trisomy 21 is 
detected. Ideograms for chromosomes 21, X and Y are presented on figures C, D and E respective.    189 
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Figure 5.13: A-CGH analysis of MDA product derive from direct application on 5µl of CoF10. A: Graph presenting the result of the 
CoF 10 sample after direct amplification of 5µl with MDA applied on Cytochip 1MB slide. B: The same result analysed with the 
prenatal algorithm in which only sex mismatch was identified. C, D and E present the ideograms for chromosomes 21, X and Y 
respectively.  190 
5.6.4.5 A-CGH analysis of CoF 11 
 
The final CoF sample that was used for molecular cytogenetic analysis was CoF 11. This 
sample was an ERPC sample from which FISH analysis of the fetal placenta showed 
chromosomal abnormalities. As two signals were obtained for chromosome X, three for 
chromosome 18 and one for chromosome Y it was concluded that the sample would have 
at least two excess chromosomes (one X and one 18). The DNA extracted from CoF 10 
was  amplified  with  GenomePlex  and  MDA  and  applied  on  Cytochip  prenatal  slides. 
Normal female DNA was used as a reference sample, amplified in a similar way as the 
test sample. The results from these experiments are shown on figure 5.13. GenomePlex 
product  produced  much  less  background  noise  compared  to  the  MDA  product  and 
showed  a  much  clearer  Y  chromosome  amplification  (figure  5.14C  and  5.14F,  table 
5.11). Both results showed a very weak deletion for chromosome X but did not show any 
amplification for chromosome 18. According to the FISH result, it was expected that the 
sample should show at least an imbalance for chromosome 18 unless the sample was 
triploid (69, XXY). In order to confirm this, FISH analysis for chromosomes 13, 15 and 
21 was done on the placenta tissue. The results showed that three signals for all the 
autosomal chromosomes were present which confirmed that the sample was male triploid 
(figure 5.15). 
 
  CoF 11 
GenomePlex  CoF 11 MDA  CoF 11 
GenomePlex 
  Cytochip prenatal  Cytochip prenatal  32K Mermaid 
SD for autosomes  0.124  0.314  0.302 
SD for chromosome X  0.154  0.373  0.285 
SD for chromosome Y  0.407  0.479  0.493 
Median between replicates  0.04  0.12  60.85 
Clones included (%)  99.41  91.11%,  0.42 
 
Table 5.11: Summary of results of the a-CGH with CoF 11 WGA products. This table 
presents  the  data  provided  by  the  analysis  software  from  three  a-CGH  experiments 
performed with CoF 11. The standard deviation (SD) of the Cytochip prenatal slides was 
higher in both  experiments compared to the equivalent  experiments performed in this 
study.   191 
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Figure 5.14: A-CGH analysis of CoF 11 GenomePlex and MDA products with Cytochip prenatal slides. A-CGH results of the CoF 
11 product after GenomePlex (A) and MDA (D). Ideograms B and C show the result for chromosomes X and Y with GenomePlex 
amplification and E and F the ideograms of chromosomes X and Y after MDA amplification. Both results have higher SD compared to 
the other Cytochip prenatal experiments but weak sex mismatch is obtained.   192 
 
 
 
 
 
 
 
 
 
Figure 5.15: FISH analysis of placenta CoF 11 for chromosomes 13, 15 and 21. Three 
signals were obtained for each chromosome which implies that the embryo was triploid. 
Chromosomes 13 (Spectrum green), 15 (Spectrum aqua) and 21 (Spectrum red). 
 
The weak deletion obtained on chromosome X was explained by the way the a CGH 
software  calculated  chromosomal  imbalances.  The  software  considers  that  for  the 
majority of the autosomal chromosomes the ratio between the test and the reference DNA 
should be 2:2 which is equal to 1. So in a triploid sample where the true chromosomal 
ratio between test and reference DNA is 3:2 the software will calculate again as equal to 
1. This means that for the X chromosome where the ratio between test and reference is 
2:2 the software will calculate it as <1. That is the reason why chromosome X showed a 
weak  deletion  in  the  graph.  Although  the  correct  result  was  not  obtained  from  this 
sample,  it  was  expected  as  CGH  techniques  cannot  detect  chromosomal  balanced 
abnormalities and triploidies. 
 
The final a CGH experiment included the application of CoF 11 GenomePlex to a 32K 
Mermaid array slide in order to compare the result with the Cytochip prenatal slide. The 
results are shown on figure 5.16 and table 5.11. Unfortunately, from the result obtained a 
weak  deletion  was  observed  in  chromosome  X  and  1q  and  weak  amplification  on 
chromosomes  21  and  Y.  The  high  SD  of  the  array  was  expected  as  the  CoF  11 
GenomePlex also produced high SD with the Cytochip prenatal slide, in contrast to all 
the other CoF GenomePlex samples that were applied to the Cytochip prenatal slide.   193 
 
 
 
 
 
 
 
 
Figure 5.16: A-CGH analysis of CoF 11 GenomePlex  product with 32K Mermaid 
slide. This graph shows the result obtained from CoF 11 GenomePlex product on a 32K 
Mermaid array. Regions in red are identified as deleted, regions in green are identified 
as amplified and regions in yellow are identified as balanced. In contrast the karyotype 
of  the  sample  from  this  a-CGH  experiment  showed  deletion  of  region 1q  and  X  and 
amplifications of chromosomes 21 and Y. 
 
A summary of all the experiments performed with CoF samples, indicating the WGA 
method, the a CGH slides used, the a CGH result and the fetal karyotype is included in 
table 5.12. 
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Sample  WGA method  a-CGH slide  Result from a-CGH  Fetus karyotype  Comparison of results 
CoF 4  MDA  Cytochip 1MB  46, XY  Expected 46, XY  Concordant 
CoF 4  MDA  Cytochip prenatal  46, XY  Expected 46, XY  Concordant 
CoF 4  GenomePlex  Cytochip 1MB  46, XY  Expected 46, XY  Concordant 
CoF 4  GenomePlex  Cytochip prenatal  46, XY  Expected 46, XY  Concordant 
CoF 7  MDA  Cytochip 1MB  46, XX  Expected 46, XX  Concordant 
CoF 7  GenomePlex  Cytochip 1MB  46, XX  Expected 46, XX  Concordant 
CoF 7  GenomePlex  Cytochip prenatal  46, XX  Expected 46, XX  Concordant 
CoF 8  GenomePlex  Cytochip prenatal  46, XX  Expected 46, XX  Concordant 
CoF 8  GenomePlex  Mermaid 32K  46, XX  Expected 46, XX  Concordant 
CoF 8  GenomePlex  Spectral Genomics  46, XX  Expected 46, XX  Concordant 
CoF 8  MDA  Spectral Genomics  45, X  Expected 46, XX  Disconcordant 
CoF 10  MDA  Cytochip 1MB  47, XY +21  47, XY +21  Concordant 
CoF 10  MDA  Mermaid 32K  47, XY +21  47, XY +21  Concordant 
CoF 10  Re MDA  Mermaid 32K  inconclusive  47, XY +21    
CoF 10  GenomePlex  Cytochip prenatal  47, XY +21 (weak amplification)  47, XY +21  Concordant 
CoF 10  MDA 2.5 l DNA  Cytochip 1MB  47, XY +21  47, XY +21  Concordant 
CoF 10  Direct CoF MDA  Cytochip prenatal  46, XY  47, XY +21  Disconcordant 
CoF 11  GenomePlex  Cytochip prenatal  46, XY (mosaic)  69, XXY  Disconcordant 
CoF 11  MDA  Cytochip prenatal  46, XY (mosaic)  69, XXY  Disconcordant 
CoF 11  GenomePlex  Mermaid 32K  47, XX  1p +21  69, XXY  Disconcordant 
 
Table 5.12: Summary of a-CGH for this chapter. This table summarises all the a-CGH results performed for this study and compares 
them with the expected karyotypes of the foetuses. For all the TOP samples no chromosomal abnormalities were expected and the a-
CGH results detected the expected sex of the fetus in most of the cases. The triploid sample was not detected by any type of array or 
WGA method. 
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5.7 Discussion 
 
This  study  focused  on  chromosome  analysis  of  CoF  samples  using  a CGH.  The 
advantage of achieving reliable CoF diagnosis is correlated with the advantages of early 
prenatal  diagnosis  from  the  5
th  week  of  gestation.  Specific  problems  arise  with  CoF 
collection and analysis, some of which I tried to be addressed in this project. The crucial 
problem  of  defining  the  actual  fetal  loss  rate  following  coelocentesis  could  not  be 
addressed here as it is a medical aspect. 
 
Maternal contamination is an issue that raises questions of the origin of the DNA from 
the CoF samples. Contamination has to do with the content of the CoF but also with the 
technique by which the samples are aspirated. A solution for avoiding contamination in 
respect  to  coelocentesis  would  be  to  discard  more  than  0.2  ml  of  CoF  fluid.  In  this 
project,  the  contamination  problem  was  avoided  by  only  choosing  samples  that  were 
validated for their purity with the use of PCR. A total of six out of the 13 samples were 
defined as pure. For the rest of the samples I could not determine whether they were pure 
or contaminated but because all three alleles matched the maternal alleles, the chance of 
contamination existed and so they were excluded from analysis. All of these samples 
were light or dark yellow in colour. CoF sample normal colour is clear transparent and 
when the colour appears to be light or dark yellow indicates that the sample contaminated 
by blood. Most of the other studies performed regarding PCR and FISH analysis have 
found  small  or  high  contamination  of  CoF  samples  (Jouannic  et  al.,  2006  and  2008; 
Jauniaux et al., 2003) even in samples where the CoF colour is clear. 
 
The technical difficulty in this study was the quantity and quality of CoF DNA obtained 
and the application on a CGH. So far, studies have reported PCR (Jauniaux et al., 2003) 
and  FISH  analysis  (Chatzimeletiou  et  al.,  2004  and  2005)  but  this  was  the  first 
application of a CGH analysis on CoF samples. The crucial point of this study was the 
different  WGA  applications  and  the  comparison  with  different  array  slides  and   196 
resolutions. The amount of DNA available for diagnosis, the WGA techniques and the 
different array slides and resolution analysis are discussed in the following pages.  
 
5.7.1 Concentration CoF DNA and minimum amount for WGA 
 
It has been found that CoF samples have a wide variability of cells density, ranging from 
0 to 10,600 cells/ml but also contain cell free DNA (cfDNA) (Jouannic et al., 2008). 
Since each cell contains 6pg DNA the maximum amount of DNA from CoF cells is 
around 60pg/ l. Real time PCR analysis showed a large variation of the final amount of 
DNA present after DNA extraction which can also be explained by the large variation of 
the cfDNA. In this study, measuring DNA by NanoDrop was not considered to be an 
accurate  measurement  as  the  minimum  detection  limit  proposed  by  the  Instrument’s 
manual is 2.5ng/ l. Nevertheless this was not of such great importance for our study as 
WGA was applied to the samples. The DNA extraction protocol that was performed for 
this project focused on extracting DNA from cells and not the cfDNA as DNA extraction 
was  applied  after  discarding  the  supernatant  following  centrifugation.  CfDNA  is 
abundant in the supernatant and has been found to be degenerate DNA of very small 
molecular  weight  (Larrabee  et  al.,  2004)  and  it  is  most  likely  to  be  of  fetal  origin 
(Makrydimas et al., 2008). The MDA sample that was applied directly to CoF without 
DNA extraction (CoF 10, section 5.6.4.4) probably amplified cfDNA together with DNA 
from a few cells. 
 
Although up to 4ml were collected for analysis, only 1ml was used for DNA extraction 
according  to  suggestions  by  other  groups  that  minimising  the  amount  of  CoF  could 
reduce the fetal loss rate (Jouannic et al., 2006). As DNA can vary a lot following DNA 
extraction it was important to set a minimum amount that could be used for WGA and 
consequently for a CGH analysis. For this reason in one sample where trisomy 21 was 
detected, WGA was repeated on 2.5 l of CoF DNA template in contrast to the 5 l of 
DNA  used  in  all  other  samples.  Minimizing  the  amount  of  DNA  used,  direct 
amplification of CoF was also performed with CoF 10, even though the results were not 
successful. An interesting experiment would be to isolate single or a small number of   197 
CoF cells under the microscope, as in single cell isolation, and then apply this to WGA 
for a CGH analysis. This was not performed as expertise was needed in order to identify 
and distinguish CoF cells from the presence of other cells (eg. maternal cells from blood 
contamination). The knowledge acquired from the single cell a CGH chapter (chapter 4) 
would have been very beneficial for successful analysis of this kind of experiment. 
 
5.7.2 Different WGA methods for CoF DNA amplification 
 
Two methods of WGA were used, MDA and GenomePlex. Both were used in the single 
cell a CGH chapter and managed to correctly amplify DNA from a single cell, at least for 
the sex mismatch discrimination. As the DNA quantity obtained from these samples was 
greater compared to a single cell, better results were expected. Most studies conclude that 
MDA is superior to GenomePlex for genome wide studies when the input DNA is from 
good quality (Park et al., 2005; Barker et al., 2004). However, according to the literature, 
GenomePlex has advantages over MDA for samples of poor DNA quality (Leanza et al., 
2007). In a study by Mead et al. (2008) GenomePlex was compared with MDA for the 
amplification of degraded DNA  with high throughput SNP arrays  and  concluded that 
overall GenomePlex presented better results. The advantage of GenomePlex has to do 
with the ability to amplify DNA of poor quality, such as formalin fixed ethanol preserved 
(FFEP) samples, better than MDA. A second advantage is that GenomePlex products do 
not produce non specific DNA, in contrast to MDA. Experimental proof for this is the 
presence of DNA after amplification of DNA free samples with MDA (Hughes et al., 
2005). This is an explanation of the high background noise with MDA samples in the a 
CGH experiments. Generally in the results from this chapter, GenomePlex products had a 
much  lower  SD,  but  in  certain  samples  (CoF  7  and  CoF  8)  the  chromosomally 
unbalanced regions of test and reference DNA did not always exceed the threshold for 
amplification or deletion. 
 
As other groups suggest, the DNA quality obtained after MDA is crucial and can predict 
the quality of an a CGH result (Buffart et al., 2007). According to a study by Buffart 
(2007) high DNA yield after MDA amplification (>10 g) is an accurate predictor for   198 
good a CGH results. In the results from this chapter, only MDA amplification of 20ng of 
gDNA  resulted  in  overall  DNA  close  to  10mg  (control  male  =9.24mg  DNA,  control 
female = 9.16mg DNA). The results obtained from hybridisation of the MDA male and 
female control products on the Cytochip 1MB slide are presented on figure 4.7, had the 
lowest SD (SD = 0.133) and presented a good sex mismatch difference. For all the other 
MDA samples that were used for a CGH experiments the final DNA yield varied from 
1.66mg to 3.8mg. 
 
An interesting modification of the MDA technique has been proposed to overcome the 
problems encountered with degraded and damaged DNA. The technique developed is 
named restriction and circulisation  aided rolling circle amplification (RCA RCA) and 
uses enzymes to cut and ligate the DNA into circular DNA template prior to MDA in 
order to avoid duplex ends. This technique was first described by Wang et al. (2004) and 
results reported so far are very promising (Wang et al., 2004). RCA RCA should be ideal 
for applying to DNA from CoF samples. This technique would be even more helpful for 
the direct amplification of CoF samples without DNA extraction as the majority of the 
DNA present is expected to be cfDNA (like CoF 10). Unfortunately, this technique was 
not used in this project due to high cost and minimum number of a CGH experiments but 
it should be used in future research. 
 
5.7.3 Molecular cytogenetic analysis of CoF by a-CGH 
 
Genetic diagnosis in prenatal samples was first reported in 1956 (Fuchs and Riis, 1956). 
The  development  of  different  techniques  for  more  secure  collection  of  samples  and 
different genetic tests for more accurate and fast diagnosis has not stopped since then. 
Recently, a CGH was introduced in the analysis of prenatal samples (Le Caignec et al., 
2005; Rickman et al., 2005; Larrabee et al., 2004; Schaefer et al., 2004).  
 
The  evolution  of  a CGH  towards  high  resolution  analysis  raised  critical  issues  for 
prenatal diagnosis use. Copy number variants (CNVs) exist in the genome and they are 
not always connected to clinical malformations (Perry et al., 2008). Detection of a not   199 
previously characterised chromosomal imbalance would raise concerns regarding the fate 
of the fetus (Vermeesch et al., 2005). For this reason, a CGH slides with target probes 
located  on  or  close  to  known  chromosomal  abnormalities  have  been  developed  with 
average resolution 5 10MB. In this project, these types of slides were used but also 1MB 
and  tilling  path  array  slides  were  applied  to  WGA  products  from  CoF  samples. 
Nevertheless, all the slides were used for detection of large chromosome changes. As in 
the single cell a CGH project, Cytochip prenatal and 1 MB slides provided the most 
accurate and reliable results. 
 
Guidelines  for  molecular  karyotyping  for  prenatal  diagnosis  have  been  published 
(Vermeesch et al., 2007). According to these guidelines several experiments involving 
self self  hybridisations,  replicate  experiments,  sex  mismatch  and  chromosome  add in 
experiments have to be performed in order to estimate the sensitivity and the specificity 
levels of specific a CGH slides in a laboratory. In this project, only sex mismatch was 
performed due to the high cost of experiments and because no clinical application would 
be  performed.  However,  this  study  focused  only  on  the  application  of  CoF  WGA 
products to a CGH analysis for large/whole chromosome changes and not on the analysis 
at the theoretical resolution of each slide. Although it was not a blind study, a trisomy 21 
was detected by the software analysis which can set the experimental resolution to 50MB. 
Due to the many artefacts present, a large number of false positives were predicted by the 
software analysis in the 1MB and the tiling path arrays but these would not have been 
detected if the prenatal algorithm was applied to all samples (as it was performed with 
CoF  10  samples,  figure  5.10).  Only  the  combination  of  GenomePlex  products  and 
Cytochip prenatal slides produced results where there were no or very few false positive 
results. However, in these experiments the log2ratio for amplification/deletion had to be 
decreased for the detection of imbalance by the software. 
 
The  detection  of  a  region  to  be  identified  as  deleted  or  amplified  was  based  on  the 
majority  of  the  clones  located  on  a  specific  chromosome  being  above  or  below  the 
threshold level. Imbalances may be identified if the post analysis measurements were 
changed but Cytochip analysis for the Bluefuse Cytochip analysis would not allow any   200 
modification  in  the  settings.  The  software  from  BlueFuse  could  not  always  identify 
deletions  and  amplifications  and  erroneously  identified  normal  regions  as 
deletions/amplifications due to artefacts and high SD, especially in the MDA samples. 
However,  in  the  CoF  10  sample  (figure  5.12)  analysis  with  the  prenatal  algorithm 
demonstrated that the trisomy can be detected if a different algorithm is used for the 
analysis. 
 
An important issue regarding the success of an a CGH experiment is the total SD. The 
only  control  experiment  that  was  performed  with  MDA  of  good  quality  DNA  with 
Cytochip 1MB slides was presented in chapter 4 where the SD was 0.133. This should be 
the minimum SD expected by Cytochip 1MB slides and MDA products. Unfortunately, 
no equivalent experiment was performed with GenomePlex or with different array slides. 
In order to minimise the SD, the reference samples were treated in a similar way as the 
test samples as has been suggested by various groups (Knijnenburg et al., 2007; Arriola et 
al., 2007). Another important issue with the success of an a CGH experiment is the final 
clone inclusion for the analysis. In all experiments, apart from the ones performed with 
the  32K  Mermaid  arrays,  the  total  clone  inclusion  exceeded  90%,  which  is  the  limit 
suggested by the guidelines. The 32K Mermaid arrays have been developed for research 
purposes and so clone inclusion >70% was considered to be acceptable. 
 
5.7.4 Conclusion 
 
In  conclusion,  reliable  aneuploidy  screening  of  all  chromosomes  with  a CGH  can  be 
achieved. The prenatal algorithm could provide reliable results for whole chromosome 
changes avoiding high SD produced by WGA. More experiments would be necessary for 
determining the resolution that analysis can be performed. 
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Chapter 6 
 
Conclusions 
 
 
6.1 Diagnosis with single cells and small numbers of cells 
 
The  main  problem  with  PGD  arises  from  the  minimum  amount  of  DNA  present  for 
diagnosis and currently the only technique that helps to overcome this problem is WGA. 
The future of PGD is to make WGA a universal step prior to any genetic test so that PGD 
can  be  performed  using  direct  and  indirect  mutation  markers,  PGH,  a CGH  or  by 
combining PGS and PGD for monogenic diseases. WGA could also be useful for the 
study of chromosome  mechanisms (compaction stages, meiosis, crossing over) during 
early development and the investigation of more complex genetic mechanisms, such as 
imprinting  which  has  been  found  to  play  a  crucial  role  in  assisted  reproductive 
technology (ART) (Huntriss et al., 2008). 
 
Similar  to  single  cell  diagnosis,  coelocentesis  is  hampered  due  to  low  DNA 
concentrations present in the coelomic fluid collected. If this problem could be solved, 
the advantages of early diagnosis by coelocentesis would be safer termination in cases of 
affected fetuses and fetal treatment before the fetus becomes immunologically intolerant. 
The way to overcome the low amount of DNA is WGA. 
 
6.2 WGA for single cells and small numbers of cells 
 
When applying WGA to a single cell, optimisation of each step would be essential for 
robust amplification. In chapter 3 it was shown that even a small modification of the lysis 
protocol can alter the WGA efficiency (exclusion of DTT, L1 method). It was also shown 
that  different  cell  types  and  lysis  methods  may  respond  differently  to  WGA.  This 
demonstrates  the  importance  of  optimisation  of  a  technique  prior  to  any  clinical  or 
research  application.  In  studies  where  different  cell  types  are  used  (cancer  studies,   202 
forensic  studies,  archaeological  studies)  testing  of  different  lysis  methods  should  be 
applied. In chapter 3, the L1 lysis method gave the best results and buccal cells were 
shown to contain poor quality DNA. 
 
There are several WGA methods developed but all of them are based on either PCR or 
MDA. MDA and GenomePlex were used in this project because they have been reported 
to be the more promising for single cell amplification (Fiegler et al., 2007; Le Caignec et 
al., 2006). Other techniques used to amplify single cells are DOP PCR, PEP, RCA RCA 
and  LA adaptor PCR. For all these techniques, apart from GenomePlex, there are no 
protocols specialised for single cells provided by the manufacturers and the minimum 
requirement of DNA input is 1ng. 
 
For molecular analysis at the single cell level only MDA can be used as it is the only 
method  that  produces  long  DNA  strands  and  can  be  reliable  for  molecular  analysis. 
GenomePlex was very recently reported as the WGA method for PGD with PCR and 
direct sequencing (Chen et al., 2008). The authors reported a total of 6 12% TAF and 6 
19%  ADO  of  the  16  GenomePlex  products  from  single  blastomeres  for  five  PCR 
reactions  (one  for  β thalassaemia  and  four  for  HLA  haplotyping).  One  ongoing 
pregnancy  was  achieved  from  two  cycles  of  embryo  transfer.  Nevertheless,  I  do  not 
consider  this  technique  reliable  due  to  the  fragmentation  step  that  is  needed  for  the 
amplification of the genome. MDA has already been applied in clinical PGD and several 
reports have referred to the benefits of the amount of DNA obtained (Renwick et al., 
2006; Burlet et al., 2006). However the disadvantage of the technique is that the results 
obtained are worse compared to optimised single cell protocols (chapter 3). Apart from 
this,  the  results  reported  from  different  groups  vary  and  each  group  reports  small 
modifications regarding the lysis buffers and amplification time. Very few papers have 
been published with extensive analysis of single cell MDA molecular analysis (Glentis et 
al., 2009; Spits et al., 2006; Renwick et al., 2006). In contrast, clinical PGD with MDA 
has been reported by several groups and in some cases very few work up experiments 
have  been  performed.  I  conclude  that  the  use  and  optimisation  of  MDA  for  PGD   203 
molecular  analysis  should  be  focused  on  PGH  or  multiple  testing,  such  as  the 
combination of direct and indirect analysis. 
 
For single cell a CGH various WGA techniques can be used. Due to the nature of a CGH, 
different standards of DNA quality compared to PCR are necessary for robust results. For 
example, single nucleotide miss incorporations and production of short DNA molecules 
would not be considered as important as even representation of the genome and non 
specific  DNA  formation.  In  this  study,  GenomePlex  seemed  to  provide  better  results 
compared  to  MDA  on  a CGH  but  the  disadvantage  of  this  technique  was  the  low 
amplification  efficiency  (70%,  7/10)  obtained  in  the  results  in  chapter  4.  More 
experiments will have to be done to measure amplification efficiency of GenomePlex in 
single cells as this would be a crucial factor for PGD. Comparing the two lysis methods 
for GenomePlex (L1 and L3) was not possible due to the small amount of experiments 
that were performed. BlueGnome is currently developing single cell a CGH protocols in 
collaboration with UCL Centre for PGD. The single cell WGA protocol consists of a 
modification of GenomePlex and uses a different polymerase for the amplification of the 
DNA. 
 
Recently, LA adaptor PCR was used for single cell a CGH and the authors claimed to 
detect imbalances as small as 5MB (Fuhrmann et al., 2008). Nevertheless, the small size 
imbalances detected were more than single copy (six to nine copies) and the success of 
this project was mainly due to the optimisation of the array platform. The first clinical 
PGS with a CGH was published with the use of two cells instead of one (Hellani et al., 
2008). 
 
Most of the WGA kits provided from companies are expected to robustly amplify the 
DNA of such quantities as seen in CoF. Both methods used managed to show reliable 
data for whole chromosome changes but GenomePlex provided much clearer profiles 
with none to very few positive controls and also managed to work on different slides. 
 
6.3 A-CGH platforms and analysis   204 
 
In this study, only BAC array platforms were used for chromosomal analysis of single 
cells and CoF. Three different resolution arrays were used (10MB, 1MB and tiling path). 
Nevertheless, the diagnostic resolution did not increase with the higher resolution slides 
as the SD increased as well. It seems that with WGA application on such small quantities 
of DNA it is not possible to achieve the theoretical resolution of the arrays. 
 
For single cell a CGH only whole chromosome changes could be detected and more work 
is necessary for reliable results. A trisomy 19 was detected (experiment D4) and was also 
confirmed by PCR. However, a trisomy 5 that was clearly identified in experiment D2 
was  not  confirmed  by  PCR.  Finally,  a  trisomy  1  was  not  detected  by  the  prenatal 
algorithm even though the majority of the clones had a positive value of log2 Ch1/Ch2 
ratio. For the CoF samples, better results were obtained with much less false positive 
results compared to single cells. According to the results obtained from chapter 5, a CGH 
with CoF samples should be considered accurate for whole/large chromosome changes. 
 
An important issue however, has to do with the desired resolution obtained by a CGH for 
PGS and prenatal diagnosis. Different slides that offer CGH analysis are oligonucleotide 
and  SNP  arrays.  The  theoretical  resolution  that  can  be  achieved  is  very  high. 
Oligonucleotide arrays use small DNA molecules (25 60mer) and each slide may contain 
hundreds of thousands of target regions that allow much higher resolution than BAC 
arrays. The background noise of oligonucleotide arrays is much lower compared to BAC 
arrays. Nevertheless, analysis at 50  100 kb resolution may allow detection of CNVs but 
it is not known if they correlate with a genetic defect. Different studies have shown that 
benign CNVs may range from 24 to 824 (Korbel et al., 2007; Wong et al., 2008; Kidd et 
al., 2008) and it is likely that “every fetus will be identified as abnormal” if it is analysed 
by high resolution a CGH (Shuster, 2007). My conclusion is that low resolution arrays 
(5 10MB) or low resolution analysis (such as the prenatal algorithm) is more likely to 
detect  the  majority  of  the  known  genetic  malformations  and  do  not  produce  difficult 
interpretation or counseling. From a recent clinical application of low resolution a CGH 
on prenatal samples it was found that only 1% (3/300) of the diagnosis had a CNV of   205 
unknown  clinical  significance  (Veyver  et  al.,  2009).  For  PGS,  only  large/whole 
chromosome changes should be considered as the main objective of PGS is to increase 
the pregnancy rate. 
 
SNP arrays are oligonucleotide arrays, but instead of following the CGH procedure, they 
work by separate hybridisations of the test and the reference DNA and the results are 
analysed by comparing the embryo and parental SNPs and by measuring the fluorescence 
intensities of test and reference DNA (Wells et al., 2008). In this way the haplotype of the 
sample is revealed and a DNA fingerprint is produced. Two recent studies with SNP 
arrays and single cells (blastomeres, lymphocytes and known cell lines) were published 
and the results were promising for future application PGS (Scott et al., 2008; Kearns et 
al.,  2008).  The  potential  of  SNP  arrays  for  PGS  is  that  chromosomal  abnormalities 
(including  uniparental  disomy)  and  single  gene  disorders  can  be  detected  in  a  single 
experiment.  However,  ethical  concerns  arise  with  this  approach.  Genotyping  of  the 
embryo will provide a huge amount of information as well as detecting chromosomal 
abnormalities and single gene defects; these include predisposition to late onset genetic 
diseases, such as diabetes and cancer or non disease related characteristics, such as height 
and skin colour. 
 
In single cell a CGH, the highest resolution reported was with BAC arrays. Fiegler et al. 
(2007) reported a resolution of 10MB for single copy changes and Fuhrmann et al. (2008) 
reported a maximum resolution of 5MB for multi copy changes. Such high analysis could 
be  very  useful  for  research  purposes.  In  the  first  clinical  PGS  a CGH  report  an 
oligonucleotide  array  platform  was  used  instead  of  a  BAC  array  but  the  analysis 
concentrated on whole chromosome changes rather than high resolution analysis (Hellani 
et al., 2008). The initial work up as a CGH experiments were performed on 20 embryos 
that had been previously diagnosed with only one chromosomal abnormality by FISH. 
Five/twenty  (25%)  results  were  detected  as  normal  (false  negative).  Surprisingly  the 
authors concluded that this was due to mosaicism and not due to misdiagnosis although 
no further investigation was performed. In the clinical application, a total of 41 embryos 
were assessed with a CGH from eight PGS cycles and a pregnancy was achieved in 5/6   206 
cycles  which  had  an  embryo  transfer.  Very  recently,  the  CARE  fertility  clinic  in 
Nottingham  reported  the  first  clinical  application  of  polar  body  a CGH  analysis  (in 
collaboration with BlueGnome) for whole chromosome changes with 1/4 cases resulting 
in pregnancy. Finally, a prospective “non selection” PGD trial was performed with the 
use  of  a CGH.  In  this  study,  all  embryos  were  assessed  by  a CGH  but  the  embryo 
selection was not influenced by the a CGH result. It was found that for all the embryos in 
which a CGH predicted a chromosomal abnormality either failed to implant or miscarried 
(100% success) whereas in 42.9% cases where a CGH did not show any chromosomal 
abnormality, an ongoing pregnancy occurred (Scott et al., 2008). 
 
The  interpretation  of  the  result  is  also  very  important.  For  diagnostic  purposes  a 
chromosomal abnormality should always be scored by the analysis software. The result of 
an experiment depends on certain criteria that are assigned prior to analysis, such as the 
normalisation protocol and the algorithm used. In WGA products from single cells where 
the  SD  is  very  high,  the  majority  of  the  clones  exceeded  the  log2  ratio  for 
amplification/deletion. Analysis with the BlueFuse Cytochip method was shown to be 
defective  for  these  samples  and  only  analysis  with  the  prenatal  algorithm  could  be 
considered reliable. Analysis methods, such as the prenatal analysis, estimate the average 
log2  ch1/ch2  ratio  for  a  number  of  consecutive  clones  at  a  chromosome  in  order  to 
estimate chromosome imbalances but consequently the analysis resolution will drop. For 
the CoF samples, detection of chromosomal imbalances without the use of the prenatal 
algorithm  could  be  scored  when  GenomePlex  products  were  applied  to  the  Cytochip 
prenatal slides. 
 
At the 2008 International Society for Prenatal Diagnosis (ISPD) conference (Vancouver) 
a CGH,  multiplex  ligation dependent  probe  amplification  (MLPA)  and  quantitive 
fluorescent PCR (QF PCR) were compared for accurate prenatal diagnosis. Results from 
various groups were presented indicating the advantages and the disadvantages of each 
technique. The difference between these techniques was that MLPA and QF PCR provide 
less  information  compared  to  a  karyotype  whereas  a CGH  can  provide  much  more 
information (with the exception of balanced translocations and triploidies) that require   207 
difficult counselling and extensive follow up studies (Ogilvie et al., 2009). Nevertheless, 
karyotyping remains the gold standard for prenatal diagnosis. 
 
6.4 Future experiments 
 
WGA  by  MDA  may  be  used  for  PGD.  Further  experiments  would  include  the 
optimisation of a number of PCR markers linked to a genetic condition using singleplex 
reactions on single cell MDA products that can be applied to every family according to 
the  markers  for  which  the  parents  are  informative.  Although  PGH  has  already  been 
applied it uses a large number of markers that have not been previously optimised for 
MDA and there is a chance of misdiagnosis due to double recombination events and high 
ADO (Renwick et al., 2007; Kakourou et al., 2007). However, MDA products could be 
used for haplotyping with fewer markers which have previously been optimised and are 
closer to the targeted mutation.  No buccal cells and proteinase K lysis should be used 
with  MDA.  MDA  could  also  be  tested  in  cases  where  optimised  protocols  for  PGD 
exhibit high ADO rates. 
 
The single cell a CGH study is already evolving. The array experiments in this project 
were  performed  at  the  North  East  Regional  Cytogenetic  laboratory  but  now  in  UCL 
Centre for PGD has organised the necessary equipment and materials (apart from the 
scanner)  in  order  to  perform  future  array  experiments  on  site.  Positive  control 
experiments have successfully been performed on site and the slides were scanned at the 
TRL.  Currently,  UCL  Centre  of  PGD  and  BlueGnome  are  collaborating  for  further 
optimisation of a CGH. A blind study is being performed with single cells isolated from 
epithelial cell lines with stable chromosomal abnormalities and amplified by a modified 
protocol based on GenomePlex. BlueGnome developed new BAC array slides (24sure 
arrays) that are being used for this project (non dye swap experiments). The results so far 
are  promising  and  reproducible  for  detection  of  whole  chromosome  changes  (a  47, 
XX+10  was  successfully  detected).  However,  analysis  from  a  complex  karyotype 
(53,X,add(x)(pter),  +der(1),+,add(6)(pter),  +add(6)(pter),  +12,  +add(17)(p21),  +21, 
+21,add(22)(p11.2)) failed to detect the majority of the abnormalities and the results were   208 
inconsistent.  Due  to  the  way  the  software  does  the  analyses,  it  is  necessary  for  the 
majority  of  the  clones  to  be  chromosomally  balanced  with  the  reference  DNA.  In 
blastomeres however, chaotic embryos exhibit many chromosomal abnormalities which 
could  affect  the  analysis  of  the  experiment.  More  sophisticated  analysis  algorithms 
should be developed for complex karyotypes at the single cell level of a CGH analysis. 
What is encouraging is that for all the a CGH experiments with the complex karyotype, 
the software predicted that the single cell was not normal and so in a clinical case it 
would be excluded for transfer. The future experiments, which are being performed by 
another  PhD  student  (Thalia  Mamas),  will  focus  on  further  optimisation  of  WGA 
techniques and application of different array platforms and labelling methods. 
 
For future research regarding CoF, the goal would be to concentrate on ERPC samples in 
order to confirm more chromosomal abnormalities with a CGH. With the knowledge of 
single  cell  isolation,  a CGH  analysis  could  also  be  performed  on  an  isolated  small 
number of cells, which could ensure the absence of contamination of the samples. Further 
investigation of the nature of cell free DNA in the samples could also be performed with 
a CGH and WGA. 
 
In  conclusion,  microarrays  are  a  powerful  tool  of  genetics  that  can  provide  much 
information and detail even from a single cell. Together with WGA, new research and 
clinical horizons have arisen regarding single cell analysis. Whatever methods are used 
for PGD, ethical dilemmas will occur as PGD can be used for more ethically sensitive 
situations. It is up to societies and scientists to decide the ethical limitations for PGD. 
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Appendix A 
 
A.1 Suppliers of chemicals 
 
The chemicals for this project were obtained from Roche, Sigma, VWR and Gibco BRL 
unless stated differently. 
 
A.2 Solutions for DNA extraction from blood 
 
The reagents used for the DNA extraction were buffers TKM1 (10 mM Tris HCl, pH 7.6; 
10 mM KCl, 10 mM MgCl2 and 2 mM EDTA) and TKM2 (TKM2 (10 mM Tris pH 7.6, 
10mM KCl, 10 mM MgCl2, 0.4 mM NaCl, and 2 mM EDTA), Igepal (Sigma, UK), 10% 
sodium dodecyl sulphate (SDS; Sigma, UK), 6M NaCl and 1% TE buffer.  
 
A.3 Solutions for DNA extraction from coelomic fluid 
 
The  Puregene  genomic  DNA  purification  kit  (Gentra  Systems,  USA)  was  used  for 
coelomic fluid DNA extraction. The kit included a Cell lysis solution, RNase A solution, 
Protein  precipitation  solution,  Glycogen  solution  (20  mg/ml)  and  DNA  hydration 
solution. Proteinase K (20mg/ml) and isopropanol was provided from Sigma. 
 
A.4 Materials and solutions for single cell isolation and lysis 
 
The  materials  for  single  cell  isolation  used  were  plastic  Petri  dishes  (Sterilin,  UK), 
dissecting  microscope,  hand  pipettes  that  are  controlled  through  aspiratory 
micromanipulation and ABI9700 thermocycler. The reagents used for alkaline lysis were 
dissociation buffer (DB; 140mM NaCl, 0.2mM KCl, 0.04mM NaH2PO4 X 2H2O, 5.5mM 
glucose, 1.2mM NaHCO3, 0.02mM EDTA, and 0.01% (w/v) phenol red) (Sigma, UK), 
bovine  serum  albumin  (BSA,  Sigma,  Dorset,  UK),  KOH  solution  and  Dithiothreitol 
(DTT, Sigma, UK) and for PK lysis phosphate buffer saline (PBS, Sigma, UK), polyvinyl 
alcohol (PVA, Sigma, UK), Proteinase K and  SDS (Sigma, UK).   234 
A.5 Materials and solutions for WGA by MDA and GenomePlex  
 
WGA both for MDA and for the GenomePlex was accomplished with the use of kits from 
companies.  All  the  WGA  reactions  were  carried  out  in  an  ABI9700  thermocycler 
(Applied Biosystems, UK). 
 
For the MDA reaction, the Repli g midi kit (Qiagen, UK) was used which contained the 
Repli g midi DNA polymerase, the Repli g midi reaction buffer, the reconstituted DLB 
buffer,  the  stop  solution  and  the  DTT  1M  solution.  Nuclease  free  water  was  from 
Promega. Denaturation solution (D1) was 15% reconstituted DLB buffer, denatutation 
solusion D2 consisted of 5 l of 1M DTT and 55 l of reconstituted buffer DLB and N1 
solution was 10% of Stop solution. 
 
For the GenomePlex amplification of gDNA the complete WGA kit (WGA2; Sigma, UK) 
was used which contained the WGA DNA polymerase, the 10X fragmentation buffer, the 
1X library preparation buffer, the library stabilization solution, the library preparation 
enzyme, the 10X amplification master mix and the nuclease free water. For single cells 
the Genomeplex single cell WGA kit (WGA4; Sigma, UK) was used which contained the 
same  reagents  as  the  WGA2  apart  from  the  1X  single cell  library  preparation  buffer 
(instead of 1X library preparation buffer), the 10X single cell lysis and fragmentation 
buffer (instead of 10X fragmentation buffer) and the Proteinase K solution (not included 
in the WGA2 kit).  
 
A.6 Materials and solutions for PCR 
 
The primers required for PCR reactions were obtained from Eurogentec Ltd UK. Hifi 
polymerase (Roche Diagnostics Ltd, UK), 10X Hifi fidelity buffer II (Roche Diagnostics 
Ltd,  UK),  dNTPs  (Promega,  USA),  glycerol  (Sigma,  UK)  and  nuclease  free  H2O 
(Promega, USA) were used for the PCR reaction. All PCR Master mixes were prepared 
in a DNA free room with positive pressure inside a hood. PCR reactions were carried out 
in an ABI9700 thermocycler (PE Applied Biosystems, UK). PCR samples were injected   235 
onto an ABI PRISM 310 genetic analyser and analysed using the Genemapper analysis 
software version 3.5 (PE Applied Biosystems, UK). Genescan 500 ROX size standard 
(PE Applied Biosystems, UK) was used for sizing of labelled PCR products. 
 
A.7 Materials and solutions for a-CGH 
 
For Spectral Genomics Constitutional Chip
TM 2.0 and 3.0 slides the reaction buffers were 
provided by the same company. The buffers included the spectral HYB buffer  I, the 
spectral HYB buffer II, the Spectral labelling buffer and deionized water. Twenty (20) x 
Random  primer  solution,  EDTA  buffer  and  Klenow  fragment  enzyme  were  from  the 
Invitrogen. The Bioprime labelling kit and Cy3 and Cy5 were from GE Healthcare. 
 
The reagents used for Array Genomics were the same used for Spectral Genomics. 
 
For the TRL Mermaid 32K arrays the Invitrogen Bioprime labelling kit was used for the 
DNA labelling. Cot 1 and Herring sperm DNA were provided from Invitrogen whereas 
Cy3 and Cy5 where provided from GE healthcare. 
 
For  BlueGnome  Cytochip  arrays  the  reagents  were  provided  from  the  company 
(BlueGnome fluorescent labelling kit). The kit included a reaction buffer, nuclease free 
H2O, Primer solution, a dNTP mix, Cy3 dCTP, Cy5 dCTP, Klenow fragment, sonicated 
herring sperm DNA and hybridisation buffer (10% dextran sulphate). Human Cot 1 DNA 
was from Invitrogen. 
 
A.8 Materials and solutions for FISH 
 
DNA probes were all provided from Vysis UK and FISH solutions were provided from 
Sigma UK.  A dissecting microscope (Olympus) was used for slide preparation as well as 
for embryo handling.  
   236 
Solutions for slide preparation and pre treatment included glass slides (VWR), 10% poly 
l lysine  solution,  fix  solution  (three  volumes  of  methanol  and  one  volume  of  glacial 
acetic  acid),  70%  acetic  acid,  PBS,  fresh  spreading  solution  (8.9ml  H2O,  1ml  1% 
Tween20 and 100 l 1M HCl), 70%, 90% and 100% ethanol, pepsin solution (1N HCl and 
10mg/ml pepsin) and 1% paraformaldehyde/PBS. 
  
For  hybridisation,  the  probe  mix  apart  from  the  probes  consisted  of  chromosome 
enumeration probe (CEP) buffer for centromeric probes or locus specific identifier (LSI) 
buffer.  Other  solutions  and  materials  used  were  denaturation  mix  (70%  formamide/ 
2xSSC), 70% 90% and 100% ethanol, 13mm coverslips and Rubber cement. 
 
For  post  hybridisation  washes  solutions  used  were    50%  formamide/2xSSC  (or 
2xSSC/60%  formamide  in  case  of  co hybridisation),  2xSSC,  4xSSC/0.05%  Tween20 
70%, 90% and 100% ethanol and Vectorshield antifade medium counterstain (1.25ng/ml 
4’, 6 diaminidino 2 phenylindole (DAPI))  
 
Fluorescent microscopy was achieved with the use of a Zeiss Axioskop microscope with 
chroma multi band pass TRITC/FICT/DAPI filter and single Spectrum Aqua filter. The 
same microscope with a built in Photometrics KAF 1400 cooled CCD (charged coupled 
device) camera was used to capture FISH images. SmartCapture software from Vysis was 
used to control the image capturing. The analysis was done with the utility of special 
computer software (Digital Scientific, UK), that converted fluorescent intensities into a 
red, green or aqua colour for each signal. 
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Primer name  Sequence  Label 
Chromosome 5     
D5S1965 -For  TGTCCCCTTGATAAAAATTACTGCG  FAM 
D5S1965 -Rev  GTGTCTGGGATTTCCTACGCAATG    
D5S2065-For  CAGCCTCATTGTTTATTGACAG  FAM 
D5S2065-Rev  AATGGCATAGTTTTGGCTC    
D5S656-For  GCTAAGAAAATACGACAACTAAATG  FAM 
D5S656-Rev  CATAATAAACTGATGTTGACACAC    
D5S346-For  ACTCACTCTAGTGATAAATCGGG  FAM 
D5S346-Rev  AGCAGATAAGACAGTATTACTAGTT    
Chromosome 7     
p.Phe508del-For  GTTTTCCTGGATTATGCCTGGCA  FAM 
p.Phe508del-Rev  GTTGGCATGCTTTGATGACGCTTC    
IVS8CA-For  AAATCTATCTCATGTTAATGCTGAAGA  NED 
IVS8CA-Rev  ACTAAGATATTTGCCCATTATCAAGTT    
IVS17TA-For  TGTCACCTCTTCATACTCATATTGG  NED 
IVS17TA-Rev  AAACTTACCGACAAGAGGAACTCTG    
Chromosome 19     
APOC2-For  GGCTACATAGCGAGACTCCATCTCC  FAM 
APOC2-Rev  GGGAGAGGGCAAAGATCGATAAAGC    
DMPK-For  CTTCCCAGGCCTGCAGTTTGCCCATC  VIC 
DMPK-Rev  GAACGGGGCTCGAAGGGTCCTTGTAGC    
D19S112-For  GCCAGCCATTCAGTCATTTGAAG  NED 
D19S112-Rev  CTGAAAGACACGTCACACTGGT    
Chromosomes X, 
Y 
   
Amelogenin-For  CCCTGGGCTCTGTAAAGAATAGTC  FAM 
Amelogenin-Rev  ATCAGAAGCTTAAACTGGGAAGCTG    
Amelogenin-Rev  ATCAGAGCTTAAACTGGGAAGCT    
 
Table A1: PCR primer sequences. This table presents all the sequences of the forward 
and reverse primers used for all the projects. The forward primers were labelled with 
FAM, NED or VIC. 
 
 
 
 
 
   238 
A.9 Agarose gel pictures of MDA products 
 
The following figures illustrate how MDA products from single cells appear on agarose 
gels  and  how  they  are  compared  to  gDNA,  MDA  products  from  gDNA  and  MDA 
products following DNA digestion by ultrasound. 
 
          1        2       3        4        5         6         7         8      50bp ladder 
 
 
 
 
 
 
 
 
 
 
 
Figure A1: Agarose gel electrophoresis of MDA products. This figure shows the result 
of 1.2% agarose gel electrophoresis of MDA products Lane 1: 50bp Ladder (Invitrogen, 
USA),  lane  2:  gDNA,  lane  3:  single  cell  T21  MDA  product  after  ultrasound  for  10 
seconds, lane 4: single cell T13 MDA product after ultrasound for 10 seconds, lane 5: 
single cell T21 MDA product without digestion, lane 6: single cell T13 MDA product 
without digestion, lane 7: MDA product of T21 DNA, Lane 8: gDNA. 
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